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°C   degrees Celsius 
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δ  NMR chemical shift [ppm] 
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CH2Cl2  dichloromethane (DCM) 
CH3CN  acetonitrile 
conc.  concentration 
COSY  correlated spectroscopy  
cm  10-2 meter 
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IR  infrared 
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kDa  kilo Dalton (= 103 Dalton) 
L  liter 
LC   liquid chromatography 
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m   meter 
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1. Introduction 
 
Nature has evolved over time to produce a bewildering diversity of secondary 
metabolites. Based on empirical observations and folklore, natural product extracts were 
the first, and for a long time, the only medicines available to mankind. Although 
according to the WHO, 80% of the world’s population - primarily those of developing 
countries - rely on plant-derived medicines for their healthcare, they are largely 
supplanted by pharmaceutical ingredients in the Western world. Furthermore, the 
dependence upon natural products is no longer obligatory and many drugs are purely 
synthetic small molecules or manufactured biologics such as vaccines, antibodies, and 
recombinant proteins (Gurib-Fakim, 2006; Ganesan, 2008).  
 
1.1. Role of Natural Products in Pharmaceutical Sciences 
 
The seminal discoveries leading to the use of pure drug substances occurred in the 18th 
and 19th centuries. In 1785 William Withering published his treatment of heart patients 
with cardiotonic foxglove extract, also known as digitalis (Aronson, 1985). This 
treatment led to the discovery of digoxin (Smith, 1930), and has been used to treat 
arrhythmia and congestive heart failure. In 1806 Freidrich Serturner (Schmitz, 1985)   
analyzed opium poppy and isolated morphine, used in pain therapy. The pharmacology 
of the small molecule morphine enabled an understanding of the opiate receptors 
subtypes, of the endorphin and enkephalin pathways (Ignelzi, 1980), and ultimately led 
to the development of analogs as therapy for pain. In 1897 Felix Hoffmann, working 
with the Bayer Company, synthesized aspirin from salicylic acid in willow bark (Bosch 
and Banos, 1998). People had been using the extract from willow bark prepared as a tea 
for centuries to treat rheumatism and headache. After structure optimization with an 
acetylation reaction to mask the phenol of salicylic acid, Aspirin was born. Using 
salicylic acid as a pharmacologic tool, it was possible to delineate the mechanisms of 
inflammation (Vane, 1971) and subsequently to design and test a battery of new 
nonsteroidal anti-inflammatory agents, including acetaminophen, ibuprofen, and 
naproxen. Although mycophenolic acid was the first fungal secondary metabolite 
obtained from Penicillium glaucoma as early as 1896 (see Bérdy, 2005), it is a well-
known story that in 1928, Alexander Fleming discovered penicillin in mold (Bennett 
   2
and Chung, 2001). The discovery of penicillin and its impact on the treatment and 
understanding of infectious disease did more for human health than any other single 
discovery. The small molecule penicillin enabled the study of antibiotic action and 
infection to the point that countless penicillin and cephalosporin could be synthesized 
and studied for the treatment of various strains of bacteria and in response to antibiotic 
resistance (Ghuysen 1997). An understanding of infectious disease was achieved, and 
an entirely new therapeutic approach was born. 
 
 
 
 
 
 
 
 
 
 
1.2. Natural products as pharmaceutical drugs in the 20th century  
 
Natural products continued to play a major role, and endogenous chemicals, such as the 
steroids, prostaglandins, and peptide hormones, provided the pharmaceutical industry 
with additional natural inspiration for drug discovery during the 20th century 
(Gaudilliere, 2005). The most recent survey covering the period 1981–June 2006 of 
molecules discovered post-1970 lists a total of 1184 new chemical entities (NCEs) 
receiving approval as pharmaceutical drugs (Newman and Cragg, 2007). Of these, 52% 
have a natural product connection, 18% are biologics, and 30% purely synthetic. The 
meta-analysis of this list made by Ganesan (2008) reveals a total of 24 unique natural 
product chemotypes that led at least to one approved drug (Table 1). A priori, natural 
products should undergo an iterative cycle of pharmacological improvement, as their 
evolutionary reason for existence is not for use as a therapeutic agent (Ganesan, 2008). 
Though, among the 24 leads in Table 1, 17 progressed to an approved drug with no 
modification. Another six natural products were modified by semisynthesis and only the 
β-lactam SQ26,180 was replaced by a synthetic analog.  
core structure of penicillins
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Table 1. The 24 natural products discovered since 1970 that led to an approved drug in 1981–2006, 
(Ganesan, 2008) 
Lead, year  Chemical class Origin  Drug, year Rank*
Validamycin, 1970 Oligosaccharide Actinomycete Acarbose, 1990 357 
   Voglibose, 1994  
Midecamycin, 1971 Macrolide Actinomycete Miocamycin, 1995  
Pseudomonic acid, 1971 Polyketide Bacteria Mupirocin, 1985 436 
Taxol, 1971 Diterpene Plant Paclitaxel, 1993 81 
   Docetaxel, 1995 123 
Cephamycin C, 1971 β-lactam Actinomycete Moxalactam, 1982  
   Cefotetan, 1984  
   Cefbuperazone, 1985 
Coformycin, 1974 Nucleoside Actinomycete Pentostatin, 1992  
Echinocandin B, 1974 Cyclopeptide Fungus Caspofungin, 2001 293 
   Micafungin, 2002  
   Anidulafungin, 2006  
Mizoribine, 1974 Nucleoside Fungus Mizoribine, 1984  
Rapamycin, 1974 Polyketide Actinomycete Sirolimus, 1999 434 
   Everolimus, 2004  
   Zotarolimus, 2005  
Compactin, 1975 Polyketide Fungus Lovastatin, 1984 264 
   Simvastatin, 1988 2 
   Pravastatin, 1989 41 
   Fluvastatin, 1994 195 
   Atorvastatin, 1997 1 
   Cerivastatin, 1997  
   Pitavastatin, 2003 71 
   Rosuvastatin, 2003  
Cyclosporine A, 1975 Cyclopeptide Fungus Ciclosporin, 1983 122 
Lipstatin, 1975 Polyketide Actinomycete Orlistat, 1987 277 
Bestatin, 1976 Peptide Actinomycete Ubenimex, 1987  
Thienamycin, 1976 β-lactam Actinomycete Imipenem, 1985 247 
   Meropenem, 1994 231 
   Panipenem, 1994  
   Faropenem, 1997  
   Biapenem, 2002  
   Ertapenem, 2002  
   Doripenem, 2005  
Artemisinin, 1977 Sesquiterpene Plant Artemisinin, 1987  
   Artemether, 1987  
   Artenusate, 1987  
   Artheether, 2000  
Forskolin, 1977 Diterpene Plant Colforsin, 1999  
Plaunotol, 1977 Diterpene Plant Plaunotol, 1987  
Avermectib B1a, 1979 Polyketide Actinomycete Ivermectin, 1987  
SQ26,180, 1981 β-lactam Actinomycete Aztreonam, 1984  
   Carumonam, 1988  
Spergualin, 1981 Peptide Bacteria Gusperimus, 1994  
Arglabin, 1982 Sesquiterpene Plant Arglabin, 1999  
FK506, 1984 Polyketide Actinomycete Tacrolimus, 1993 103 
Daptomycin, 1986 Cyclodepsipeptide Actinomycete Daptomycin, 2003  
Calicheamicin γ1, 1988 Polyketide Actinomycete Gemtuzumab, 2000   
*final column gives the ranking among the global top 500 drugs of 2006, according to IMS Health. 
   4
Although leadfinding new bioactive carbon skeletons is essential for the development of 
new drugs, known successful lead compounds continue to give us optimized 
pharmaceutically approved drugs or currently in clinical trials. Two of these examples 
are Larotaxel (XRP9881) and Cabazitaxel (XRP6258), novel taxoid compounds that 
appear to be potent microtubule stabilizers (NCI Drug Dictionary: Larotaxel. 
http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=42554. Accessed 1 
December 2010; Engels et al., 2005). Larotaxel and Cabazitaxel are active in cell lines 
resistant to doxorubicin, vinblastine, paclitaxel, and docetaxel (Gelmon et al., 2000; 
Fumoleau et al., 2005). Both compounds appear to cross the blood-brain barrier (Sessa 
et al., 2002). Furthermore, Larotaxel shows in vivo synergy in combination with 
doxorubicin, cisplatin, vinorelbine, and trastuzumab (Vrignaud et al., 2005; Vrignaud et 
al., 2007). Larotaxel is currently in phase III trials in patients with advanced pancreatic 
cancer and in patients with advanced bladder cancer. Cabazitaxel is also currently in a 
phase III trial in patients with hormone-refractory prostate cancer following docetaxel-
based therapy. (http://www.oncology.sanofi-aventis.com. Accessed 1 December 2010).  
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1.3.  Terrestrial Fungal-derived Natural Products as Pharmaceutical Drugs 
 
A wide range of pharmaceutically significant compounds belonging to all structural 
classes were found to be produced by fungi (Mutschler et al., 2008). Since the discovery 
of the fungal metabolite penicillin by Fleming in 1928 and its subsequent development 
as antibiotic drug, secondary metabolites of fungal origin have been proved to be an 
important source for new pharmaceuticals and drug lead compounds, as shown by the 
presently bestselling pharmaceutical drugs, the fungal-derived statins, cholesterol-
lowering drugs based on inhibition of HMG-CoA reductase which are widely consumed 
daily and play an important role in lowering the risk of cardiovascular disease (Laws et 
al., 2004). 
Besides the mentioned fungal-derived compounds in Table 1 (compound discovery 
post-1970), other fungal metabolites that are present on the pharmaceutical market 
should be mentioned, such as semi-synthetic or synthetic penicillins and cephalosporins, 
the alkaloid ergotamine (Ergo-Kranit®), the antibiotic polyketide griseofulvin (Likuden 
M®), the immunosuppressive mixed-biosynthesized compound mycophenolate mofetil 
(CellCept®, derivative of mycophenolic acid) used for preventing renal transplant 
rejection as well as the antibacterial terpenoid fusidic acid (Fucidine®) (Hamilton-
Miller, 2008; Buttler, 2005), 
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A class of antimicrobial agents that remained largely undeveloped for human clinical 
use is the pleuromutilins (Hunt, 2000). These antimicrobials are derivatives of the 
naturally occurring pleuromutilin produced by Pleurotus mutilus, an edible 
mushroom. In veterinary practice, tiamulin and valnemulin (two semisynthetic 
pleuromutilin analogs) are used for the control and treatment of serious infections in 
swine (Hunt, 2000, Brooks et al. 2001). Recently, retapamulin, a 
semisynthetic pleuromutilin compound was approved in the U.S. and Europe for the 
treatment of skin infections (Daum et al., 2007; Jacobs, 2007; Laustsen et al., 2008). 
Retapamulin has a unique mode of action, selectively inhibiting the elongation phase of 
bacterial protein synthesis at a unique site on the prokaryotic ribosome (Hunt, 
2000). This antibacterial drug currently shows no target-specific cross-resistance to 
other classes of antibiotics and has potent activity in vitro against Staphylococcus 
aureus and Streptococcus pyogenes, including strains that are resistant to ß-lactams, 
macrolides and quinolones, as well as strains that are resistant to current topical 
therapies including fusidic acid and mupirocin (Bouchillon et al., 2005; McCloskey et 
al., 2005; Stevens et al., 2005). 
 
N S
O
O
O
H
OH
retapamulinpleuromutilin
HO
O
O
O
H
OH
 
 
But to date, fungal metabolites or derivatives thereof have not been launched as 
anticancer chemotherapeutics. Interestingly, several plant-derived anti-cancer agents are 
being reported to be produced from endophytic fungi isolated from the original plant 
sources.  Stierle and coworkers have demonstrated in 1993, that the well-established 
and world’s bestselling anticancer drug taxol from the plant Taxus brevifolia, is also 
produced by the endophytic fungus Taxomyces andreanae (Stierle et al., 1993). In the 
meantime, taxol was discovered as product of many various endophytic fungi (Yang et 
al., 1994; Wang et al. 2000; Ji et al., 2006). Also recently the aryl tetralignan 
podophyllotoxin has been reported to be produced by endophytes, namely 
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Phialocephela fortinii, isolated from the rhizomes of the host plant Podophyllum 
peltatum (Eyberger et al., 2006). Podophyllotoxin, which was originally isolated from 
the rhizoma of Podophyllum peltatum, is a valuable natural product as precursor for 
several therapeutic agents, including the anticancer drugs etoposide, teniposide and 
etoposide phosphate (Canel et al., 2000). In other recent reports, camptothecin was also 
found to be produced by endophytic fungi (Puri et al., 2005; Strobel & Daisy, 2003; 
Strobel et al., 2004). There is an urgent demand for other sources than the primary 
source plant, whose wild populations are being destroyed more and more and the 
pharmaceutical demand will not be covered anymore if no other sources are made 
available (Eyberger et al., 2006).  
 
 
 
 
 
 
 
 
1.4. Compounds from Terrestrial Fungi in Clinical Trials 
 
There are currently two fungal-derived molecules that serve as templates for analogs 
used in clinical trials, fumagillin and illudin S (Buttler, 2005). Fumagillin arises from a 
mixed sesquiterpenoid (C15-nucleus) and polyketidic (C10 side chain) biosynthesis and 
is produced by the fungus Aspergillus fumigatus (Birch & Hussain, 1969). It has been 
the template for analogues undergoing oncological clinical trials. Fumagillin is an 
angiogenesis inhibitor, which suppresses the formation and growth of new blood 
vessels, namely the angiogenesis, by direct blocking endothelial cell proliferation 
(Ingber et al., 1990). Semi-synthetic derivatives, such as TNP-470, PPI-2458 and CKD-
732 entered clinical trials for the treatment of breast, prostate, and brain cancer, as well 
as Kaposi sarcoma (Kruger & Figg, 2000, Lee et al., 2004; Kim et al., 2007, Bernier et 
al., 2005; Chun et al., 2005; Ingber et al., 1990). TNP-470 acts through an irreversible 
binding to methionine aminopeptidase 2, which then leads to intracellular signalling 
interference (Zhang et al., 2006; Lu et al., 2006). Although clinical trials of the 
fumagillin derivative PPI-2458 against cancer were later terminated (Buttler, 2008), the 
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same antiproliferative mechanism of action might be used for the treatment of 
rheumatoid arthritis, and PPI-2458 has been investigated towards this disease. 
Furthermore, fumagillin has been proven to be highly active as antimicrosporidial agent 
in mice (Didier et al., 2006) and has been found to inhibit HIV-1 viral protein R (VPR) 
activity (Asami et al., 2006). Preliminary evidence has recently been put forward that 
angiogenesis inhibitors also inhibit the growth of atherosclerotic plaques (Moulton, 
1999). Remarkably, fumagillin was approved for use in the treatment of intestinal 
microsporidiosis in France in 2005, a disease caused by the parasite Enterozytozoon 
bieneusi, which is of major concern to immunocompromised patients as it can cause 
diarrhoe (Burton, 2002; Alvarado et al., 2009). 
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Another anticancer lead compound of fungal origin is the sesquiterpene illudin S, which 
was first isolated from the basidiomycete Omphalotus illudens (formerly Clitocybe 
illudens) and was shown to be extremely cytotoxic against the human leukemia cell line 
HL-60 in vitro (IC50 = 3 ng/mL), but exhibiting a low therapeutic index in mouse 
xenograft solid tumor systems (Anchel et al., 1950; McMorris & Anchel, 1965; 
McMorris et al., 1996). Though, the improved semi-synthetic compound irofulven has a 
significantly superior therapeutic index in comparison to the parent natural product 
illudin S and possesses selectivity towards human tumor cells in which apoptosis is 
induced (e.g. MV522 lung carcinoma cell assay with an IC50 value of 73 nM for 
irofulvene), with only a marginal apoptotic effect on normal human cells (Baekelandt, 
2002; Woynarowska et al., 2000, McMorris 2001). Irofulvene possesses a greater 
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efficacy than illudin S due to its slower and more selective action. It has entered phase I 
and II clinical trials against several types of cancer (Seiden et al., 2006). 
 
 
 
 
 
 
 
1.5. Marine Natural Products as Pharmaceutical Drugs 
 
The marine ecosystem, covering more than 70 % of the planet’s surface, is home to an 
immense diversity of life. Though, due to the extreme depth of the oceans, they 
represent more than 99 % of our planet’s natural habitat when setting the terrestrial 
habitat up to 100 m of height (Schuh, 2008). Marine natural products are conspicuously 
absent in table 1, as their systematic exploration became widespread only recently. In 
the United States there are three FDA approved marine-derived drugs, namely 
cytarabine, vidarabine and ziconotide. Currently, trabectedin has been approved by the 
European Agency for the Evaluation of Medicinal Products (EMEA), and is completing 
key Phase III studies in the US for approval. The current clinical pipeline includes 13 
marine-derived compounds that are either in Phase I, Phase II or Phase III clinical trials 
(Mayer et al., 2010). 
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Table 2, Marine-derived compounds in clinical development and approved as pharmaceutical 
drugs (Mayer et al., 2010) 
Clinical status Compound name Structural class Origin Disease area 
Approved Cytarabine, Ara-C Nucleoside Sponge Cancer 
  Vidarabine, Ara-A nucleoside Sponge Antiviral 
  Ziconotide Peptide Snail Pain 
  Trabectedin (ET-743) Alkaloid Tunicate Cancer 
  (EU registered only)       
Phase III Eribulin Mesylate (E7389) Macrolide Sponge Cancer 
  Soblidotin (TZT 1027) peptide Bacterium Cancer 
Phase II DMXBA (GTS-21) Alkaloid Worm Cognition/Schizophrenia 
  Plinabulin (NPI-2358) Diketopiperazine Fungus Cancer 
  Plitidepsin Depsipeptide Tunicate Cancer 
  Elisidepsin Depsipeptide Mollusc Cancer 
  PM1004 Alkaloid Nudibranch Cancer 
  Tasidotin, Synthadotin (ILX-651) Peptide Bacterium Cancer 
  Pseudopterosins Diterpene glycoside Soft coral Wound healing 
Phase I Bryostatin 1 Polyketide Bryozoa Cancer 
 Hemiasterlin (E7974) Tripeptide Sponge Cancer 
  
Marizomib (Salinosporamide A; 
NPI-0052) 
Beta-lactone-
gamma lactam Bacterium Cancer 
 
A recent development in the area of antitumor agents from natural sources was the 
approval of the alkaloid trabectedin for advanced soft 
tissue sarcoma (Verweij, 2009) and patients with 
relapsed platinum-sensitive ovarian cancer (Yap et 
al., 2009) by the EMEA (European Medicines 
Agency) in September 2007 
(http://www.emea.europa.eu). Currently the product 
is being developed in Phase II trials in breast, lung, 
prostate and pediatric cancer, and Phase III trials for 
first-line therapy in STS (Mayer et al., 2010). Yondelis® is being developed and 
marketed by Pharmamar (http://www.pharmamar.com/products.aspx). Trabectedin, was 
originally isolated from a marine invertebrate, the tunicate Ecteinascidia turbinata 
which was found in the Caribbean and Mediterranean sea (Rinehart, et al. 1990, Wright, 
et al. 1990), but is now produced semi-synthetically (Cuevas et al., 2000; Newman et 
al., 2000; Rinehart et al., 1990; Wright et al., 1990; http://www.pharmamar.com). 
Trabectedin binds guanine-specific to the minor groove of DNA, but its precise 
mechanism of action remains poorly understood (Herrero et al., 2006; Pommier et al., 
1996). 
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Cytarabine (Ara-C, developed by Bedford Laboratories, http://www.bedfordlabs.com/, 
and Enzon Pharmaceuticals, http:// www.enzon.com/), is a synthetic pyrimidine 
nucleoside which was developed from spongothymidine, a 
nucleoside originally isolated from the Caribbean sponge Tethya 
crypta (Newman et al., 2009). Cytarabine is an S-phase specific 
antimetabolite cytotoxic agent, which when converted 
intracellularly to cytosine arabinoside triphosphate competes with 
the physiologic substrate deoxycitidine triphosphate, thus resulting 
in both inhibition of DNA polymerase and DNA synthesis. 
Cytarabine received FDA approval in 1969. FDA-labeled 
indications for conventional cytarabine are treatment of acute lymphocytic leukemia, 
acute myelocytic leukemia, blast crisis phase of chronic myelogenous leukemia, 
meningeal leukemia (Thomas, 2009; Absalon et al., 2009; MARTINDALE, 2009) and 
intrathecal treatment of lymphomatous meningitis. 
Vidarabine (Ara-A) is a synthetic purine nucleoside which was developed from 
spongouridine, a nucleoside originally isolated from the Caribbean sponge Tethya 
crypta (Newman, et al., 2009), and which is currently obtained 
from Streptomyces antibioticus. Adenine arabinoside inhibits viral 
DNA polymerase and DNA synthesis of herpes, vaccinia and 
varicella zoster viruses. Although its marketing status is currently 
listed as discontinued by the FDA in the US market, vidarabine 
(Vira-A1) received FDA approval in 1976. FDA-labeled 
indications for conventional vidarabine (Vira-A ophthalmic 
ointment, 3%) are treatment of acute keratoconjunctivitis, 
recurrent epithelial keratitis caused by herpes simplex virus type 1 and 2, and superficial 
keratitis caused by herpes simplex virus that has not responded to topical idoxuridine 
(Herplex1) (MARTINDALE, 2009). Vidarabine (Vira-A1), previously marketed by 
King Pharmaceuticals (http://www.kingpharm.com/) was discontinued in June of 2001 
by an executive decision, possibly associated with the lower therapeutic window of 
vidarabine relative to newer antiviral compounds currently on the market (Mayer et al., 
2010).  
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Ziconotide (Prialt®, Elan Corporation, PLC 
(http://www.elan.com/therapies/products/prialt.asp) is the synthetic equivalent of a 
naturally occurring 25-amino acid peptide, ω-conotoxin MVIIA, originally isolated 
from the venom of the fish-hunting marine snail Conus magus (Olivera, 2000). 
Receiving FDA-approval in 2004, Ziconotide is a potent analgesic with a completely 
novel mechanism of action (Bingham et al., 2010; Kerr and Yoshikami, 1984). Various 
subtypes of voltage-gated calcium channels have been identified in the nervous system. 
Ziconotide reversibly blocks N-type calcium channels located on primary nociceptive 
afferent nerves in the superficial layers of the dorsal horn of the spinal cord. Binding of 
ziconotide to presynaptic N-type calcium channels reduces the release of excitatory 
neurotransmitter release from the primary afferent nerve terminals (Miljanich, 2004; 
McGivern, 2006). Tolerance to drug effects is a major limiting factor in opiate-based 
therapies; unlike opiates, ziconotide does not produce tolerance (Wang et al., 2000; 
Gaur et al., 1994). Ziconotide is currently used for the management of severe chronic 
pain in patients with cancer or AIDS (Staats et al., 2004; Rauck et al., 2009), for whom 
intrathecal (IT) therapy is warranted, and who are intolerant or refractory to other 
treatments, such as systemic analgesics, adjunctive therapies or IT morphine.  
 
 
Cys-Lys-Gly-Lys-Gly-Ala-Lys-Cys-Ser-Arg-Leu-Met-Tyr-Asp-Cys-Cys-Thr-Gly-Ser-Cys-Arg-Ser-Gly-Lys-Cys-NH2  
 
 
ω-Conotoxin MVIIA  
 
1.6. Marine-derived fungal compounds in clinical trials 
 
As interests have turned to marine microorganisms, marine fungi have proved to be a 
rich and promising source of novel bioactive natural products. Most of these 
microorganisms grow in a unique and extreme habitat and therefore have the capability 
to produce unusual secondary metabolites. It is believed that the metabolites possibly 
act as a chemical defense adaptation of fungi competing for substrates. The production 
of these unique secondary metabolites by marine fungi is most likely due to their 
adaptation to a very distinct set of environmental pressures (Bhadury et al., 2006). 
   13
Although some marine-fungal compounds are in pre-clinical trials, the most promising 
marine-fungal derived analogue in clinical trials is the anticancer agent plinabulin which 
is based on the diketopiperazine halimide (also known as phenylahistidin), isolated from 
the fungus Aspergillus ustus (Kanoh et al., 1997). Initially halimide was isolated as a 
mixture of enantiomers, but the (-) enantiomer alone exhibited a 50-fold increase of in 
vitro antitumor activity against human cancer cell lines, along with inhibition of tubulin 
polymerisation by interacting with the colchicine-binding site on tubulin (Kanoh et al., 
1999a & 1999b).  
HN
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HN
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(-)-halimide plinabulin  
To optimise biological activity, a series of 200 synthetic analogues were generated by 
the company Nereus Pharmaceuticals, San Diego, U.S.A., and finally led to compound 
NPI-2358 (Plinabulin), which is since 2009 in Phase II clinical studies as a vascular 
disrupting agent against advanced non-small cell lung cancer refractory to current 
therapy (http://www.nereuspharm.com). A recent study showed that plinabulin acts 
moreover as a tumor vascular-disrupting agent by inducing rapid depolymerisation of 
existing microtubules in the highly proliferating tumor vascular endothelial cells, as 
evidenced by in vitro assays with human umbilical vein endothelial cells (HUVECs) 
(Nicholson et al., 2006). Tumor vascular-disrupting agents thereby attack established 
tumor blood vessels, resulting in occlusion of vasculature in the tumor, which induces 
tumor cell hypoxia and finally necrosis. 
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2. Scope of the present study 
 
Due to the rapidly increasing number of pathogenic bacteria, viruses and tumor cells 
that possess resistance towards established therapies, lead structures for the 
development of new drugs are in high demand.  
Marine microorganisms, such as fungi often occur associated with macroorganisms like 
algae, sponges or tunicates and produce secondary metabolites with novel structures and 
potential pharmaceutical significance.  
The goal of this study was the evaluation of new natural products of marine-derived 
fungi in order to find novel lead structures for drug development, with a focus on 
anticancer leads. To achieve this aim seven fungal strains living associated with marine 
algae and sponges were cultivated during 40 to 60 days, and the extracts tested for 
bioactivity. Subsequently, the natural products were isolated, their structures determined 
and their bioactivity established. 
The research relies in tracing active principles from the selected extracts by performing 
NMR guided fractionation, together with the application of various preparative 
chromatographic systems (e.g., VLC, HPLC). The structure elucidation of the obtained 
pure compounds relies on interpretation of 1D and 2D NMR spectroscopic data, as well 
of mass spectrometry data, UV, IR and CD spectra. 
Additionally, the isolated compounds can be submitted to a vast panel of biological 
assays, such as antimicrobial, antiplasmodial, antidiabetic, antiinflammatory, antiviral 
or psychoactive activity, amongst others. 
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3.    General Methodology 
3.1.  General Experimental Procedures  
 
Optical rotations were measured on a Jasco DIP 140 polarimeter. UV and IR spectra 
were obtained employing a Perkin-Elmer Spectrum BX instrument. CD spectra were 
recorded in MeOH at room temperature using a JASCO J-810-150S. All NMR spectra 
were recorded in MeOD, CDCl3 or (CD3)2CO employing a Bruker Avance 300 DPX 
spectrometer. Spectra were referenced to residual solvent signals with resonances at δH/C 
3.35/49.0 for MeOD, δH/C 7.26/77.0 for CDCl3 and δH/C 2.04/29.8 for (CD3)2CO. 
HREIMS were recorded on a Finnigan MAT 95 spectrometer. HRESIMS were recorded 
on a Bruker Daltonik micrOTOF-Q Time-of-Flight mass spectrometer with ESI source. 
HPLC was carried out using a system composed of a Waters 515 pump together with a 
Knauer K-2300 differential refractometer. HPLC columns were from Knauer (250 x 8 
mm, 5 μm, Eurospher-100 Si and 250 x 8 mm Eurospher-100, C18, 5 μm, flow rate 2 
mL/min) and from Macherey-Nagel (Nucleodur C18 EC Isis and Nucleodur C18 
Sphinx RP, both with 250 x 4.6 mm, 5 μm, flow rate 1 mL/min). 
Merck silica gel 60 (0.040–0.063 mm, 70-230 mesh) was used for vacuum liquid 
chromatography (VLC). Columns were wet-packed under vacuum using petroleum 
ether (PE). Before applying the sample solution, the columns were equilibrated with the 
first designated eluent. Standard columns for crude extract fractionation had dimensions 
of 13 x 4 cm.  
 
 
3.2.  Fungal material:  
 
Marine-derived fungus Stachylidium sp. was isolated from the sponge Callyspongia sp. 
cf. C. flammea and identified by Dr. P. Massart and Dr. C. Decock from the Belgian 
coordinated collections of microorganisms of the Catholic University of Louvain, 
(BCCM/MUCL). A specimen is deposited at the Institute for Pharmaceutical Biology, 
University of Bonn, isolation number “293K04”, running number “220”. 
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The marine-derived fungus Cadophora malorum (Kidd & Beaumont) W. Gams was 
isolated from the green alga Enteromorpha sp. and identified by P. Massart and C. 
Decock, BCCM/MUCL, Catholic University of Louvain, Belgium. A specimen is 
deposited at the Institute for Pharmaceutical Biology, University of Bonn, isolation 
number “SY3-1-1MIT”, running number “417”. 
 
The marine-derived fungus Verticillium tenerum was isolated from an unknown alga 
and identified by Isabelle Charue, BCCM/MUCL, Catholic University of Louvain, 
Belgium. A specimen is deposited at the Institute for Pharmaceutical Biology, 
University of Bonn, isolation number “293K04”, running number “780”. 
 
 
3.3.  Methodology for the performed bioactivity assays 
 
The referred compounds were tested in antibacterial (Escherichia coli, Bacillus 
megaterium), antifungal (Mycotypha microspora, Eurotium rubrum, and Microbotryum 
violaceum), and antialgal (Chlorella fusca) assays as described by Schulz et al., 1995 
and Schulz et al., 2002.  
Compounds were tested towards a panel of proteases including chymotrypsin, trypsin, 
human leukocyte elastase (HLE), papain, porcine cease, and acetylcholine esterase as 
described by Neumann, et al., 2009. 
Compounds were tested for protein kinases inhibition assays (DYRK1A and CDK5) 
according to Bettayeb et al., 2008.  
The triglyceride accumulation inhibition in the 3T3-L1 murine adipocytes assay were 
performed as described by Shimokawa et al., 2008.  
Cytotoxic activity assay against a panel of 5 cancer cell lines, NCI-H460/lung, 
A549/lung, MCF7/breast and SF268/CNS and CAKI/renal at the 100 µM level was 
performed according to Saroglou et al., 2005 and Monks et al., 1991.  
Compounds were tested for antiplasmodial activity assay against Plasmodium berghei 
as described by Prudêncio et al., 2008. 
The sporogenic activity assay was performed according to Kitahara et al., 1984 and 
Sawai et al., 1985. 
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Inhibition of the viral HIV-1 and HIV-2 induced cytopathogenic effect in MT-4 cells 
assays were performed according to Pannecouque et al., 2008 and Zhan et al., 2008.  
Severe Acute Respiratory Syndrome coronavirus (SARS) assays were performed 
according to Kumaki et al., 2008. 
The Herpes Simplex Virus-2 (HSV-2) activity assay methods are described by Harden 
et al., 2009.  
The Respiratory Syncytial virus (RSV) activity assays were conducted according to 
Barnard et al., 1993 and Barnard et al., 1997. 
Two influenza viruses (Flu A and Flu B) activity assays were performed as described by 
Sidwell and Smee, 2000.  
Hepatitis B virus assay was performed according to Sells et al., 1998 and Korba and 
Gerin, 1992.  
The Epstein-Barr virus (EBV) assay was performed according to Smee et al., 1997. 
The activity assays against two strains of antibiotic resistant Mycobacterium 
tuberculosis were performed according to Bauer et al., 1966.  
The methodology for the inhibition of the NF-kB protein complex is described by 
Schumacher et al., 2010.  
The compounds were tested against a panel of anti-diabetic activity assays as described 
by Marrapodi and Chiang, 2000, Dey et al., 2007 and Seale et al., 1997.  
The agonistic/antagonistic binding assays against a panel of forty four psychoactive 
receptors (activity considered with at least 50 % inhibition at the 10 μM level against 
5HT1A, 5HT1B, 5HT1D, 5HT1E, 5HT2A, 5HT2B, 5HT2C, 5HT3, 5HT5A, 5HT6, 
5HT7, Alpha1A, Alpha1B, Alpha1D, Alpha2A, Alpha2B, Alpha2C, Beta1, Beta2, 
Beta3, BZP Rat Brain Site, D1, D2, D3, D4, D5, DAT, DOR, Gaba A, H1, H2, H3, H4, 
KOR, M1, M2, M3, M4, M5, MOR, NET, SERT, Sigma1, Sigma2). Ocasionally the 
compounds were also tested for specific receptors, i.e., CB1, CB2, GabaB, NMDA-PCP 
site, Oxytocin, PBR, mGluR5_Rat Brain, V1A, V1B and V2. All experimental 
procedures are desribed by the assay provider at http://pdsp.med.unc.edu/UNC-
CH%20Protocol%20Book.pdf.  
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4.  Marilines A – D, Novel Phthalimidines from the Sponge-derived    
Fungus Stachylidium sp. 
 
 
 
 
 
Abstract 
The marine-derived fungus Stachylidium sp. was isolated from the sponge Callyspongia 
cf. C. flammea. Chemical investigation of the bioactive fungal extract led to the 
isolation of the novel phthalimidine derivatives marilines A - D (1-4). The absolute 
configuration of the enantiomeric compounds 1 and 2 was assigned by means of 
theoretical Circular Dichroism calculations. The skeleton of marilines A - D is most 
unusual, and its biosynthesis is suggested to require unusual biochemical reactions in 
fungal secondary metabolism. Both enantiomers marilines A and B (1, 2) inhibited 
human leucocyte elastase (HLE) with an IC50 value of 0.86 μM, and 
acetylcholinesterase (AChE) with IC50 values of 0.18 μM (offset = 49 %) and 0.63 μM 
(offset = 54 %), respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structural Formulae of Compounds 1 – 4 
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Introduction 
 
Inspired by the impressive level of biodiversity in the marine environment, the 
pharmacological potential of natural products from marine organisms has been 
investigated enthusiastically (Glaser and Mayer, 2009). Phthalimidines are secondary 
metabolites mostly isolated from fungi, but also reported from plants and bacteria. 
Fungal-derived phthalimidines are described as having a wide spectrum of bioactivities, 
e.g. the phytotoxic activity of cichorine, a metabolite isolated from Alternaria cichorii 
and Aspergillus silvaticus that causes necrotic lesions in Russian knapweed (Kawahara 
et al., 1988; Stierle et al., 1993). Porritoxin is known to be a non-specific toxin isolated 
from Alternaria porri, inhibiting the growth of lettuce and stone-leek roots, two 
important commercial plants (Suemitsu et al., 1992; Suemitsu et al., 1995; Horiuchi et 
al., 2003; Horiuchi et al., 2002; Moreau et al., 2006). Stachybocins and 
spirodihydrobenzofuranlactams were isolated from Stachybotrys sp. and are reported to 
possess endothelin receptor antagonistic effects. The latter has also HIV-1 protease 
inhibitory properties (Ogawa et al., 1995; Roggo  et al., 1996). The antifungal 
pestalachlorides isolated from Pestalotopsis adusta (Li et al., 2008), the aldose 
reductase inhibitors salfredins from Crucibulum sp. (Matsumoto et al., 1995) or the 
cytotoxic hericenone B isolated from Hericium erinceum (Kawagishi et al., 1990) 
additionally demonstrate the broad spectrum of bioactivity found for fungal-derived 
phthalimidine-like structures. 
  
During our search for new natural products produced from the marine-derived fungus 
Stachylidium sp., four novel pthalimidine derivatives, marilines A-D, were isolated from 
a culture grown on agar-biomalt medium supplemented with artificial sea salt. Albeit 
phthalimidine-like structures are not rare, the structural skeleton of marilines A - D is 
most unusual, and its biosynthesis is suggested to require unique reactions in fungal 
secondary metabolism. Marilines A-D were tested in a broad range of assays to 
determine their biological activity. Both enantiomers, marilines A and B (1, 2) inhibited 
human leucocyte elastase (HLE) with the same potency (IC50 0.86 μM). 
Acetylcholinesterase (AChE) was inhibited with an IC50 of 0.18 μM (offset = 49 %) and 
0.63 μM (offset = 54 %), for marilines A and B, respectively. Compounds 1 and 2 also 
showed weak antiplasmodial and antiproliferative activity, and were antagonistic in 
several assays employing psychoactive receptors. 
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Results 
 
Compounds 1 and 2 were initially obtained and analysed as a mixture of enantiomers. 
The molecular formula was deduced by accurate mass measurement (HREIMS) to be 
C33H43NO5, requiring thirteen degrees of unsaturation. The 13C NMR and DEPT135 
spectra contained 33 carbon resonances, including nine resulting from methyl groups, 
seven from sp2 methines, one from a sp3 methine, further four signals from methylene 
groups and 12 resonances were assigned to quaternary carbons. 1H NMR and 1H-1H 
COSY spectra showed four resonance signals in the aromatic region (δ 6.95 s, 6.67 d, 
6.56 dd, 7.19 d) indicating together with 13C NMR and 1H-13C HMBC data the presence 
of two benzylic moieties, one of them 1,2,4- and the other penta-substituted (Tables 1, 2 
and Appendix - 2D NMR Tables). Furthermore, the molecule was found to contain 
three 1,1,2-substituted double bonds (δC 120.6, 141.5, 124.6, 132.0, 120.8, 137.9), 
which were part of a mono- and a hemiterpene moiety. The C-1’ to C-10’ part of the 
molecule was deduced from two proton coupling spin systems, the first from H-2’ to 
H2-1’ and H3-9’, and the second ranged from H-4’ through to H3-10’ and H3-8’. 1H-13C 
HMBC data correlated H3-9’ to C-2’, C-3’ and C-4’, which disclosed the structure of 
this terpenoid fragment. Based on literature comparisons (Tanaka et al., 1985) we 
established the configuration of the 2’/3’ as E. 1H NMR resonance signals that arose 
from the hemiterpene unit C-1’’ to C-5’’ included two singlet methyl resonances, i.e. 
CH3-4’’(δH 1.68, brs) and CH3-5’’(δH 1.67, brs), both with 1H-13C HMBC correlations 
to C-3’’ and the sp2 methine CH-2’’ (δH 5.35). H-2’’ coupled to the oxygenated 
methylene protons H2-1’’, thus completing this partial structure. 
A 13C NMR signal at δ 57.5 (CH-8) was found to be characteristic for a carbon 
neighboring a nitrogen atom, which according to its chemical shift in the 15N NMR 
spectrum (δN 132.4) was part of an amide functionality. The 1H-1H COSY showed 
correlations from H-8 to H3-9. Furthermore, 1H-13C HMBC spectra showed correlations 
between H-8 and the carbonyl carbon C-1, as well as to C-6, C-7 and C-2 of the penta-
substituted aromatic ring. 1H-13C HMBC correlations between H3-9 and C-7 as well as 
1H-15N HMBC correlations between H3-9 and the amide nitrogen (see Appendix - 
Complete 2D NMR data) gave evidence for a phthalimidine skeleton, i.e. the C-1 to C-9 
part of the structure. One of the substituents of the aromatic ring of the phthalimidine 
moiety was established to be a methyl group (CH3-11, δH 2.12, s), which was positioned 
at C-4 as deduced from HMBC correlations (Tables 1 and 2). The quaternary carbons 
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C-3 and C-5 have 13C NMR shifts typical for aromatic carbons bound to oxygen. The 
methoxyl group OCH3-10 was established to be located at C-3, as evident from 1H-13C 
HMBC correlations. CH2-1’ of the monoterpene moiety was attached to oxygen as 
concluded from the chemical shifts of C-1’ (δC 66.2) and H2-1’ (δH 4.68 and 4.72). H2-
1’ showed long range heteronuclear coupling with C-5 of the aromatic ring via an 
oxygen bridge, thus placing the terpene moiety at C-5. The latter deduction was also 
supported by 1H-1H NOESY correlations from H2-1’ to H-6. 
Further three resonance signals in the 1H NMR spectrum resulted from a tri-substituted 
benzene ring. H-16 and H-17 (J = 8.6 Hz) were placed in ortho position to each other, 
while H-14 and H-16 (J = 2.6 Hz) were meta-positioned. 1H-13C HMBC correlations 
from H2-1’’ to C-13 and from OCH3-18 to C-15 showed that the oxygenated quaternary 
aromatic carbons C-13 (δC 156.8) and C-15 (δC 160.8) were connected with a 
hemiterpene (C-1’’ to C-5’’) and a methoxyl moiety (OCH3-18), respectively. 1H-1H 
NOESY correlations of H3-18 to H-14 and H-16, and of H2-1’’ to H-14 confirmed the 
position of these substituents. 1H-15N HMBC measurements showed two distinct 
correlations from H3-9 and H-17 to the nitrogen atom (δN 132.4), evidencing that the tri-
substituted benzene ring is connected at C-12 to the phthalimidine nucleus. 1H-1H 
NOESY correlations from H-17 to H3-9 and to H-8 confirmed the structure. Compounds 
1 and 2 have the same planar structure, but differ concerning their configuration at C-8, 
i.e. they are enantiomers. We propose the trivial names mariline A (1) and B (2) for 
these compounds. 
 
The molecular formula of 3 was deduced by accurate mass measurement (HRESIMS) to 
be C23H33NO4, requiring eight degrees of unsaturation. The C-1 to C-8 and C-1’ to C-
10’ parts of the molecule were established to be identical to those of compounds 1 and 2 
based on 13C and 1H NMR, as well as 1H-13C HMBC and 1H-1H COSY spectra (Tables 
1, 2 and Appendix - 2D NMR tables) The structure of 3 however, was missing the 
second aromatic ring and instead an ethyl-1-ol moiety was linked to the nitrogen atom. 
This was evidenced by heteronuclear long range correlations from H2-12 to C-8 and C-1 
through the nitrogen atom. Furthermore, the methylene CH2-13 showed proton coupling 
with CH2-12, whereby the 13C NMR shift of C-13 indicated that it was connected to a 
hydroxy group (δC 61.7). This completed the planar structure of compound 3, for which 
we propose the trivial name mariline C. 
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The molecular formula of 4 was deduced by accurate mass measurement (HRESIMS) to 
be C11H13NO3, requiring six degrees of unsaturation. NMR data (Tables 1, 2 and 
Appendix - 2D NMR tables) suggested the presence of a phthalimidine nucleus with 
most substituents on the aromatic ring as present in 1, 2 and 3. Compound 4, however 
possessed a free hydroxy group, which was confirmed by an IR absorption band at 3346 
cm-1. The latter was placed at C-5 (δC 162.3), which was clearly an oxygenated aromatic 
carbon atom. Spectroscopic data for compound 4 did not show any signals for a 
substituent on the nitrogen atom, which is thus present as an NH group. We propose the 
trivial name mariline D for 4. 
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Table 1. 13C NMR Spectroscopic Data for Compounds 1 – 4 
  1 & 2  3  4 
position   δN, δC, mult.a, b, c   δC, mult.a, b, c    δC, mult.a, b,c 
N  132.4, N     
1  166.2, qC  167.3, qC  171.7, qC 
2  116.4, qC  116.3, qC  114.5, qC 
3  157.2, qC  156.9, qC  158.4, qC 
4  119.4, qC  119.3, qC  118.9, qC 
5  161.9, qC  161.7, qC  162.3, qC 
6  101.8, CH  101.8, CH  105.0, CH 
7  150.0, qC  150.0, qC  152.1, qC 
8  57.5, CH  56.9, CH  53.2, CH 
9  19.4, CH3  18.9, CH3  20.8, CH3 
10  62.1, CH3  62.1, CH3  62.5, CH3 
11  8.8, CH3  8.8, CH3  8.6, CH3 
12  120.1, qC  43.6, CH2   
13  156.8, qC  61.7, CH2   
14  101.2, CH     
15  160.8, qC     
16  105.5, CH     
17  131.9, CH     
18  55.7, CH3     
1'  66.2, CH2  66.2, CH2   
2'  120.6, CH  120.6, CH   
3'  141.5, qC  141.5, qC   
4'  40.1, CH2  40.1, CH2   
5'  27.0, CH2  27.0, CH2   
6'  124.6, CH  124.6, CH   
7'  132.0, qC  132.1, qC   
8'  25.8, CH3  25.8, CH3   
9'  16.7, CH3  16.7, CH3   
10'  17.7, CH3  17.7, CH3   
1''  66.1, CH2     
2''  120.8, CH     
3''  137.9, qC     
4''  18.2, CH3     
5''   25.7, CH3         
a acetone-d6 (1, 2, 3) , and MeOD (4) 300/75.5 MHz. b Assignments are based on extensive 1D and 2D 
NMR experiments (1H-13C, 1H-15N HMBC, HSQC, COSY). c Implied multiplicities determined by DEPT. 
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Table 2. 1H NMR Spectroscopic Data for Compounds 1 – 4 
  1 & 2  3  4 
position  δHa, b (J in Hz)  δHa, b (J in Hz)  δHa, b (J in Hz) 
N             
1       
2       
3       
4       
5       
6  6.95, s  6.92, s   6.68, s 
7       
8  4.97, q (6.8)  4.62, q (6.8)  4.53, q (6.8) 
9  1.27, d (6.8)  1.44, d (6.8)  1.42, d (6.8) 
10  3.99, s  3.98, s  3.95, s 
11  2.12, s  2.09, s  2.15, s 
12    a: 3.33, dt (14.0, 5.5)   
    b: 3.85, dt (14.0, 5.5)   
13    3.71, m   
14  6.67, d (2.6)     
15       
16  6.56, dd (2.6, 8.6)     
17  7.19, d (8.6)     
18  3.81, brs     
1'  a: 4.68, dd (6.6, 12.3) a: 4.65, dd (6.6, 12.3)   
  b: 4.72, dd (6.6, 12.3) b: 4.71, dd (6.6, 12.3)   
2'  5.53, t (6.6)  5.51, t (6.6)   
3'       
4'  2.12, m  2.12, m   
5'  2.14, m  2.14, m   
6'  5.10, t (6.6)  5.10, t (6.6)   
7'       
8'  1.63, brs  1.63, brs   
9'  1.77, brs  1.76, brs   
10'  1.59, brs  1.58, brs   
1''  a: 4.54, dd (6.6, 12.0)    
  b: 4.58, dd (6.6, 12.0)    
2''  5.35, t (6.6)     
3''       
4''  1.68, brs     
5''   1.67, brs         
a acetone-d6 (1, 2, 3) , and MeOD (4), 300/75.5 MHz. b Assignments are based on extensive 1D and 2D 
NMR experiments (1H-13C, 1H-15N HMBC, HSQC, COSY). 
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Stereochemistry 
 
Compounds 1-4 possess a single chiral carbon, i.e. C-8. The measurement of specific 
optical rotations yielded in all cases a value close to zero, and furthermore, CD 
measurements produced only marginal CD effects. The structure of the molecules 
suggested a CD effect at around 260 nm due to the proximity of the chiral center to the 
chromophore. It was thus assumed that we may have obtained racemic mixtures. In the 
case of marilines A and B (1, 2) this was confirmed by chromatographic separation of 
the enantiomers using chiral HPLC. The enantiomers 1 and 2 were isolated from three 
independent cultures and found to be present in ratios of approximately 3:2, 3:7 and 1:1 
as deduced from the final weights obtained. 
 
We found several previously reported cases of racemization reactions on natural 
products with a chiral center in lactam, lactone and dihydrofuran rings (Harper et al., 
2003; Li et al., 2008; Strobel, et al., 2002; Wolfgang and Kund, 1990), which suggested 
a post-biosynthetic racemization also for 1 or 2. This racemization could occur via a 
resonance stabilized cationic intermediate, as previously described for similar 
compounds (Harper et al., 2003; Li et al., 2008). Especially noteworthy is a previous 
literature report on the easy racemization of the phthalimidine-like compound pagoclone 
(Stuck et al., 2003). It was reported that this isoindolinone already racemized at low 
basic or acidic conditions and moderately elevated temperatures. Racemization of 
pagoclone was found to be optimal with 0.005N KOH at 50 ºC for 2h, and suggested to 
occur via a retro-Michael/Michael reaction. This type of reaction is, however unlikely to 
occur in the case of 1 and 2. Nevertehless, to evaluate whether racemization occured 
during the extraction and isolation process, enantiomerically pure marilines A and B 
were subjected to increasing concentrations of KOH and HCl as outlined in the 
experimental section, however even harsh conditions produced no racemization as 
evidenced by chiral HPLC analysis. 
 
CD spectra of 1 and 2 were measured and opposite CD effects were discerned for the 
enantiomers (Figure 2).  
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(Compound 1)  
 
 
    
 
(Compound 2) 
 
 
 
Figure 2. CD spectra of compound 1 (mariline A) and 2 (mariline B)  
 
 
The configuration at C-8 is currently being elucidated by theoretical CD calculations.  
 
Compounds 3 and 4 were also collected as racemic mixtures, as no effects in CD spectra 
and no optical rotation values were obtained. Exhaustive attempts to separate the 
enantiomers with three different chiral stationary HPLC columns were unsuccessful. 
 
 
Biological activity 
 
Marilines A and B inhibited the protease HLE with an IC50 value of 0.86 μM for both 
enantiomers. Acetylcholinesterase (AChE) activity was inhibited with an IC50 value of 
0.18 μM (offset = 49 ± 3 %) for mariline A and 0.63 μM (offset = 54 ± 3 %) for 
mariline B. The large offset (i.e. a remaining activity in the presence of inhibitor) in the 
AChE inhibition assay probably means that the compounds do not bind to the protease 
active site. When performing calculations with equations which do not considers the 
offset, marilines A and B have IC50 values of 4.4 and 6.6 μM, respectively. Mariline C 
(3) showed no activity toward the proteases HLE and AChE at the 10 μM level (see 
Appendix - Bioactivity results). Compound 4 was not tested in these assays, due to the 
small amounts isolated. Marilines A-D were assayed towards further proteases and 
found to be inactive (see Appendix - Bioactivity results). 
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Mariline A was tested against five cancer cell lines and exhibited a mean GI50 of 24.44 
μM, whilst mariline B was tested against 19 cancer cell lines and showed a GI50 of 5.00 
μM. The observed antiproliferative pattern of mariline B did not correlate with that of 
any of the standard antiproliferative compounds with known mechanism of action as 
deduced by COMPARE analyses. The first match on the standard agents database 
(correlation 0.427) was rhizoxin, a metabolite produced by a bacteria associated with a 
fungus (see see Appendix - Bioactivity results). Mariline C (3) and D (4) were also 
evaluated for cytotoxic activity against a panel of 5 cancer cell lines (NCI-H460/lung, 
A549/lung, MCF7/breast and SF268/CNS and CAKI/renal at the 100 µM level) and 
mariline C exhibited low antiproliferative activity with an GI50 of 48.32 μM, while 
mariline D exhibited no activity. 
 
Marilines A-C were shown to have antiplasmodial activity against Plasmodium berghei 
with an IC50 of 6.68 μM, 11.61 μM and 13.84 μM, respectively.  
Marilines C and D showed also antagonist activity on the canabinoid receptor CB2 with 
Ki values of 5.97 μM and 5.94 μM, respectively.  
Mariline B further exhibited antagonist activity against the histamine receptor H2 with a 
Ki value of 5.92 μM, the dopamine receptor DAT with a Ki value of 5.63 μM and the 
adrenergic receptor Beta3 with a Ki value of 5.63 μM (see Appendix - Bioactivity 
results).  
 
Mariline A and B were further evaluated for inhibition of the protein kinases DYRK1A 
and CDK5 assays (tested at 10 mM dose) and for the inhibition of further proteases: 
Chymotrypsin, trypsin, papain and acetylcholine esterase (tested at the 100 µM level), 
but showed no activity. 
Mariline B (2) was tested against two antibiotic resistant Mycobacterium tuberculosis, 
strains MTB72 and R46 (tested at the 50 µg/mL disc level), but did not show relevant 
activity. 
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Discussion 
 
Compounds with a related phthalimidine (isoindolinone) nucleus as found for 1 – 4 are 
known from fungal metabolism, however they all lack the methyl group at C-8. The 
structurally most simple phthalimidines possess an unsubstituted nitrogen atom as found 
in mariline D (4), i.e. 6-hydroxy-4-methoxy-5-methylphthalimidine (cichorine) 
(Kawahara et al., 1988; Stierle et al., 1993), zinnimidine (Suemitsu et al, 1995), 
duricaulic acid (Achenbach et al., 1985), memnobotrin A and the related 
staybotrylactam (Jarvis et al., 1999) and the more complex xylactam (Wang et al, 2005). 
Reported N-substituted phthalimidines include compounds with a phenylethyl 
(Kawagishi et al., 1990; Nozawa et al., 1997), ethyl-1-ol (Horiuchi et al., 2003; 
Horiuchi et al., 2002) or a carbonic acid (Ogawa et al, 1995, Matsumoto et al., 1995) 
moiety attached. Of these, examples of fungal phthalimidines structurally related to 
marilines A and B (1, 2) include hericenone B and stachybotrin C (Kawagishi et al., 
1990; Nozawa et al., 1997), both with a phenylethyl moiety connected to the nitrogen 
atom. In compounds 1 and 2, however the nitrogen is substituted with a derivatised 
phenyl ring, hitherto only present in a similar way in the phthalimidine structure 
clitocybin A (Kim et al, 2008). Porritoxin, porritoxin sulfonic acid (Horiuchi et al., 
2003; Horiuchi et al., 2002), memnobotrin B (Jarvis et al., 1999) and stachybotramide 
(Ayer et al., 1993) contain an N-ethyl-1-ol moiety and are structurally related to 
mariline C (3) (all related structures are depicted in see Appendix – Spectroscopic data 
supporting information) 
 
Racemization 
 
8R and 8S enantiomers of phthalimidines are described for pestalachloride A, where a 
2,4-dichloro-5-methoxy-3-methylphenol moiety is attached to the chiral carbon C-8 (Li 
et al., 2008). Also, the isobenzofuranone isopestacin was found to occur as a racemic 
mixture (3R/3S), with diverging configuration at the carbon neighbouring the lactone 
functional group (Strobel, et al., 2002). A similar case is the dihydro isobenzofuran 
derivative pestacin, which occurs as a racemic mixture of 1R and 1S enantiomers, 
whereby the chiral carbon C-1 is in -position to the oxygen in the dihydrofuran ring 
(Harper et al., 2003). Racemization in the case of pestalachloride A, isopestacin and 
pestacin was proposed to occur after biosynthesis via resonance stabilized cationic 
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intermediates. Based on structural considerations a similar mechanism may be feasible 
for 1 and 2, however less favoured since the substituent at C-8 is a methyl group 
whereas in pestalachloride A (and in a similar fashion in isopestacin and pestacin) an 
aromatic moiety is located at the respective position. Since racemization does not occur 
when marilines A or B are exposed to different reaction conditions, it may be concluded 
that both enantiomers are products of the biosynthetic process and not of post-
biosynthetic racemization reactions. 
 
Hypothesis on Biosynthesis 
Phthalimidine nucleus/Carbon skeleton/Origin of nitrogen: 
 
Compounds 1-4 are phthalimidine derivatives and related to their oxygen-containing 
counterparts named phthalides, which are more common in nature (Lin et al., 2005). 
Biosynthetic studies focusing on phthalide structures, e.g. for mycophenolic acid 
(Bedford et al., 1973) or for phthalide-like metabolites isolated from Talaromyces 
flavus (Ayer and Racok, 1990) were previously performed by means of feeding 
experiments with labeled precursors, evidencing the tetraketide nature of the phthalide 
nucleus. Compounds 1-4, possess the basic skeleton of the tetraketide 3-methyl-
orsellinic acid, however the acetate-derived methyl group in orsellinic acid would be 
replaced by an ethyl group in the precursor molecules of 1-4 (Geris and Simpson, 2009) 
(Figure 3). To our knowledge no biosynthetic studies were performed for phthalimidine-
like molecules. Phthalimidine biosynthesis, however most probably involves similar 
polyketide-type reactions as known for phthalides. 
The most unusual structural characteristic of the phthalimidine derivatives 1-4 is the 
methyl substituent at C-8. The latter seems to require either, a propionate starter unit 
(see A in Figure 3) or a methylation (e.g. via a SAM-dependent methyl-transferase) at 
C-8 (see B in Figure 3). A third possibility would be the loss of a carbon atom from a 
pentaketide intermediate (not depicted in Figure 3). To our knowledge to date, these 
types of reaction are not known in fungal polyketide metabolism. 
 
Methylation (see B in Figure 3) would occur most probably at the acetate starter unit, 
because the methylene carbons in the poly-ß-keto acid would be more prone as the site 
of attack for a SAM-dependent methyl-transferase than the terminal methyl group of the 
starter unit (see B in Figure 3). A somewhat similar case represents the myxobacterial 
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metabolite myxovirescin A, isolated from Myxococcus xanthus, where methylation of 
the starter unit was also found. In this case feeding studies and the overall organization 
of the myxovirescin A gene cluster suggested that the biosynthesis of this compound 
takes place firstly by fusion of an acetate unit with a malonate, followed by methylation, 
reduction and hydroxylation to produce the starter unit 2-hydroxyvalerianic acid 
(Simunovic et al., 2006). For the cyanobacterial compound homoanatoxin-a, the 
incorporation of a SAM-mediated methyl group is suggested to occur in a similar 
fashion (Namikoshi et al. 2004). 
Incorporation of an intact propionate starter unit (see A in Figure 3) has been reported 
for a number of bacterial metabolites, e.g. anthracycline antibiotics such as aclarubicin, 
or doxorubicin (Fujii and Ebizuka, 1997). Umezawa et al. showed that the common 
anthracycline intermediate aklavinone, a metabolite isolated from S. galilaeus, is 
derived from propionyl-CoA and nine malonyl-CoA extender units (Yoshimoto et al., 
1981). The best-studied use of a propionate as starter is for daunorubicin from S. 
peucitus and its C14-hydroxylated derivative doxorubicin from S. coeruleorubicus, 
which are among the most important antitumor antibiotics in current use (Hutchinson, 
1997; Grim et al., 1994). With regard to the biosynthetic origin of propionyl-CoA, it is 
proposed that the primer is derived from multiple sources such as amino acid catabolism 
and degradation of odd-numbered fatty acids, but decarboxylation of methylmalonyl-
CoA appears to be less likely (Weissman et al., 1998). 
It appears that the type of reactions probably involved in the formation of marilines, to 
date was only found in bacteria. Hence, these data open up interesting questions on why 
biosynthetic steps reported for bacteria are encountered in fungal metabolism. 
Preliminary studies in our laboratory indicate the presence of bacteria associated with 
the mycelium of the investigated fungus (data not shown). 
 
The origin of the nitrogen atom of the lactam ring in phthalimidines is probably derived 
from amino acid metabolism. Based on the structural characteristics in several 
phthalimidines this seems quite obvious, e.g. staplabin analogues containing serine, 
phenylalanine, leucine or tryptophan partial structures (Geris and Simpson, 2009). 
Similarly, the nitrogen precursor of hericenone B and stachybotrin C (Kawagishi et al., 
1990; Nozawa et al., 1997) with a phenylethyl moiety connected to the nitrogen atom, is 
probably phenylalanine or tyrosine. 
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For marilines A and B (1, 2) it seems likely that 4-hydroxyaniline, produced via 
chorismic acid and p-amino-benzoic-acid (Sasaoka et al., 1980; Tsuji et al., 1981; Tsuji 
et al., 1985a; Tsuji et al., 1985b;) (Figure 2 and ppendix – Spectroscopic data 
supporting information) may be the precursor for the C-12 to C-17 comprising aromatic 
ring and the nitrogen atom. Incorporation studies of chorismic acid and 4-amonobenzoic 
acid into the 4-hydroxyaniline moiety of N-(-glutamyl)-4-hydroxyaniline in Agaricus 
bisporus supports the formation of aniline derivatives in fungi (Tsuji et al., 1985a; Tsuji 
et al., 1985b). Furthermore, several dihydroxyaniline derivatives are known to be 
produced in fungal metabolism, e.g. 4-hydroxy-2-methoxyacetanilide isolated from a 
spruce fungal endophyte and Aspergillus sp. (Findlay et al., 2003) (see depicted 
structures in Appendix - Spectroscopic data supporting information). Regarding 
mariline C (3), the N atom may originate from ethylamine (see Figure 3), previously 
reported to be biosynthetically derived through decarboxylation of alanine (Takeo, 
1974; Deng et al., 2008). For mariline D (4), glutamine, glutamate or ammonia may 
introduce the nitrogen atom. 
 
The carbon skeleton of marilines A and B could be considered unprecedented, due to 
the existence of the unique extra-methyl group at C-8 amongst all known 
phthalides/phthalimidines. Feeding experiments are under way in order to determine the 
building blocks for these most unusual molecules. 
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Figure 3. Proposed biosynthetic pathways for Mariline A – D. 
 
It is worthwhile to mention that marilines were produced solely on solid biomalt 
medium supplemented with sea salt, whereas in other media such as Czapek or YPM no 
phthalimidines were formed. In all four individual culture experiments on biomalt 
medium supplemented with sea salt, marilines A and B were isolated, whilst marilines 
C and D were separated only once and in low amounts. The fungus was also not able to 
grow on biomalt without a sea salt supplement. 
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Bioactivity 
 
The most interesting activity obtained from the multitude of bioactivity tests was found 
towards human leukocyte elastase (HLE). This serine protease that has been associated 
with several pathological conditions including cystic fibrosis, rheumatoid arthritis and 
infectious diseases (Bieth et al., 1998) HLE is further considered to be the primary 
source of tissue damage associated with such inflammatory diseases as pulmonary 
emphysema and adult respiratory distress syndrome (Vender, 1996; Chua and Laurent, 
2006; Pham, 2006; Taggart et al., 2005). Small molecular weight HLE inhibitors could 
be therapeutically useful in the treatment of such diseases, and a number of inhibitors 
are currently in development (Esper and Martin, 2005; Abbenante and Fairlie, 2005). 
 
Experimental section 
General Experimental Procedures. See chapter 3 - General methodology. Specifically 
for marilines A-B, to separate enantiomeric mixtures the HPLC column Lux Cellulose-1 
from Phenomenex (250 x 4.5 mm; 5 µm) was used with a flow rate of 1 mL/min 
(hexane : isopropanol 90:10). The 1H-15N HMBC spectrum was referenced externally to 
urea (15N chemical shift is reported relative to liquid ammonia). 
 
Fungal material. See chapter 3 - General methodology. 
 
Culture, extraction and isolation. Compounds 1 to 4 were isolated from two different 
cultures of Stachylidium sp., a first with 12 L and a second with 10 L media volume. 
Both were performed on an agar-biomalt medium (biomalt 20g/L, 15 g/L agar) 
supplemented with sea salt during 2 months (12 L culture) and 40 days (10 L culture). 
An extraction with 5 L EtOAc yielded 5.9 g and 2.1 g of extract, respectively, which 
were subjected to VLC fractionation in a silica open column using a gradient solvent 
system with petroleum ether - acetone at 10:1, 5:1, 2:1, 1:1, 100 % acetone and 100 % 
MeOH, resulting thus 6 VLC fractions for each culture. Compounds 1 and 2 were 
isolated from both cultures, being hereby described the 12 L culture isolation 
procedures. Compound 4 was isolated from the first culture (12 L), whilst compound 3 
was isolated from the second culture (10 L). 
Compounds 1 and 2 were isolated from VLC 2, followed by HPLC fractionation using 
petroleum ether - acetone 11:1 (fraction 2 of 7) and RP-HPLC fractionation using 90 % 
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MeOH (fraction 3 of 4, 12.6 mg, tR 31 min). The racemic mixture was then separated 
using a Phenomenex Lux Cellulose-1 HPLC column using hexane : isopropanol 90:10 
(Mariline A, 7.2 mg, tR 21 min; Mariline B, 4.8 mg, tR 29 min). 
Compound 3 was isolated from VLC 4, followed by HPLC fractionation using 
petroleum ether - acetone 9:2 (fraction 5 of 7, 2.6 mg, tR 48 min) 
Compound 4 was isolated from VLC 4, followed by HPLC fractionation using 
petroleum ether - acetone 2:1 (fraction 4 of 7), followed by RP-HPLC with an 
Macherey-Nagel Ísis column using 30 % MeOH (fraction 2 of 3, 1.4 mg, tR 7 min). 
 
Mariline A (1): colorless oil (600 µg/L 0.12 %); [α] D23 +14 (c 0.225, acetone); UV 
(MeOH) λmax 219 nm (log Є 4.11), 268 (log Є 3.73); IR (ATR) νmax 3330 (br), 2925, 
1668, 1605 cm-1; 1H NMR and 13C NMR (Tables 1 and 2); LREIMS m/z 533.3 (M)+; 
HREIMS calcd. m/z 533.3141 for C33H43NO5 (M)+, found 533.3139; CD (c 2.8 × 10–4  
mol/L, MeOH) λ (ε) = 202 (-9.0), 218 (+12.4), 248 (+6.1), 298 (-3.2). 
 
Mariline B (2): colorless oil (400 µg/L, 0.08 %); [α] D23 -14 (c 0.175, acetone); UV 
(MeOH) λmax 219 nm (log Є 4.1), 268 (log Є 3.7); IR (ATR) νmax 3330 (br), 2925, 1668, 
1605 cm-1; 1H NMR and 13C NMR (Tables 1 and 2); LREIMS m/z 533.3 (M)+; 
HREIMS calcd. m/z 533.3141 for C33H43NO5 (M)+, found 533.3139; CD (c 3.1 × 10–4  
mol/L, MeOH) λ (ε) = 202 (+15.8), 218 (-12.2), 248 (-5.2), 293 (+4.3). 
 
Mariline C (3): white amorphous solid (260 µg/L, 0.124 %); UV (MeOH) λmax 207 nm 
(log Є 4.46), 262 nm (log Є 3.95); IR (ATR) νmax 3391 (br), 2926, 1664, 1607 cm-1; 1H 
NMR and 13C NMR (Tables 1 and 2); LRESIMS m/z 388.5 (M+H)+; HRESIMS calcd. 
m/z 410.2302 for C23H33NO4Na (M+Na)+, found 410.2290; no CD spectra revealed the 
presence of a racemic mixture. 
 
Mariline D (4): amorphous solid (108 µg/L, 0.022 %); UV (MeOH) λmax 216 nm (log Є 
3.90), 259 nm (log Є 3.71); IR (ATR) νmax 3346 (br), 2926, 1670, 1610 cm-1; 1H NMR 
and 13C NMR (Tables 1 and 2); LRESIMS m/z 206.0 (M-H)-, m/z 207.9 (M+H)+; 
HRESIMS calcd. m/z 230.0788 for C11H13NO3Na (M+Na)+, found 230.0786; no CD 
spectra revealed the presence of a racemic mixture. 
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Racemization experiments. Racemization experiments were based on literature data 
(Stuck et al., 2003)., where racemization of a phthalimidine nucleus was achieved with 
very low acidic/alkaline concentrations (0.0005 M KOH). Each experiment contained 
200 µg of mariline A dried on a stream of N2 in a glass vial which was suspended in 400 
µL solution with the following conditions: a) water, b) 0.0005 M KOH, c) 0.0025 M 
KOH, d) 0.5 M KOH, e) 0.0005 N HCl, d) 0.5 N HCl. 200 µg mariline B were also 
tested at the range of 0.5 N KOH. All samples were then incubated in a water bath at 55 
ºC for 2 hours, after which they were neutralized with the same molar proportion of 
acid/alkaline solution. After drying the sample in gaseous nitrogen the samples were 
injected in a HPLC chiral phase column with the same solvent system used to separate 
the enantiomers marilines A and B for detection of racemization (see General 
Experimental Procedures). 
 
Biological activity assays. See chapter 3 - General methodology. 
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5.   Marilones A – J, Unusual Phthalides from the Sponge-derived 
Fungus Stachylidium sp. 
 
 
 
Abstract 
The marine-derived fungus Stachylidium sp. was isolated from the sponge Callyspongia 
sp. cf. C. flammea. Culture on a biomalt medium supplemented with sea salt led to the 
isolation of eight new phthalide derivatives with unusual structural motives, i.e. 
marilones A – J (1-8, 10, 11), and the known compound silvaticol (9). In the epimeric 
compounds 10 and 11 the phthalide (=isobenzofuranone) nucleus is modified to an 
isobenzofuran ring with ketal and acetal functionality. The skeleton of marilones A, B, 
D and F-J is most unusual, and its biosynthesis is suggested to require unusual 
biochemical reactions considering fungal secondary metabolism. Marilone A (1) was 
found to have antiplasmodial activity against Plasmodium berghei with an IC50 of 12.1 
µM. Marilone B (2) showed selective antagonistic activity towards the serotonin 
receptor 5HT2B with a Ki value of 7.7 µM. 
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Figure 1. Secondary metabolites 1 – 11 isolated from Stachylidium sp. 
 
 
 
   38
Introduction 
 
Phthalides are a class of structurally most diverse secondary metabolites with more than 
180 naturally occurring compounds described (Lin et al., 2005). They are produced by a 
wide range of organisms, i.e. marine and terrestrial fungi belonging to genera such as 
Aschochyta (Seibert et al., 2006), Aspergillus (Fujita et al., 1984; Achenbach et al., 
1985), Alternaria (Suemitsu et al., 1995; Kawahara et al., 1988), Penicillium (Smith, 
1952), Hericium (Kawagishi et al., 1990) or Talaromyces (Ayer and Racok, 1990), but 
also by plants and liverworts (Lin et al., 2005). 
Phthalides exhibit an equally broad spectrum of bioactivity, including modulation of the 
central nervous system, protection against brain eschemia, modulation of platelet 
aggregation and cardiac function, inhibition of smooth muscle cell proliferation, anti-
angina activity, smooth muscle relaxation, as well as antibacterial, antifungal, antiviral 
and phytotoxic activity (Lin et al., 2005). The medically most important member of this 
family of natural products is mycophenolic acid, firstly isolated from Penicillium 
brevicompactum, and used in form of its derivative mycophenolate mofetil as an 
immunosupressant drug (Dewick, 2009). 
 
During our search for new natural products produced from the marine-derived fungus 
Stachylidium sp., several structurally unusual phthalide derivatives, i.e. marilones A - J, 
were isolated from a culture on agar-BMS media supplemented with artificial sea salt 
(Scheme 1). Albeit phthalide-like structures are not rare, the structural skeleton of 
marilones A, B, D, F - J is most unusual, and its biosynthesis is suggested to require 
unique reactions in fungal secondary metabolism. Marilone A (1) exhibited 
antiplasmodial activity against Plasmodium berghei with an IC50 of 12.1 µM. Marilone 
B (2) showed a specific antagonistic effect on the serotonin receptor 5HT2B with a Ki 
value of 7.7 µM.  
 
 
Results 
 
The molecular formula of 1, was deduced by accurate mass measurement (HREIMS) to 
be C21H28O4, requiring eight degrees of unsaturation. The 13C NMR and DEPT135 
spectra contained 21 carbon resonances, including six resulting from methyl groups, 
   39
three from sp2 methines, one from a sp3 methine, whereas further three signals resulted 
from methylene groups and eight resonances were assigned to quaternary carbons 
(Tables 1, 2 and Appendix – Complete 2D NMR data). The 1H NMR spectrum of 1 
displayed a singlet resonance for the aromatic methine (6-CH) at δ 6.95 indicating 
together with UV and 13C NMR data the presence of a penta-substituted benzene ring. 
The methyl group 10-CH3 (δC 8.8) was linked to C-4 of the aromatic ring due to 
heteronuclear long range correlations of the methyl protons with C-3, C-4 and C-5. The 
methoxyl group 9-OCH3 (δH 3.98) had a heteronuclear long range correlation to C-3 of 
the aromatic ring, thus clearly delineating it’s position. Besides the aromatic proton 6-H, 
the 1H NMR spectrum showed two further resonance signals in the downfield shifted 
region (δH 5.52 and 5.09) indicating together with 13C NMR and 1H-13C HMBC data the 
presence of a geranyl substituent. The C-1’ to C-10’ part of the molecule was deduced 
from two proton coupling spin systems observed in the 1H-1H COSY spectrum, namely 
1’-H2 to 2’-H (J = 6.6 Hz) and 4’-H2 to 6’-H through 5’-H2. 1H-13C HMBC data showed 
correlations from 9’-H3 to C-2’, C-3’ and C-4’, and from methyl protons 8’-H3 and 10’-
H3 to C-6’and C-7’, disclosing a geranyl fragment. Based on literature comparisons we 
established the configuration of 2’/3’ as E (Tanaka et al., 1985). The aromatic 
quaternary carbon C-5 (δC 164.2) had a carbon resonance indicating a connection to an 
oxygen atom. The monoterpenyl substituent was established to be connected to C-5 
through an oxygen atom due to heteronuclear long range correlations of 1’-H2 (δH 4.69, 
4.74) to C-5. 
The 1H-13C HMBC spectrum exhibited a correlation from 6-H to C-8. Furthermore, the 
13C NMR resonance of C-8 at δ 77.0 was found to be characteristic for a carbon bound 
to an oxygen atom. The 1H-1H COSY spectrum showed a coupling of 8-H with 11-H3 (J 
= 6.6 Hz), and the 1H-13C HMBC spectrum contained correlations from 8-H to C-6, C-7 
and C-2 of the penta-substituted aromatic ring, as well as to the carbonyl carbon C-1. 
Ring double bond equivalents required a second ring within compound 1, and together 
with heteronuclear correlations of 8-H to C-1 and the carbon resonance of C-1 at δC 
168.2 indicating the presence of a carbonyl group, gave evidence for a C-8-methylated 
phthalide skeleton, i.e. the C-1 to C-11 part of the structure. Since the resonance signal 
for 6-H did not show heteronuclear long range correlations to that of the carbonyl C-1, 
but correlated with the sp3 methine C-8, the carbonyl group was assigned at C-1. This 
way, a phthalide-nucleus identical to that of the known natural product nidulol was 
formed.[6] To further prove that the carbonyl group is positioned at C-1 and not at C-8 of 
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1, 1H NMR spectra of 1 were compared with those of nidulol, silvaticol (9) and 
derivatives (see Appendix – Spectroscopic data supporting information). The latter are 
known regioisomeric phthalides with the carbonyl group at C-1 and C-8, respectively. 
Differences in 1H NMR resonances can be discerned especially for 6-H, resonating at δH 
6.59 (CDCl3) for nidulol and δH 7.04 (CDCl3) for silvaticol (Kawahara et al., 1988). The 
1H NMR spectrum of 1 (δH 6.54 in CDCl3) was shown to be similar to that of nidulol 
and the nidulol derivative, 5-(3',3'-dimethylallyloxy-7-methoxy-6-methylphthalide with 
6-H resonating at δH 6.62 (see Appendix – Spectroscopic data supporting information 
and Suemitsu et al., 1995). For compound 1 the trivial name marilone A is suggested.  
 
The molecular formula of 2 was deduced by accurate mass measurement (HREIMS) to 
be C11H12O4, requiring six sites of unsaturation. The NMR spectral data (see Tables 1, 2 
and Appendix – Complete 2D NMR data) indicated that compound 2 is identical to 1, 
except for the missing geranyl moiety attached to the hydroxy group at C-5. We propose 
the trivial name marilone B for compound 2. 
 
The molecular formula of 3, was deduced by accurate mass measurement (HREIMS) to 
be C20H26O4, requiring eight degrees of unsaturation. The spectroscopic data of 3 
revealed that the compound is very similar to 1 (Tables 1, 2 and Appendix – complete 
2D NMR data). In contrast to compound 1, however, resonance signals for a methylene 
group, i.e. 1-CH2 (δC 68.9) were found in the NMR spectra, instead of those for a 
methine (8-CH) and methyl group (11-CH3) as in 1. The resonance signal for 6-H did 
not have a heteronuclear long range correlations to C-1, but correlated with the carbonyl 
carbon C-8. Hence, the carbonyl group in 3 was assigned to be located at C-8, thus, 
forming a phthalide-nucleus as present in silvaticol (9). For compound 3, the name 
marilone C is suggested. 
 
The molecular formula of 4, was deduced by accurate mass measurement (HRESIMS) 
to be C12H18O4, requiring four sites of unsaturation. The NMR spectroscopic data 
(Tables 4, 5 and Appendix – complete 2D NMR data) indicated again a penta-
substituted benzene ring identical to that in 1-3. A 1H NMR coupling from the methine 
8-H to 12-H3 (J = 6.3 Hz) was discerned in the 1H NMR spectrum, whereas C-8 had a 
carbon shift (δC 65.9) characteristic for oxygen substitution. The methoxyl function 11-
OCH3 was connected to the methylene 1-CH2 as deduced from heteronuclear long range 
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correlations of the methoxyl protons to C-1. Compound 4 is thus a monocyclic 
compound, for which we propose the trivial name marilone D. 
 
The molecular formula of 5, was deduced by accurate mass measurement (HRESIMS) 
to be C11H16O4, requiring four sites of unsaturation. The structure of 5 was found to be 
almost identical to that of 4 (Tables 4 and 5 and Appendix – complete 2D NMR data). 
The only difference between them was discerned to be the substitution of C-8. In case of 
compound 4 this carbon was substituted with the methyl group (12-CH3), whereas in 
compound 5 C-8 was an oxygenated methylene group. Consequently, the 1H NMR 
spectrum of 5 exhibited a singlet resonance for a methylene group at δH 4.64. We 
propose the trivial name marilone E for compound 5. 
 
The molecular formula of 6 was deduced by accurate mass measurement (HRESIMS) to 
be C18H28O4, requiring five sites of unsaturation. The 13C NMR and DEPT135 spectra 
indicate the presence of 18 resonances, including five for methyl, four sp3 methylene, 
one sp2 methine, two sp3 methine groups and six for quaternary carbons (see Table 3). 
Compound 6 has the close to identical penta-substituted aromatic ring as found for 1-5 
(notice: carbons/hydrogens have different number assignment), as proven by 1H-13C 
HMBC correlations from 12-H to C-8, C-10, C-11, C-13 and C-14. The methyl group 
15-CH3 was attached to the sp3 methylene 14-CH2, completing the substituent at C-13. 
Based on 1H-13C HMBC and 1H-1H COSY correlations we found that the aromatic 
substituent at C-8 was an aliphatic chain giving rise to two 1H-1H spin systems, 
interrupted by a ketone functionality (C-5, δC 214.8). The 1H-1H COSY spectrum 
revealed a spin system ranging from 1-H3 to 4-H2, including the hydroxylated 3-H (δH 
3.85), and from 6-H to 16-H3 and 7-H2. 4-H2, 6-H, 16-H3 and 7-H2 displayed 
heteronuclear long range correlations to the ketone carbon C-5 and thus connected the 
partial structures that were deduced from 1H coupling data. Heteronuclear long range 
correlations also cleared the connection of 7-CH2 to C-8 of the aromatic ring. For 
compound 6 the name marilone F is suggested. 
 
The molecular formula of 7 was deduced by accurate mass measurement (HRESIMS) to 
be C11H12O4, requiring six sites of unsaturation. Spectroscopic data clearly suggested, 
that compound 7 shares the penta-substituted aromatic ring with compounds 1-6. The 
sp3 methine 1-CH displayed a 13C NMR resonance signal typical for a carbon bound to 
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oxygen (δC 67.1) and showed 1H-1H coupling with 9-H2 (J = 6.5 and 1.6 Hz). 1-H had 
heteronuclear long range correlations with C-2, C-3 and C-7 of the aromatic ring, 
suggesting that it is connected to C-2 of the aromatic moiety. All of the protons, 1-H, 6-
H and 9-H2 had heteronuclear long range couplings to a carbonyl carbon (C-8, δC 
206.4), which is thus connected to C-7 of the aromatic ring. Thus, in 7 the second ring is 
not heterocyclic, and cyclisation during biosynthesis probably involved the C-11 methyl 
carbon of 1 to give the methylene group 9-CH2 in 7. For compound 7 the name marilone 
G is suggested. 
 
The molecular formula of 8 was deduced by accurate mass measurement (HREIMS) to 
be C8H10O3, requiring four sites of unsaturation. The 13C NMR and DEPT135 spectra 
included eight resonances, i.e. two for methyl, one for a sp2 methine, and one further 
resonance for a sp3 methylene group. Further four resonances were due to quaternary 
carbons, which thus made up half of the carbons encountered in the molecule (see 
compound spectroscopic data). The methyl protons 7-H3 coupled with 6-H2 (J = 7.5 Hz) 
as evident from 1H NMR data, and both had heteronuclear long range correlations with 
C-5, the latter being a quaternary carbon connected to oxygen (δC 164.9). The methyl 
group 8-CH3 had heteronuclear long range correlations with C-1, C-2 and C-3, and was 
assigned at C-2 (δC 98.2). C-3 was characterized by a downfield shifted carbon 
resonance, which indicated it to be connected to oxygen (δC 165.6). The HMBC 
correlations of 4-H and 8-H3 to C-3 placed this hydroxylated quaternary carbon between 
C-2 and C-4. The quaternary carbon C-1 (δC 166.0) was identified as being part of a 
carboxylic functionality, also evidenced by an IR absorption at 1645 cm-1. 
Consideration of the molecular formula required compound 8 to be monocyclic. Thus, 
C-1 was connected to C-5 through an oxygen atom forming a six-membered lactone 
ring. We propose the trivial name marilone H for compound 8, which is already 
described as a synthetic compound (Suzuki et al., 1973).  
 
Spectroscopic data of 9 were determined to be identical to those of silvaticol (see 
Appendix – Spectroscopic data supporting information and Kawahara et al., 1988). 
 
The molecular formulae of 10 and 11 were deduced by accurate mass measurement 
(HREIMS) and found to be identical, i.e. C23H34O5, requiring seven degrees of 
unsaturation. The 13C NMR and DEPT135 spectra contained 23 carbon resonances, 
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including eight resulting from methyl, three from sp2 methines, one from a sp3 methine 
and three from methylene groups, whereas eight resonances were assigned to quaternary 
carbons. 1D and 2D NMR spectroscopic data of both compounds revealed that the 
penta-substituted aromatic ring and the substituents at C-3, C-4 and C-5 were identical 
to those in 1 and 3 (Tables 1, 2 andAppendix – Complete 2D NMR data). 
Compounds 10 and 11 have the same planar structure, but differ in stereochemistry. For 
clarity in the description of the structure elucidation, only the spectroscopic data of 10 
will be described initially. The NMR spectra revealed signals for three methoxyl groups 
9-OCH3, 12-OCH3 and 13-OCH3 (δC at 59.8, 49.7 and 54.2, respectively). 
Heteronuclear long range correlations from 12-H3 and 13-H3 to C-8 and C-1, 
respectively allowed to locate the methoxyl moieties at the respective carbons. The 
carbons C-1 (δC at 105.4) and C-8 (δC at 111.4) displayed strongly downfield shifted 
resonances for sp3 carbons, indicating that both of them were connected to two oxygen 
atoms. 
The methine proton 1-H, had heteronuclear long range correlations to C-3, C-7 and C-8, 
making the presence of a furan ring with a ketal and an acetale functionality most likely. 
HMBC couplings from 11-H3 with C-7 and C-8 connected this methyl group to C-8. 
Differences between 10 and 11 were established to be related to the configuration at C-
8. This was evident from different NOE interactions. Namely, in 10 the protons of the 
methyl group 11-CH3 had a NOE correlation with 13-OCH3, whilst 12-OCH3 at C-8 had 
a NOE correlation with 1-H. In 11 the NOE correlations were the opposite, i.e. 11-CH3 
correlates with 1-H and 13-OCH3 correlates with 12-OCH3 (see Figure 2).  
Initially, it seemed likely, that compounds 10 and 11 are artifacts of compound 1, 
probably produced during extraction and isolation by methanolysis. However, heating 
of compound 1 for two hours at 50 ºC in methanol did not produce 10 and 11. For 
compounds 10 and 11 the names marilone I and J are suggested, respectively. 
 
 
 
 
 
 
 
Figure 2. Key NOE correlations for compounds 10 and11 
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Table 1. 13C-NMR spectroscopic data for compounds 1, 2, 3, 10 and 11. 
    1   3  10 11   2 
position   δC, mult.a, b   δC, mult.a, b  δC, mult.a, b  δC, mult.a, b  δC, mult.a, b 
1  168.2, qC    68.9, CH2  105.4, CH  104.8, CH   168.2, qC 
2  110.0, qC  128.4, qC  121.4, qC  121.5, qC  109.1, qC 
3  158.0, qC  153.9, qC  154.8, qC  154.9, qC  158.9, qC 
4  120.4, qC  124.8, qC  119.0, qC  119.2, qC  118.8, qC 
5  164.2, qC  159.7, qC  160.4, qC  160.4, qC  163.2, qC 
6  100.8, CH  102.0, CH  100.2, CH  100.2, CH  103.6, CH 
7  154.2, qC  125.8, qC  141.7, qC  141.3, qC  153.9, qC 
8    77.0, CH  171.1, qC  111.4, qC  110.8, qC    76.6, CH 
9    62.1, CH3    59.3, CH3    59.8, CH3    59.8, CH3    62.0, CH3 
10      8.8, CH3      9.8, CH3      9.3, CH3      9.3, CH3      8.6, CH3 
11    20.9, CH3      28.1, CH3    27.8, CH3    21.0, CH3 
12        49.7, CH3    50.5, CH3   
13        54.2, CH3    55.5, CH3   
1'    66.5, CH2    66.4, CH2    66.1, CH2    66.2, CH2   
2'  120.1, CH  120.5, CH  120.8, CH  120.9, CH   
3'  142.1, qC  141.6, qC  141.1, qC  141.1, qC   
4'    40.1, CH2    40.1, CH2    40.1, CH2    40.1, CH2   
5'    26.9, CH2    26.9, CH2    27.0, CH2    27.0, CH2   
6'  124.6, CH  124.6, CH  124.6, CH  124.7, CH   
7'  132.1, qC  132.1, qC  132.0, qC  132.0, qC   
8'    25.8, CH3    25.8, CH3    25.8, CH3    25.8, CH3   
9'    16.7, CH3    16.7, CH3    16.6, CH3    16.7, CH3   
10'     17.7, CH3     17.7, CH3    17.7, CH3    17.7, CH3     
aAcetone-d6 (1, 2, 3, 10, 11), 75.5 MHz. bImplied multiplicities determined by DEPT.  
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Table 2. 1H-NMR spectroscopic data for compounds 1, 2, 3, 10 and 11. 
    1   3  10  11   2 
position   δHa, b (J in Hz)   δHa, b (J in Hz)  δHa, b (J in Hz)  δHa, b (J in Hz)   δHa, b (J in Hz) 
1    5.50, s 6.32, s  6.02, s   
2           
3          
4          
5          
6  6.95, s  7.03, s 6.60, s  6.59, s  6.75, s 
7          
8  5.43, q (6.6)       5.37, q (6.6) 
9  3.98, s  3.96, s 3.90, s  3.89, s  3.98, s 
10  2.09, s  2.15, s 2.07, s  2.06, s  2.10, s 
11  1.54, d (6.6)   1.62, s  1.55, s  1.48, d (6.6) 
12     2.85, s  2.94, s   
13     3.38, s  3.50, s   
1'  a: 4.69, dd (6.6, 12.1) 4.71, d (6.6) 4.64, d (6.6)  4.63, d (6.6)   
  b: 4.74, dd (6.6, 12.1)       
2'  5.52, t (6.6)  5.51, t (6.6) 5.48, t (6.6)  5.48, t (6.6)  
3'          
4'  2.10, m  2.10, m 2.08, m  2.07, m   
5'  2.13, m  2.14, m 2.11, m  2.11, m   
6'  5.09, m  5.10, m 5.11, m  5.10, m   
7'          
8'  1.63, br s  1.63, br s 1.64, br s  1.64, br s   
9'  1.76, br s  1.78, br s 1.75, br s  1.75, br s   
10'   1.58, br s   1.58, br s  1.59, br s  1.58, br s     
aAcetone-d6 (1, 2, 3, 10, 11), 300 MHz. b Assignments are based on extensive 1D and 2D NMR 
experiments (HMBC, HSQC, COSY).  
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Table 3. 1D and 2D NMR spectroscopic data for compound 6 
position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1   10.1, CH3 0.85, t (7.3) 2 2, 3 
2   30.6, CH2 1.35, m 1, 3 1, 3 
3   69.4, CH 3.85, m 2, 4 1 
4   49.5, CH2 a :2.41, dd (4.4, 16.5) 3, 4b 2, 3, 5 
  b: 2.51, m 4a 2, 3, 5 
5 214.8, qC    
6   48.1, CH 2.87, m 7a, 7b, 16 5, 7, 8, 16 
7   29.8, CH2 a: 2.81, m 6, 7b 5, 6, 8, 9, 13, 16 
  b: 2.53, m 6, 7a  5, 6, 8, 9, 13, 16 
8 122.1, qC    
9 159.2, qC    
10 115.6, qC    
11 155.6, qC    
12 111.5, CH 6.51, s  8, 10, 11, 14 
13 141.9, qC    
14   26.3, CH2 2.52, m 15 8, 12, 13, 15 
15   15.8, CH3 1.10, t (7.5) 14 13, 14 
16   15.9, CH3 0.94, d (6.7) 6 5, 6, 7 
17   60.4, CH3 3.65, s  9 
18     9.4, CH3 2.08, s   9, 10, 11 
aAcetone-d6, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. 
e Implied multiplicities determined by DEPT.  
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Table 4. 13C-NMR spectroscopic data for compounds 4 and 5 
    4   5 
position   δC, mult.a, b   δC, mult.a, b 
1    66.1, CH2    66.9, CH2 
2  119.6, qC  120.3, qC 
3  159.3, qC  160.0, qC 
4  116.1, qC  117.5, qC 
5  157.1, qC  157.9, qC 
6  108.5, CH  111.6, CH 
7  147.2, qC  141.4, qC 
8    65.9, CH    62.6, CH2 
9    61.8, CH3    62.2, CH3 
10      9.1, CH3      9.2, CH3 
11    57.8, CH3    58.1, CH3 
12    25.4, CH3   
a Acetone-d6 (4), MeOD (5), 75.5 MHz. bImplied multiplicities determined by DEPT.  
 
 
 
Table 5. 1H-NMR spectroscopic data for compounds 4 and 5 
    4  5 
position   δHa (J in Hz)  δHa (J in Hz) 
1 
  
a: 4.39, d (9.9) 
b: 4.43, d (9.9)  
4.53, s 
 
2     
3     
4     
5     
6  6.91, s  6.77, s 
7     
8  5.06, q (6.3)  4.64, s 
9  3.67, s  3.74, s 
10  2.09, s  2.15, s 
11  3.32, s  3.42, s 
12   1.33, d (6.3)    
aAcetone-d6 (4), MeOD (5), 300 MHz.  
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Stereochemistry 
 
Compounds 1, 2 and 4 possess a single chiral center at C-8. The measurement of the 
specific optical rotation for these compounds yielded values close to zero, and 
furthermore, the CD measurements showed hardly any CD effect for the referred 
compounds. The latter was expected at around 260 nm due to the proximity of the chiral 
center to the chromophoric penta-substituted benzene ring. We thus assumed the 
presence of racemic mixtures for these chiral compounds. Extensive trials to separate 
the enantiomers employing three different HPLC chiral stationary phases were 
performed, but unsuccessful. However, the presence of racemic mixtures was proven for 
the analogous, nitrogen-containing compounds, i.e. pththalimidine derivatives isolated 
from the same fungus (Almeida et al., unpublished data). 
The chiral centre C-1 in compound 7 also seems to be present in R and S configuration, 
since measurements of optical rotation yielded values close to zero.  
 
Biological activity 
 
Marilones A, B and C (1-3) were tested for antiplasmodial activity, and marilone A 
exhibited an IC50 of 12.1 µM against Plasmodium berghei (see Appendix – Bioactivity 
results). Interestingly, marilone C (3) showed no activity at the 25 µM level, indicating 
that the methyl group 11-CH3 and/or the position of the ketone functionality is essential 
for this bioactivity. 
Marilones A, B, C, D (1-4) and I (10) were tested for cytotoxic activity toward three 
cancer cell lines (NCI-H460, MCF7 and SF268). Marilone A and C (1, 3) showed weak 
antiproliferative activity with an average GI50 of 36.7 and 26.6 µM, respectively 
(seeAppendix – Bioactivity results). 
Marilone B (2) and H (8) were assayed in a panel of 44 psychoactive receptors, 
including 11 serotonin receptors, and marilone B showed specific antagonistic effect on 
the serotonin receptor 5HT2B with a Ki value of 7.7 µM. 
Marilones A, B and C were tested in protein kinases (DYRK1A and CDK5) inhibition 
activity assay, inhibition of the viral HIV-1 and HIV-2 induced cytopathogenic effect in 
MT-4 cells, in antibacterial (Escherichia coli, Bacillus megaterium), antifungal 
(Mycotypha microspora, Eurotium rubrum, and Microbotryum violaceum), and 
antialgal (Chlorella fusca) assays at the 50 µg/mL disc level, they were evaluated for 
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inhibition of the following panel of proteases: Chymotrypsin, trypsin, the protease 
elastase HLE, papain, porcine cease and acetylcholine esterase (tested at the 100 µM 
level) but exhibited no activity in any of these tests.  
Marilones A and C were also evaluated against 3-T3-L1 murine adipocytes assay and 
exhibited no activity. 
Marilones A and B were evaluated against three sub-types of Influenza A virus (H1N1, 
H5N1 and H3N2), Influenza B virus (Flu B) and exhibited no activity. 
Marilone A was evaluated against the Severe Acute Respiratory Syndrome coronavirus 
(SARS) and Hepatitis B virus but did not show any activity. 
Marilone B was evaluated against the Herpes Simplex Virus-2 (HSV-2) and the 
Respiratory Syncytial virus (RSV) and exhibited no activity. 
Marilones A and D were further tested against two antibiotic resistant Mycobacterium 
tuberculosis strains, MTB72 and R46 (tested at the 50 µg/mL disc level), but did not 
show any relevant activity. 
Marilones C, G and H were tested in a panel of anti-diabetic activity assays: PPAR 
ligand assay, PPAR co-activator assay, PTP-1B inhibitor assay and glucose uptake 
assay (both 3T3-l1 cells and primary rat/mouse adipocytes, tested at the 100 µM dose), 
but did not show any activity. 
Marilones C, G, H and E were tested for the inhibition of the NF-kB protein complex 
assay (at the 100 µM), but did not show any activity. 
 
 
Discussion 
 
Similar molecules and biosynthesis 
Phthalide derivatives are compounds of the polyketide metabolism, which are common 
in nature (Lin et al., 2005). Secondary metabolites 1 and 2 discovered in the marine-
derived Stachylidium sp. were found to be derivatives of the natural product nidulol, 
whilst compound 3 was a derivative of silvaticol (9) (see Appendix – Spectroscopic data 
supporting information), formerly described from the fungus Aspergillus silvaticus 
(Kawahara et al., 1988). Nidulol and silvaticol (9) are regioisomeric compounds and 
differ in terms of the position of the carbonyl group, which either is placed peri to the 
aromatic hydrogen as in 3 and 9, or it is peri positioned to the aromatic methoxyl 
moiety, e.g. in 1 and 2. The here investigated Stachylidium species is thus able to 
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produce both types of phthalides, which are suspected to differ significantly in terms of 
their biosynthesis (Figure 3). 
Whereas compound 3 is simply the O-prenylated form of silvaticol (9), the nidulol 
derivatives 1 and 2 are distinguished by an additional methyl substituent (11-CH3) at C-
8. In terms of biosynthesis, i.e. polyketide metabolism, this substitution is most unusual 
and unique amongst all the known phthalides. The non-phthalide compounds of the 
Stachylydium metabolites, i.e. 4, 6-8, also share this structural characteristic of an 
additional carbon atom (C-12 in 4, C-15 in 6, C-9 in 7, C-7 in 8), which is hard to 
explain by the usual fungal polyketide metabolism. 
 
Biosynthetic studies focusing on phthalide structures, e.g. for mycophenolic acid 
(Bedford et al. 1973), nidulol and silvaticol (Ayer and Racok, 1990), were previously 
performed by means of feeding experiments with labeled precursors, evidencing the 
tetraketide nature of the phthalide nucleus (Figure 2). Compounds 1-7, possess a basic 
skeleton which is related to that of the well known tetraketide 3-methyl-orsellinic acid 
(Geris and Simpson, 2009). Closing of the lactone ring would for compounds 1 and 2 
require the oxidation of C-8 to obtain a hydroxy group, which subsequently could form 
a lactone with the C-1 carboxyl group (Figure 3A). In contrast to that for 3 and 9, a 
reduction of the C-1 carboxyl group to an alcoholic function and an oxidation of C-8 to 
a carboxylic function would be required (Figure 3B). 
 
Most intriguing however is, that in compounds 1, 2, 4, 6 and probably also 7 the acetate-
derived methyl group 8-CH3 in the methyl orsellinic acid precursor would be replaced 
by an ethyl group (Figure 3). Thus, biosynthesis seems to require either, a propionate 
starter unit (see C in Figure 3) or a methylation (e.g. via a SAM-dependent methyl-
transferase) at C-8 (see D in Figure 3). A third possibility would be the loss of a carbon 
atom from a pentaketide intermediate (not depicted in Figure 3). To our knowledge, to 
date these types of reactions are not known in fungal polyketide metabolism. Feeding 
experiments are under way in order to determine the building blocks for these most 
unusual molecules. 
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Figure 3. Tetraketide nature of the phthalides nidulol (A) and silvaticol (B), and 
hypothetical biosynthetic pathways (C, D) for marilones A and B (1, 2). 
 
 
It is worthwhile to mention that marilones were produced solely on solid biomalt 
medium (BMS) supplemented with sea salt, whereas in other media such as Czapek or 
YPM no phthalides were formed.  
 
 
Experimental Section 
General Experimental Procedures. See chapter 3 - General methodology. 
Fungal material. As described in chapter 3 - General methodology. 
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 Cultivation, extraction and isolation. Compounds 1-9 were isolated from a 60 days 
culture (12 L) of Stachylidium sp. on an agar-biomalt medium supplemented with sea 
salt (BMS). An extraction with 5 L EtOAc yielded 5.9 g of extract which was subjected 
to a VLC fractionation in an open column using silica as solid phase and a gradient 
solvent system with petroleum ether - acetone of 10:1, 5:1, 2:1, 1:1, 100 % acetone and 
100 % MeOH, resulting in six VLC fractions. Compounds 10 and 11 were isolated from 
a second 10 L culture on BMS (cultivation time: 60 days), from which 1.0 g extract was 
obtained. 
Compounds 1 and 3 were isolated from VLC fraction 1. VLC fraction 1 was 
fractionated using petroleum ether – acetone 90:1 and 10:1 in order to eliminate fatty 
acid content of the sample. The VLC fraction 10:1 was subjected to NP-HPLC 
fractionation using petroleum ether – acetone 30:1 to yield a mixture of both 
compounds (sub-fraction 4 of 7). Further fractionation using MeOH - H2O 8:2 (RP-
HPLC, Isis column) yielded compound 1 (sub-fraction 1 of 2; 19 mg, tR 13 min) and 
compound 3 (sub-fraction 2 of 2; 14.2 mg, tR 15 min). 
Compounds 2 and 9 were isolated from VLC fraction 2, followed by NP-HPLC 
fractionation using PE-acetone 11:1 to yield a mixture of both compounds (fraction 6 of 
7). Further fractionation using 40 % MeOH / 60 % H2O (RP-HPLC, Isis column) 
yielded compound 2 (fraction 1 of 2; 5.2 mg, tR 35 min) and the know compound 9, 
silvaticol (fraction 2 of 2; 5.6 mg, tR 38 min). 
Compound 4 was isolated from VLC fraction 3, followed by NP-HPLC fractionation 
using petroleum ether - acetone 5:1 (fraction 4 of 10). This sub-fraction was further 
purified using 50 % MeOH / 50 % H2O (RP-HPLC, Isis column; fraction 2 of 4, 4.2 mg, 
tR 10 min). 
Compound 5 was isolated from VLC fraction 3, followed by NP-HPLC fractionation 
using petroleum ether - acetone 5:1 (fraction 7 of 10). This sub-fraction was further 
purified using 50 % MeOH / 50 % H2O (RP-HPLC, Isis column; fraction 2 of 4, 4 mg, 
tR 3 min). 
Compound 6 was isolated from VLC fraction 2, followed by NP-HPLC fractionation 
using petroleum ether - acetone 11:1 (fraction 3 of 7). This sample was further 
fractionated with 90 % MeOH / 10 % H2O (RP-HPLC, Isis column, fraction 2 of 4, 1.5 
mg, tR 15 min) 
Compound 7 was isolated from VLC fraction 3, followed by NP-HPLC fractionation 
using petroleum ether - acetone 5:1 (fraction 9 of 10). This sub-fraction was further 
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purified using 50 % MeOH / 50 % H2O (RP-HPLC, Isis column; fraction 1 of 4). 
Finally we reached purification using 30 % MeOH / 70 % H2O (RP-HPLC, Isis column, 
fraction 6 of 6, 2.5 mg, tR 14 min). 
Compound 8 was isolated from VLC fraction 3, followed by NP-HPLC fractionation 
using petroleum ether - acetone 5:1 (fraction 3 of 10). This sub-fraction was further 
separated using petroleum ether - acetone 13:1 (fraction 3 of 4), which was finally 
purified with 40 % MeOH / 60 % H2O using RP-HPLC (fraction 2 of 2, 5.8 mg, tR 12 
min). 
Compounds 10 and 11 were isolated in a second culture in the same procedures as for 
compounds 1 and 2, except the last RP-HPLC fractionation which was performed with 
85 % MeOH /15 % H2O (compound 10, sub-fraction 1 of 2; 1.6 mg, tR 9 min and 
compound 11, sub-fraction 2 of 2; 1.7 mg, tR 11 min). 
 
In two other cultures of the same fungus in the same medium (2 months; 40 days), only 
marilone A and marilone C were detected (both in quantities lower than 2.5 mg). 
 
Marilone A (1): transparent oil (1.6 mg/L, 0.32 %); UV λmax (MeOH)/nm: 219 (log  
4.38), 261 (log  2.95); IR (ATR) νmax 2964, 1745, 1603 cm-1; 1H NMR and 13C NMR 
(Tables 1 and 2); LREIMS m/z 344.2 (M)+; HREIMS calcd. for C21H28O4 (M)+ m/z 
344.1988, found 344.1996.  
 
Marilone B (2): white amorphous solid (0.4 mg/L, 0.09 %); UV λmax (MeOH)/nm: 215 
(log  4.09), 260 (log  2.83); IR (ATR) νmax 3238 (br), 2931, 1708, 1601 cm-1; 1H 
NMR and 13C NMR (Tables 1 and 2); LREIMS m/z 208.1 (M)+; HREIMS calcd. for 
C11H12O4 (M)+ m/z 208.0736, found 208.0737. 
 
Marilone C (3): transparent oil (1.3 mg/L, 0.27 %); UV λmax (MeOH)/nm: 223 (log  
4.10), 255 (log  2.80); IR (ATR) νmax 2921, 1760, 1619 cm-1; 1H NMR and 13C NMR 
(Tables 1 and 2); LREIMS m/z 330.2 (M)+; HREIMS calcd. for C20H26O4 (M)+ m/z 
330.1831, found 330.1833. 
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Marilone D (4): white amorphous solid (350 µg/L, 0.068 %); UV λmax (MeOH)/nm: 
212 (log  4.04), 226 (log  3.82), 271 (log  3.27); IR (ATR) νmax 3338 (br), 2929, 
1610, 1458, 1414 cm-1; 1H NMR and 13C NMR (Tables 3 and 4); LRESIMS m/z 224.9 
(M-H)-; HRESIMS calcd. for C12H18O4Na (M+Na)+ m/z 249.1097, found 249.1101.  
 
Marilone E (5): white amorphous solid (333 µg/L, 0.068 %); UV λmax (MeOH)/nm: 
210 (log  4.25), 229 (log 3.94), 276 (log  3.18); IR (ATR) νmax 3347 (br), 2929, 
1602, 1457, 1418 cm-1; 1H NMR and 13C NMR (Tables 3 and 4); LRESIMS m/z 211.1 
(M-H)-; HRESIMS calcd. for C11H16O4Na (M+Na)+ m/z 235.0941, found 235.0948.  
 
Marilone F (6): white amorphous solid (125 µg/L, 0.025 %); [α]D23 -33 (c 0.1, MeOH); 
UV λmax (MeOH)/nm: 206 (log  4.14), 275 (log  3.12); IR (ATR) νmax 3361 (br), 2929, 
1702, 1609, 1457, 1407 cm-1; 1H NMR and 13C NMR (Table 5); LRESIMS m/z 307.6 
(M-H)-, m/z 309.5 (M+H)+; HRESIMS calcd. for C18H28O4Na (M+Na)+ m/z 331.1880, 
found 331.1886.  
 
Marilone G (7): white amorphous solid (208 µg/L, 0.042 %); UV λmax (MeOH)/nm: 
220 (log  4.17), 266 (log  3.73); IR (ATR) νmax 3268 (br), 2930, 1697, 1605 cm-1; 1H 
NMR (MeOD): 1-H: δ 5.54, dd (1.6, 6.5); 6-H: δ 6.87, s; 9-Ha: 3.08, dd (6.5, 19.1); 9-
Hb: 2.50, dd (1.6, 19.1); 10-H3: 4.01, s; 11-H3: 2.23, s; 13C NMR (MeOD): CH-1, δ 
67.1; qC-2, δ 139.4; qC-3, δ 158.4; qC-4, δ 128.1; qC-5, δ 159.8; qC-6, δ 103.3; qC-7, δ 
137.2; qC-8, δ 206.4; CH2-9, δ 48.4; CH3-10, δ 61.1; CH3-11, δ 10.0; (2D NMR in 
Appendix – Complete 2D NMR data); LRESIMS m/z 206.9 (M-H)-; HRESIMS calcd. 
for C11H11O4 (M-H)- m/z 207.0652, found 207.0650. 
 
Marilone H, 5-ethyl-3-hydroxy-2-methyl-pyran-1-one (8): amorphous solid (0.483 
ug/L, 0.098 %); UV λmax (MeOH)/nm: 207 (log  4.05), 285 (log  3.69); IR (ATR) νmax 
3330 (br), 2929, 2674, 1645, 1578 cm-1; 1H NMR (acetone-d6): 4-H: δ 6.02, s; 6-H2: δ 
2.42, q (7.5); 7-H3: δ 1.13, t (7.5); 8-H3: δ 1.81, s; 13C NMR (acetone-d6): qC-1, δ 166.0; 
qC-2, δ 98.2; qC-3, δ 165.6; CH-4, δ 99.1; qC-5, 164.9; CH2-6, δ 27.1; CH3-7, δ 11.3; 
CH3-8, δ 8.5; (2D NMR in Appendix – Complete 2D NMR data); LRESIMS m/z 153.1 
(M-H)-, HREIMS calcd. for C8H10O3 (M)+ m/z 154.0630, found 154.0628. 
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Marilone I (10): white amorphous solid (160 µg/L, 0.084 %); UV λmax (MeOH)/nm: 
214 (log  4.09), 272 (log  2.98) IR (ATR) νmax 2930, 1610, 1463 cm-1; 1H NMR and 
13C NMR (Tables 1 and 2); LREIMS m/z 330.2 (M)+; HREIMS calcd. for C23H34O5 
(M)+  m/z 390.2406, found 390.2417. 
 
Marilone J (11): white amorphous solid (170 µg/L, 0.089 %); UV λmax (MeOH)/nm: 
214 (log  4.10), 272 (log  2.98); IR (ATR) νmax 2925, 1610, 1464 cm-1; 1H NMR and 
13C NMR (Tables 1 and 2); HREIMS calcd. for C23H34O5 (M)+ m/z 390.2406, found 
390.2412. 
 
 
Methodology for the performed biological assays.  As described in chapter 3 - 
General methodology. 
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6.  Stachylines A – D from the Sponge-derived Fungus Stachylidium     
sp. 
 
 
 
 
 
 
Abstract 
The marine-derived fungus Stachylidium sp. was isolated from the sponge Callyspongia 
cf. C. flammea. Four new, putatively tyrosine-derived and O-prenylated natural 
products, stachylines A – D (1 – 4), were obtained from the fungal extract. The 
structures of 1 – 4 were elucidated based on extensive spectroscopic analyses. The 
absolute configuration of compound 2 was established by Mosher’s method. Stachyline 
A (1) possesses a rare terminal oxime group and occurs as an interchangeable mixture 
of E/Z- isomers. 
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Figure 1. Structure formulae of Compounds 1 - 4 
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Introduction 
 
The marine environment harbours approximately half of the global biodiversity and is 
estimated to contain between 3 and 500 million different species, offering an almost 
infinite resource for novel compounds (Tziveleka et al., 2003). Among these organisms 
marine-derived fungi became known as prolific producers of structurally most 
intriguing compounds (Bhadury et al., 2006). In general, tyrosine derivatives have only 
rarely been reported from fungi, and in most cases such compounds were obtained from 
strains originating from environmentally extreme habitats, e.g. tyrosol carbamate which 
was isolated from the deep-water fungus Arthrinium sp. (Sashidhara et al., 2009). 
Phytomyces sp., producing O-prenylated tyrosine derivatives, is an extremophile 
collected from an acid mine waste rich in toxic metals (Stierle et al., 2003). Another 
unusual case is aspergillusol A, an α-glucosidase inhibitor obtained from the sponge-
derived fungus Aspergillus aculeatus which is reported to be the only known fungal 
tyrosine derivative to possess an oxime group (Ingavat et al., 2009). 
Secondary metabolites with an oxime substituent are rare, and most of the reported 
examples have potent bioactivity, e.g. the actinomycete-derived nocardicins displayed 
strong antibiotic activity (Hashimoto et al., 1976), and brevioxime from Penicillium 
brevicompactum inhibited the biosynthesis of insect juvenile hormones (Amade et al., 
1993). P. olsonii produced 2-(4-hydroxyphenyl)-2-oxoacetaldehyde oxime (PHBA) 
which regenerated phosphorylated cholinesterase (Moya et al., 1997). The oxime 
geometrical isomers collismycins A and B were isolated from Streptomyces sp. MQ22 
which inhibited dexamethasone glucocorticoid receptor binding (Shindo et al., 1994). 
 
During our search for new cytotoxic natural products an extract of the marine-derived 
fungus Stachylidium sp. was found to be active. During chromatographic separations it 
became clear that this fungus produces a vast array of secondary metabolites with 
intriguing structural features, among them the four novel, putatively tyrosine-derived 
and O-prenylated natural products, stachylines A – D (1 - 4). Stachyline A (1) is 
distinguished by an oxime terminal group, probably derived through biosynthetic 
reactions similar to those known for cyanogenic glycosides and nocardicin A formation 
(Cimino et al., 1975; Isaaki et al., 1993; Bjarnholt and MØller, 2008; Kelly and 
Townsend, 2002; Kelly and Townsend, 2002). The molecules were evaluated in a 
number of biological assays, to date however no considerable activity was detected. 
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Results  
 
The RP-18 HPLC chromatogram of 1 contained two peaks (ratio 1:1), which when re-
injected after their individual isolation, again resulted in the same chromatogram. This 
result suggested that compound 1 exists as a mixture of interchangeable isomers. NMR 
spectra also presented two sets of data, one for each isomer (see Tables 1 and 2). For 
clarity in the description of the structure elucidation, only one set of data will be 
considered initially. 
The molecular formula of 1 was deduced by accurate mass measurement 
(HREIMS/HRESIMS) to be C13H17NO3, requiring six sites of unsaturation. The 13C 
NMR and DEPT135 spectra showed the presence of thirteen resonances for one methyl, 
five sp2 methine, one sp3 methine, one sp2 methylene, two sp3 methylene groups and 
three quaternary carbons (see Tables 1 and 2). The UV maximum at 276 nm indicated 
the presence of an aromatic moiety, whereas an IR absorption at around 3300 cm-1 arose 
from a hydroxy group in the molecule.  
1H NMR and 1H-13C HSQC data (see Tables 1 and 2) included two resonances for 
magnetically equivalent protons, i.e. H-2/H-6 and H-3/H-5 resonating at δH 7.17 and 
6.88, respectively. This spectroscopic feature was interpreted as characteristic for a 
para-substituted aromatic ring. From the same spectra the presence of an exomethylene 
moiety, CH2-4’, was evident (δH 4.89, 5.08; δC 112.1). The 13C NMR spectrum showed 
two resonances for carbons connected to oxygen atoms, namely at δC 72.1 (C-1’) and 
73.9 (C-2’) (see Table 1), and the protons attached to these carbon atoms, H2-1’ and H-
2’ were coupled as evidenced by 1H-1H COSY correlations. 1H-1H COSY correlations 
indicated the presence of another spin system between H2-4’ and H3-5’. The partial 
structures deduced from these two spin systems were connected making use of 1H-13C 
HMBC correlations. Thus, correlations from H3-5’ to C-2’, C-3’ and C-4’ delineated an 
unsaturated and hydroxylated isoprene unit (see Appendix – Complete 2D NMR data). 
This was confirmed by further heteronuclear long range correlations from H2-4’ to C-3’ 
and C-2’. 1H-13C HMBC correlations between H-1’ to qC-4 showed that the isoprene 
unit was connected via C-4 to the para-substituted aromatic moiety. Due to the 
downfield shift of C-1’ and C-4 (δC 72.1, 158.5) connection of both parts of the 
molecule occurred through an oxygen atom.  
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According to the molecular formula, the second substituent on the aromatic ring of 1 
must have the composition C2H4NO. 1H-13C HMBC correlations could be detected from 
the aromatic protons H-2/H-6 to the methylene carbon C-7, making the connection of 
the second side chain via C-1 most likely. Through an 1H-1H COSY experiment, the 
methylene protons CH2-7 were shown to be part of a spin system including H-8 (δH 
6.73), whereby the latter was bound to an sp2 hybridized carbon. The remaining 
presence of a nitrogen, oxygen and proton atom was assigned to an unusual oxime 
moiety (see Tables 1 and 2). The latter is known to be able to adopt interchangeable 
configurations (Tennant et al., 1979). E- and Z- isomers in the case of 1 presented 
clearly distinguishable NMR shifts for the C-8 to C-2/C-6 part of the molecules (see 
Tables 1 and 2). The assignment of NMR shifts for the E- and Z- isomers was supported 
using the ACD NMR predictor software (ACD/Labs®). The configuration at C-2’ of 
compound 2 was found to be S as deduced by Mosher’s method. Based on the negative 
optical rotation of compound 1, which was also observed for 2, and the close 
biosynthetic relationship between both compounds, the S configuration is also proposed 
for C-2’ of 1 (see Figure 2). For compound 1 the trivial name E- and Z-stachyline A is 
proposed. 
The molecular formula of 2 was deduced by accurate mass measurement (HREIMS) to 
be C13H16O4, requiring six sites of unsaturation. The 13C and 1H NMR spectra were 
closely related to those of compound 1 (see Table 2). One of the substituents on the 
aromatic ring was again an O-prenyl moiety as in 1, also connected via qC-4 and C-1’ 
(see Tables 1, 2 and Appendix – complete 2D NMR data). The second substituent on 
the aromatic ring of 2 was however, different and established by interpretation of 1H-13C 
HMBC long range correlations. Thus, the methylene protons H2-7 had a heteronuclear 
coupling with C-2 and C-6 of the aromatic ring. Additionally, H2-7 had HMBC long 
range correlations to the quaternary carbon C-8, which according to its characteristic 
13C NMR resonance was part of a carboxylic acid group (δC 173.0). Compound 2 was 
thus an O-prenylated phenyl acetic acid. 
The absolute configuration at C-2’ was determined by modified Mosher’s method. The 
evaluation of the corresponding 1H-13C HSQC NMR spectra revealed differences of the 
proton shifts between the (S)- and (R)-MTPA esters (see Figure 2 and Appendix – 
complete 2D NMR data). The calculated differences in chemical shifts [δ of protons in 
the (S)-MTPA-ester minus δ of the corresponding protons in the (R)-MTPA-ester] led to 
the assignment of the (S)-absolute configuration for C-2´. Since compounds 1 - 4 all 
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showed a negative specific optical rotation, it was assumed that they all share the (S-) 
configuration at C-2’. Compound 2 is an O-prenylated phenyl acetic acid, for which we 
propose the trivial name stachyline B. 
 
 
 
 
Figure 2. Deduction of the absolute configuration at C-2´ using modified Mosher’s method with ΔS-R 
values of MTPA-esters of compound 2. 
 
The molecular formula of 3 was deduced by accurate mass measurement (HREIMS) to 
be C13H18O3, requiring five sites of unsaturation. 1D and 2D NMR data of 3 were 
closely similar to those of 2 (see Tables 1, 2 and Appendix – Complete 2D NMR data), 
except for the absence of resonances for the carboxylic acid group in the 13C NMR 
spectrum and the presence of an additional resonance for a sp3 methylene group. The 
latter had a downfield shifted 13C NMR resonance (δC 64.1), which evidenced 
connection to an oxygen atom. Thus, 3 can be regarded as the C-8 reduction product of 
2, for which the trivial name stachyline C is suggested. 
The molecular formula of 4 was deduced by accurate mass measurement (HRESIMS) to 
be C13H18O4, requiring five sites of unsaturation. 1D and 2D NMR spectroscopic data of 
compound 4 exhibited many identical features when compared with those of 2 (see 
Tables 1, 2 and Appendix – complete 2D NMR data). A difference, however concerned 
the exo-methylene proton signals which were absent in the 1H NMR spectrum of 4, 
whilst signals for a methyl (H3-4’, δH 0.97) and a methine group were present (H-3’, δH 
1.86). 1H-1H COSY correlations confirmed the structure, since a spin system connected 
all atoms within the isoprene unit from H2-1’ to H3-5’ and H3-4’ (see Table 2 and 
Appendix – complete 2D NMR data). For compound 4 the trivial name stachyline D is 
proposed. 
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Table 1: 13C NMR Spectroscopic Data for Compounds 1 - 4. 
     1*  2  3   4 
position   δC, mult.a, b, c  δC, mult.a, b, c δC, mult.a, b,c δC, mult.a, b, c 
1  130.1, qC  128.0, qC  132.5, qC  127.9, qC 
2  130.5, CH  131.2, CH  130.7, CH  131.2, CH 
3  115.5, CH  115.3, CH  115.2, CH  115.2, CH 
4  (Z-), 158.5, qC (E-), 158.7, qC  158.8, qC  158.3, qC  159.0, qC 
5  115.5, CH  115.3, CH  115.2, CH  115.2, CH 
6  130.5, CH  131.2, CH  130.7, CH  131.2, CH 
7  (Z-), 31.0, CH2 (E-), 35.4, CH2    40.5, CH2    39.4, CH2    40.4, CH2 
8  (Z-), 150.0, CH (E-), 149.7, CH  173.0, qC    64.1, CH2  173.2, qC 
1’    72.1, CH2    72.1, CH2    72.1, CH2    71.6, CH2 
2’    73.9, CH    73.9, CH    74.0, CH    74.6, CH 
3’  146.1, qC  146.1, qC  146.2, qC    31.6, CH 
4’  112.1, CH2  112.1, CH2  112.0, CH2    17.7, CH3 
5’     18.7, CH3    18.8, CH3    18.8, CH3     19.4, CH3 
aacetone-d6,, 75.5 MHz. bAssignments are based on extensive 1D and 2D NMR experiments (HMBC, 
HSQC, COSY, see Appendix – 2D NMR complete data). c Implied multiplicities determined by DEPT. 
*Carbon resonances were attributed to the (Z-) or (E-) configuration, according to ACD/NMR Predictor® 
software. 
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Table 2. 1H NMR Spectroscopic Data for Compounds 1 - 4. 
    1*  2  3   4 
position   δHa, b (J in Hz)  δHa, b (J in Hz)  δHa, b (J in Hz)   δHa, b (J in Hz) 
1          
2  (Z-), 7.17, d (8.4) (E-), 7.13, d (8.4)  7.20, d (8.4)  7.13, d (8.4)  7.19, d (8.4) 
3  6.88, d (8.4)  6.87, d (8.4)  6.84, d (8.4)  6.87, d (8.4) 
4          
5  6.88, d (8.4)  6.87, d (8.4)  6.84, d (8.4)  6.87, d (8.4) 
6  (Z-), 7.17, d (8.4) (E-), 7.13, d (8.4)  7.20, d (8.4)  7.13, d (8.4)  7.19, d (8.4) 
7  (Z-), 3.60, d (5.5) (E-), 3.39, d (6.2)  3.51, br s  2.72, t (7.1)  3.52, br s 
8  (Z-), 6.73, t (5.5) (E-), 7.40, t (6.2)    3.68, t (7.1)   
1’  a: 4.01, dd (3.7, 9.5)  a: 4.01, dd (4.0, 9.8)  a: 4.00, dd (4.3, 9.8)  a: 4.00, dd (4.0, 9.8) 
  b: 3.90, dd (7.3, 9.5)  b: 3.90, dd (7.2, 9.8)  b: 3.89, dd (7.2, 9.8)  b: 3.89, dd (6.6, 9.8)
2’  4.39, m  4.40, dd (4.0, 7.2)  4.39, dd (4.3, 7.2)  3.68, m 
3’        1.86, m 
4’  a: 4.89, br s  a: 4.88, br s  a: 4.89, br s  0.97, d (6.8) 
  b: 5.08, br s  b: 5.08, br s  b: 5.09, br s   
5’   1.78, s  1.79, s   1.79, s   0.97, d (6.8) 
aacetone-d6, 300 MHz. bAssignments are based on extensive 1D and 2D NMR experiments (HMBC, 
HSQC, COSY see Appendix – 2D NMR complete data). *Proton resonances were attributed to the (Z-) or 
(E-) configuration, according to ACD/NMR Predictor® software. 
 
 
Further compounds isolated were established to be known molecules, including etrogol 
(5) (Stierle et al., 2003), tyrosol (6) (Hashimoto et al., 1976), phenyl acetic acid (7) 
(Nair and Burke, 1988), benzoic acid (8) (Chen, 1958) and para-hydroxyphenyl acetic 
acid (9) (Chen, 1958; Crowden and Ralph, 1961). 
 
 
 
Figure 3. Structural formulae of the known compounds 5 - 9 
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Biological activity 
 
Stachyline A, B and C (1, 2, 3) were evaluated for cytotoxic activity against a panel of 3 
cancer cell lines (NCI-H460, MCF7 and SF268, tested at the 100 µM dose), but did not 
show activity. 
Stachyline A and B (2) were tested each against a panel of forty four psychoactive 
receptors, namely 5ht1a, 5ht1b, 5ht1d, 5ht1e, 5ht2a, 5ht2b, 5ht2c, 5ht3, 5ht5a, 5ht6, 
5ht7, Alpha1A, Alpha1B, Alpha1D, Alpha2A, Alpha2B, Alpha2C, Beta1, Beta2, Beta3, 
BZP Rat Brain Site, D1, D2, D3, D4, D5, DAT, DOR, Gaba A, H1, H2, H3, H4, KOR, 
M1, M2, M3, M4, M5, MOR, NET, SERT, Sigma1, Sigma2, (activity considered with 
at least 50 % inhibition at the 10 μM level), but exhibited no potent activity. One could 
mention though the 48.3 % antagonistic effect of Stachyline B specifically against the 
Adrenergic receptor Alpha 2C (at 10 µM dose, quadruplicate measurements). 
Stachylines C (3) and D (4) were also tested against five dopamine receptors (D1 – D5) 
but also did not show activity. 
Stachyline A (1) was tested in antibacterial (Escherichia coli, Bacillus megaterium), 
antifungal (Mycotypha microspora, Eurotium rubrum, and Microbotryum violaceum), 
antialgal (Chlorella fusca) assays at a dose of 50 µg/ml disc level but did not show 
activity.  
Stachyline B (2) was further tested in protein kinases DYRK1A and CDK5 inhibition 
activity assay (tested at 10 mM dose), for antiplasmodial activity assay against 
Plasmodium berghei (tested at 25 µM single dose), against two antibiotic resistant 
Mycobacterium tuberculosis strains, MTB72 and R46 (tested at the 50 µg/ml disc 
level), for the inhibition of the NF-kB protein complex assay (at the 100 µM) and in a 
panel of anti-diabetic activity assays: PPAR ligand assay, PPAR co-activator assay, 
PTP-1B inhibitor assay and glucose uptake assay (both 3T3-l1 cells and primary 
rat/mouse adipocytes, tested at the 100 µM dose) but did not show activity in any of the 
tests.  
Stachyline D (3) was evaluated against Influenza B virus (tested at 100 µg/mL dose) 
and for the inhibition of the viral HIV-1 and HIV-2 induced cytopathogenic effect in 
MT-4 cells (tested at the 50 µg/mL dose) but did not show activity. 
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Discussion 
 
Stachylines A-D are presumably tyrosine-derived metabolites, a group of compounds 
rarely encountered in fungal metabolism. The oxime group in compound 1 is even more 
intriguing. Phenylpyruvic acid oxime derivatives (Isaaki et al., 1993), brominated 
tyrosine-derived compounds like the bastadins and psammaplins (Calcul et al., 2010), as 
well as biosynthetically possibly related nitrile containing metabolites (Flemming, 
1999) occur in marine sponges. The Stachylidium sp. used for this investigation was 
isolated from a marine sponge. 
It was observed that the configuration of the oxime moiety in compound 1 was labile, 
and upon chromatographic isolation of the E- and Z-isomers, respective isomerisation 
took place instantaneously. None of the isomers seemed to be thermodynamically more 
stable under the prevailing conditions, since a 1:1 ratio of isomers was obtained (see 
Appendix – Spectroscopic data supporting information). In contrast to that, the 
geometrical isomers collismycin A and B from Streptomyces sp. MQ22 were reported to 
be not interchangeable in many organic solvents and at room temperature. Only by 
heating in ortho-dichlorobenzene at 120 °C they were gradually interchangeable 
(Shindo et al., 1994). For 2-(4-hydroxyphenyl)-2-oxoacetaldehyde oxime (PHBA) 
isolated from Penicillium olsonii, the E-configuration was described without mentioning 
any isomerisation reactions (Amade et al., 1993). 
Although the oxime functional groups are rare in natural products they occur in a 
variety of phyla, e.g., sponges, bacteria, fungi, and plants. Tyrosine-derivatives with an 
oxime moiety were found in actinomycetes, such as the β-lactam antibiotic nocardicin A 
from Nocardia uniformis (Hashimoto et al., 1976). Higher plants are also capable of 
producing oxime groups, since the biosynthesis of glucosinolates and cyanogenic 
glycosides, e.g. dhurrin from Sorghum bicolor proceeds via aldoximes (Bjarnholt and 
MØller, 2008; Flemming, 1999; Akazawa et al., 1960; Sibbesen et al., 1995). From 
these studies, oximes can be regarded as biosynthetic precursors of nitriles. 
Aspergillusol A was reported to be the first fungal tyrosine-derivative with an oxime 
moiety (Ingavat et al., 2009), however a previous publication had described the 
isolation of 2-(4-hydroxyphenyl)-2-oxoacetaldehyde oxime (PHBA) from Penicillium 
olsonii (Amade et al., 1993). Hence, the current report is the third one of a fungal 
tyrosine-derived oxime derivative.  
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Concerning the biosynthesis of naturally occurring oximes it is not clear which isomer 
is produced initially. The aldoxime intermediate in the biosynthesis of the cyanogenic 
glycoside dhurrin has been reported to initially have the E-configuration, subsequently 
undergoing non-enzymatic isomerisation (Bjarnholt and MØller, 2008; Sibbesen et al. 
1995). Nocardicin A with Z-oxime configuration is thought to be preferentially 
produced over the E-configurated nocardicin B, due to favourable intramolecular 
hydrogen-bonding in biosynthetic intermediates (Kelly and Townsend, 2002; Kelly and 
Townsend, 2005). In the case of bastadins and psammaplins, it was assumed that the Z-
oxime configuration is initially produced during biosynthesis, followed by isomerisation 
to the thermodynamically more favored E-isomers during extraction and isolation of the 
compounds (Calcul et al., 2010). 
Stachylines A-D are proposed to be biosynthetically derived from tyrosine (Figure 4). 
For stachyline A the biosynthetic process may be similar to that of cyanogenic 
glycosides, e.g. dhurrin, in that the precursor tyrosine is N-hydroxylated by CYP 450 
enzymes to N,N-dihydroxytyrosine and subsequently decarboxylated and dehydrated to 
form an aldoxime (Bjarnholt and MØller, 2008). A similar pathway was described for 
the norcardicin biosynthesis (Kelly and Townsend, 2002; Kelly and Townsend, 2005). 
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Figure 4. Proposed biosynthesis of stachylines A – D. 
 
 
Experimental section 
General Experimental Procedures. See chapter 3 - General methodology. 
 
Fungal material. See chapter 3 - General methodology. 
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Culture, extraction and isolation. Compounds 1 to 4 were isolated from three 
different cultures of Stachylidium sp. The first and second culture comprised 12 L and 
10 L of agar-biomalt medium (biomalt 20 g/L, 15 g/L agar) supplemented with sea salt 
incubated for 2 months (12 L) and 40 days (10 L) in Fernbach flasks at room 
temperature. The third culture was performed with 9.6 L liquid YPM medium (yeast 
extract 5 g/L, peptone from YPM 3 g/L, mannitol 25 g/L) incubated for 10 days. An 
extraction with 5 L EtOAc yielded 5.9 g, 2.1 g and 1.0 g of extract, respectively which 
were subjected to a VLC fractionation on silica gel, using a step gradient solvent system 
with petroleum ether - acetone from 10:1, 5:1, 2:1, 1:1 to 100 % acetone and, 
subsequently 100 % MeOH, resulting in 6 VLC fractions for each culture. Compounds 
2 and 3 were isolated from the first culture (12 L), whilst compound 4 was isolated from 
the second culture (10 L) and compound 1 was isolated from the third culture (YPM 
medium). The known compounds 6 and 9 were isolated from the first culture and the 
know compounds 5, 7 and 8 from the first and third culture (isolation described for the 
YPM culture). 
Compound 1 was isolated from VLC fraction 3 by NP-HPLC separation using 
petroleum ether - acetone (7:1) to yield 6 fractions. Sub-fraction 3 and 4 corresponded 
to a mixture of isomers of compound 1 (E- and Z-, 4.4 mg), which was again separated 
by RP-HPLC using 50 % MeOH (tR 11 min and 15 min), but immediately formed the 
initial mixture of isomers in a ratio of 1:1. Compounds 2 and 3 were isolated from VLC 
fraction 3 by NP-HPLC using petroleum ether - acetone (11:2) to yield 10 fractions. 
Further RP-HPLC fractionation with sub-fraction 5 using 50 % MeOH yielded 5 more 
sub-fractions, in which sub-fraction 4 was a mixture of compounds 2 and 3. Finally, we 
performed NP-HPLC fractionation using petroleum ether - acetone (7:1) to afford 
compound 2 (fraction 1 of 2, 4.1 mg, tR 19 min) and compound 3 (fraction 2 of 2, 2.2 
mg, tR 26 min). Compound 4 was isolated from VLC fraction 4, followed by HPLC 
fractionation using petroleum ether - acetone (9:2; sub-fraction 2 of 7) which was 
further purified using RP-HPLC with 60 % MeOH (fraction 2 of 4, 1.8 mg, tR 10 min). 
Etrogol (5) was isolated from VLC fraction 3, followed by HPLC fractionation using 
petroleum ether - acetone (7:1) to yield 5 sub-fractions. Sub fraction 1 was further 
purified using petroleum ether - acetone (7:1) to yield pure etrogol (fraction 3 of 3, 3.1 
mg, tR 26 min). Tyrosol (6) was isolated from VLC fraction 3 followed by HPLC 
fractionation using petroleum ether - acetone (5:1) to yield 10 fractions. Further RP-
HPLC fractionation with sub-fraction 6 using 30 % MeOH yielded the pure compound 
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(fraction 3 of 7, 2.5 mg, tR 19 min). Phenyl acetic acid (7) and benzoic acid (8) were 
isolated from VLC fraction 3, followed by HPLC fractionation using petroleum ether - 
acetone (11:1) to yield 5 fractions. Benzoic acid was present in fraction 2 (7.9 mg, tR 16 
min) and phenylacetic acid in fraction 3 (11.2 mg, tR 25 min). Para-hydroxyphenyl 
acetic acid (9) was isolated from VLC fraction 3 followed by HPLC fractionation using 
petroleum ether - acetone (5:1) to yield 10 fractions. Further RP-HPLC fractionation 
with sub-fraction 6 using 30 % MeOH yielded the pure compound (fraction 4 of 7, 1.8 
mg, tR 27 min). 
 
Stachyline A, mixture of E-/Z-isomers, 1:1 (1): white amorphous solid (458 μg/L, 
0.43 %); [α] D23 -15 (c 0.29, MeOH); UV (MeOH) λmax (log ε) 225 nm (3.60), 222 nm 
(2.84), 276 nm (2.76) ; IR (ATR) νmax 3300 (br), 2922, 1610, 1510 cm-1; 1H NMR and 
13C NMR (Tables 1 and 2 and Appendix – Complete 2D NMR data); ESIMS m/z 236.1 
[M+H]+; HREIMS m/z 235.1208 [M]+ (calcd. for C13H17NO3, m/z 235.1208); 
HRESIMS m/z 258.1125 [M+Na]+ (calcd. for C13H17NNaO3, m/z 258.1101).  
 
Stachyline B (2): white amorphous solid (340 μg/L, 0.07 %); [α] D23 - 12 (c 0.33, 
MeOH); UV (MeOH) λmax (log ε) 204 nm (3.35), 227 nm (3.75), 276 nm (3.05), 283 nm 
(2.75); CD (c 1.06 × 10–6 mol/L, MeOH), λ (ε) = 197 (+ 1.78); IR (ATR) νmax 3364 
(br), 2929, 1610, 1511 cm-1; 1H NMR and 13C NMR (Tables 1 and 2 and Appendix – 
Complete 2D NMR data); EIMS m/z 236.1 [M]+; HREIMS m/z 236.1051 [M]+ (calcd. 
for C13H16O4,  m/z 236.1049).  
 
Stachyline C (3): white amorphous solid (183 μg/L, 0.04 %); [α] D23 - 16 (c 0.33, 
MeOH); UV (MeOH) λmax (log ε) 205 nm (3.43), 225 nm (3.85), 277 nm (2.95), 283 nm 
(2.95); CD (c 1.25 × 10–6 mol/L, MeOH) λ (ε) = 199 (+ 1.94); IR (ATR) νmax 3235 
(br), 2937, 2551, 1685, 1509 cm-1; 1H NMR and 13C NMR (Tables 1 and 2 and 
Appendix – Complete 2D NMR data); EIMS m/z 222.1 [M]+; HRESIMS m/z 245.1162 
[M+Na]+ (calcd. for C13H18NaO3, m/z 245.1148).  
 
Stachyline D (4): white amorphous solid (180 µg/L 0.09 %); [α] D23- 6 (c 0.12, MeOH); 
UV (MeOH) λmax (log ε) 205 nm (3.86), 226 nm (3.86), 276 nm (3.08), 283 nm (2.90); 
IR (ATR) νmax 3265 (br), 1687, 1512 cm-1; 1H NMR and 13C NMR (Tables 1 and 2 and 
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Appendix – Complete 2D NMR data); ESIMS m/z 237.1 [M-H]-; HRESIMS m/z 
261.1096 [M+Na]+ (calcd. for C13H18NaO4,  m/z 261.1097). 
 
 
Preparation of the (R)- and (S)-MTPA esters of compound 2. The secondary alcohol 
(1 eq, 1 mg, 4.23 x 10-6 µmol) was dissolved with the corresponding MTPA-Cl (10 eq) 
in an adequate quantity of deuterated pyridine and DMAP (1 eq) in an NMR tube. The 
reaction was followed by 1H-NMR to observe the downfield proton shift of H-2’. After 
1 hour reaction time, the final 1H-NMR was recorded, the sample dried and re-dissolved 
in D-acetone for 1H-13C HSQC measurements. The Δ(S-R) values between (S)- and (R)- 
MTPA esters were recorded with the help of both 1H-NMR and 1H-13C HSQC (see 
Figure 1 and Appendix - Spectroscopic data supporting information). 
 
Bioassays. See chapter 3 - General methodology. 
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7. Novel Furyl Derivative from the Sponge-derived Fungus 
Stachylidium sp. 
 
 
 
 
 
Abstract 
The marine-derived fungus Stachylidium sp. was isolated from the sponge Callyspongia 
sp. cf. C. flammea. One new furyl derivative, 2-(furan-3-yl)acetic acid (1) were isolated 
from the fungal extract which was obtained from a agar-BMS medium supplemented 
with artificial sea salt. The structure of 1 was elucidated based on extensive 
spectroscopic analysis. Three further and known furyl derivatives, namely 1-(furan-2-
yl)ethane-1,2-diol (2), furan-2,5-diyldimethanol (3) and 2-furoic acid (4) were found.  
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Figure 1. Structures of Compounds 1 - 4 
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Introduction 
 
Interactions that occur between organisms are often mediated by small molecules, e.g. 
N-acyl-homoserine lactones, 2-heptyl-3-hydroxy-4-quinoline (PQS) (Dudler and Eberl, 
2006; Camili and Bassler, 2006). In addition to controlling the production of active 
compounds in bacteria, there is a growing number of reports indicating that small 
molecules like N-acyl-homoserine lactones autoinducers modulate gene expression of 
eukaryotic organisms (Sperantio, 2004; Shinner et al., 2005).  
Furyl derivatives are also found in a wide taxonomical range of bacterial and fungal 
species. Methyl 2-furancarboxylate is found in Loktanella (Dickschat et al., 2005), 
while the related compound 2-acetylfuran (Andreae, 1990) is a metabolite of 
myxobacteria (Dickschat et al., 2004; Dickschat et al., 2005a), Streptomyces citreus 
(Pollak and Berger, 1996) and marine bacteria (Dickschat et al., 2005b). Interestingly, 
the typical fungal metabolite 3-methylfuran has been reported from three Streptomyces 
strains (Schöller et al., 2002; Schulz and Dickschat, 2007), whereas the regioisomer 2-
methylfuran is reported from Thermoactinomyces (Wilkins, 1996). 
During our search for new natural products produced from the marine-derived fungus 
Stachylidium sp., one new (1) and three known furyl derivatives (2 – 4) were isolated 
from a culture of this fungus on agar-BMS media supplemented with artificial sea salt. 
 
 
Structure elucidation 
 
The molecular formula of 1 was established by HREIMS to be C6H6O3, requiring four 
sites of unsaturation. The 13C NMR and DEPT135 spectra indicated the presence of six 
resonances, including three sp2 methines, one sp3 methylene and two quaternary carbons 
(Compound Spectroscopic Description and Table 1). The three methine protons were 
assigned to be part of a furyl moiety. H-1 and H-4 have downfield shifted proton 
resonances in the 1H-NMR spectra, indicating that the furyl oxygen atom is placed 
between them. H-2 was placed next to H-1 making use of 1H-1H-COSY correlations. 
Key heteronuclear long range correlations from the sp3 CH2-5 to the furyl carbons C-2, 
C-3, C-4 and the carboxyl carbon C-6 (δc 172.3) completed the assignment of 1 as 2-
(furan-3-yl)acetic acid. Compound 1 is a new natural products but was previously 
synthesized (Paolucci and Rosini, 2007; Kassianidis et al., 2005).  
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The structure of the furyl derivatives 2, 3 and 4 was established to be namely 1-(furan-
2-yl)ethane-1,2-diol (2) , furan-2,5-diyldimethanol (3) and 2-furoic acid (4), 
respectively by comparison of spectroscopic data with those previously reported for 
these natural products (Lu et al., 2008, Schneider et al., 1996; Hong et al., 1981). 
  
Table 1. 1D and 2D NMR spectroscopic data for compound 1 
 
position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 143.6, CH 7.476, m 2 2, 3, 4 
2 112.5, CH 6.43, s (br) 1 1, 3, 4, 5 
3 119.1, qC    
4 141.3, CH 7.482, m 5 1, 2, 3, 5 
5    30.6, CH2 3.45, s 4 2, 3, 4, 6 
6 172.3, qC    
a CD3COCD3, 300/75.5 MHz. b Assignments  are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT. 
 
 
 
 
               (1) 
Figure 2. Key HMBC correlations of compound 1 
 
 
Biological activity assays 
 
 (R)-1-(furan-2-yl)ethane-1,2-diol (2) were tested for antiplasmodial activity assay 
against Plasmodium berghei (tested at 25 µM single dose), in antibacterial (Escherichia 
coli, Bacillus megaterium), antifungal (Mycotypha microspora, Eurotium rubrum, and 
Microbotryum violaceum), antialgal (Chlorella fusca) assays at a dose of 50 µg/ml disc 
level but did not show any activity.  
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Compounds 1 – 4 are currently being tested for agonistic/antagonistic quorum sensing 
effect in the bacterial species Chromobacterium violaceum. 
 
Discussion 
 
Small molecules like furyl derivatives are widely present in fungal and bacterial extracts 
(Dickschat et al., 2004; Dickschat et al., 2005a; Dickschat et al., 2005b; Pollak and 
Berger, 1996; Schöller et al., 2002; Schulz and Dickschat, 2007), and they could work 
in the quorum sensing responsible for eukaryotic-bacterial as well as bacterial-bacterial 
chemical interactions, (Dudler and Eberl, 2006). Interestingly, peptides, phthalides and 
phthalimidines indicating the presence of bacterial metabolism were isolated from the 
same fungal extract (unpublished data). We are currently undergoing studies to identify 
the possible origin of these compounds, as well as the possible interaction/origin of the 
hereby reported furyl derivatives. 
 
 
Experimental section 
General Experimental Procedures. See chapter 3 - General methodology. 
 
Fungal material. See chapter 3 - General methodology.   
 
Culture, extraction and isolation. Compounds 1 and 2 were isolated from two 
different cultures of Stachylidium sp., the first and second performed on 12 L and 10 L 
respectively of agar-biomalt medium (biomalt 20g/L, 15 g/L agar) supplemented with 
sea salt during 2 months (12 L) and 40 days (10 L). An extraction with 5 L EtOAc 
yielded respectively 5.9 g and 2.1 g of extract which were subjected to a VLC 
fractionation in a silica open column using a gradient solvent system with petroleum 
ether - acetone at 10:1, 5:1, 2:1, 1:1, 100% acetone and 100% MeOH, resulting thus 6 
VLC fractions from each culture. Compound 2, 3 and 4 were isolated from the first 
culture (12 L), whilst compound 1 was isolated from the second culture (10 L).  
Compound 1 was isolated from VLC fraction 3, followed by HPLC fractionation using 
petroleum ether - acetone 5:1 (sub-fraction 2 of 10) which was further purified using 
NP-HPLC with petroleum ether - acetone 9:1 (fraction 3 of 4, 3.2 mg, tR 21 min). 
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Compound 2 was isolated from VLC fraction 3, followed by HPLC fractionation using 
petroleum ether - acetone 5:1 (sub-fraction 7 of 10) which was further purified by 
HPLC reverse phase fractionation using 50% MeOH (sub-fraction 1 of 4). Finally we 
used RP-HPLC using 10% MeOH to yield the pure compound (fraction 2 of 7, 3.1 mg, 
tR 4 min). 
Compound 3 was isolated from VLC fraction 3, followed by HPLC fractionation using 
petroleum ether - acetone 5:1 (sub-fraction 7 of 10) which was further purified by 
HPLC reverse phase fractionation using 50% MeOH (sub-fraction 1 of 4). Finally we 
used RP-HPLC using 10% MeOH to yield the pure compound (fraction 3 of 7, 2.6 mg, 
tR 4 min). 
Compound 4 was isolated from VLC fraction 3, followed by HPLC fractionation using 
petroleum ether - acetone 5:1 (sub-fraction 7 of 10) which was further purified by 
HPLC reverse phase fractionation using 50% MeOH (sub-fraction 1 of 4). Finally we 
used RP-HPLC using 10% MeOH to yield the pure compound (fraction 4 of 7, 1.6 mg, 
tR 4 min). 
 
2-(furan-3-yl)acetic acid (1): white amorphous solid (320 µg/L 0.152 %); UV (MeOH) 
λmax 206 nm (log Є 3.76); IR (ATR) νmax 2907 (Br), 1693 cm-1; 1H NMR [H-1, δ 7.476, 
m; H-2, δ 6.43, s (br); H-4, δ 7.482, m; H-5, δ 3.45, s] and 13C NMR (C-1, δ 143.6, CH;  
C-2, δ 112.5, CH; C-3, δ 119.1, qC; C-4, δ 141.3, CH; C-5, δ 30.6, CH2; C-6, δ 172.3, 
qC; 2D NMR in Table 1); LRESIMS m/z 124.9 (M-H)-; HRESIMS calcd. m/z 125.0233 
for C6H5O3 (M-H)-, found 125.0240.  
 
 
Methodology for the performed biological assays. See chapter 3 - General 
methodology. 
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8. Endolides A – J, N-methylated Peptides from the Sponge-derived 
Fungus Stachylidium sp. 
 
 
 
 
 
Abstract 
Marine organisms are rich sources of structurally diverse bioactive compounds. 
Recently, a great deal of interest has been expressed regarding marine-derived bioactive 
peptides because of their numerous health beneficial effects (Kim and Wijesekara, 
2010). 
During our search for new natural products produced from the marine-derived fungus 
Stachylidium sp., ten novel cyclic N-methylated peptides, Endolides A – J, were 
isolated from the extract of the fungus. These peptides (structure formulae not shown) 
are currently undergoing absolute configuration analysis by means of the advanced 
Marfey’s method and X-ray crystallography. We have already submitted Endolides A - 
J to a total of 311 individual biological activity assays, in such areas like cytotoxicity, 
antimicrobial, antiviral, antiplasmodial, psychoactive or anti-inflammatory activity, 
amongst others. 
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9.  Hydroxylated Sclerosporin Derivatives from the Marine-derived 
Fungus Cadophora malorum† 
 
 
 
 
Abstract 
The marine-derived fungus Cadophora malorum was isolated from the green alga 
Enteromorpha sp. Growth on a biomalt medium supplemented with sea salt yielded an 
extract from which we have isolated sclerosporin and four new hydroxylated 
sclerosporin derivatives, namely 15-hydroxysclerosporin (2), 12-hydroxysclerosporin 
(3), 11-hydroxysclerosporin (4) and 8-hydroxysclerosporin (5). The compounds were 
evaluated in various biological activity assays. Compound 5 showed a weak fat-
accumulation inhibitory activity against 3T3-L1 murine adipocytes. 
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Figure 1. Structure formulae of compounds 1 - 5 
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Introduction 
 
In recent years, research on the chemistry of marine organisms has experienced a 
tremendous increase, due to the need for compounds possessing bioactivity with 
possible pharmaceutical application or other economically useful properties (Anderson 
et al., 2000). From these organisms, marine fungi are recognized as a valuable source 
for new and bioactive secondary metabolites that have the potential to lead to 
innovations in drug therapy (Haefner, 2003). Sclerosporin is a rather rare antifungal and 
sporogenic cadinane-type sesquiterpene (Katayama et al., 1983; Datta et al., 2007). This 
substance, initially isolated from Sclerotinia fruticula showed an induction of asexual 
arthrospore formation in fungal mycelia (Katayama et al., 1983; Kitahara et al., 1984).  
Interestingly, its (-)-form isolated from Diplocarpon mali did not showed sporogenic 
activity towards S. frutícula (Kitahara et al., 1984; Sawai et al., 1985). 
 
During our search for new natural products produced from the marine-derived fungus 
Cadophora malorum, (+)-sclerosporin (1) and four new hydroxylated sclerosporin 
derivatives (2 – 5) were isolated from a spore culture on agar-BMS media supplemented 
with artificial sea salt.  
 
 
Results and Discussion 
 
The molecular formulae of compounds 2 - 5 were deduced by HREIMS to be identical, 
i.e. C15H22O3, indicating five degrees of unsaturation. The 13C NMR spectra for all four 
compounds showed 15 closely similar resonance signals, evidencing that each of the 
compound belonged to the same structural type. In each case a 13C NMR downfield 
shifted resonance signal at δ 168 – 170 was found, typical for a carboxylic acid 
functionality (C-14), whereas a further resonance signal at around δ 70 indicated a 
hydroxy substituted methylene for compounds 2 and 3, a hydroxy substituted methine 
for compound 5, and for compound 4 a hydroxylated quaternary carbon (see Tables 1-2, 
respectively). IR spectroscopic measurements showed a broad absorption band at 3300 
cm-1 for 2 - 5, also confirming the presence of a hydroxy substituent in each case. 
1H-1H COSY data for 2 revealed a spin system ranging from H2-3 via H-1 and H-6 to 
H2-9 and to H3-12/H3-13, thus outlining major parts of the planar structure. Protons H2-
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15 showed a 1H-1H long range coupling to H-5, which together with an HMBC 
correlation from H2-15 to C-3 and from H-5 to C-6 completed the first ring of 2. HMBC 
correlations from H-9 to C-14 connected the carboxylic acid moiety with C-10, which in 
turn had to be bound to C-1 due to a HMBC correlation from H-1 to C-10 and to C-9. 
The planar structure of compound 2 was thus that of sclerosporin (1) hydroxylated at C-
15.  
Sclerosporin itself was also obtained during this study. The molecular formula of 1 was 
deduced by accurate mass measurement (HREIMS) to be C15H22O2. The final structure 
of 1 was identified as that of the known compound (+)-sclerosporin by comparing its 
NMR data and optical rotation with published values (Datta et al., 2007; Kitahara et al., 
1984). 
The carbon skeleton of compounds 3 - 5 and the position of the double bonds were also 
found to be identical to that of 1, as deduced from 1D and 2D NMR analyses. All 
compounds are thus cadinane type sesquiterpenes with a sclerosporin nucleus (see 
Tables 1-2) and differ merely concerning the site of hydroxylation.  
The position of the hydroxy group in 3 and 4 was established making use of 1H-1H 
COSY and HMBC data. Thus, in 3 the 13C NMR resonance signal for C-12 (δ 64.9) was 
shifted downfield, and H-12 (δ 3.52) showed coupling with H-11, placing the hydroxy 
substituent at C-12. The 13C NMR spectrum of 4 exhibited a downfield shifted 
quaternary carbon (δ 72.6, C-11) along with singlet proton resonances for the methyl 
groups CH3-12/CH3-13 in the 1H NMR spectrum, thus the hydroxy substituent had to be 
placed at C-11. The 13C NMR spectrum of 5 exhibited only two resonances for 
methylene groups (C-2, C-3) instead of three such moieties as in 2 - 4. Instead of the 
methylene group CH2-8 in 2 – 4, in 5 a methine group resonating at δ 68.7 and δ 4.13 in 
the 13C and 1H NMR spectra respectively was found. The 1H-1H COSY spectrum 
revealed correlations between H-8 and H-9 as well as H-7, positioning the hydroxy 
substituent in 5 at C-8. The planar structures of 2 - 5 were thus established to be 15-
hydroxysclerosporin (2), 12-hydroxysclerosporin (3), 11-hydroxysclerosporin (4) and 8-
hydroxysclerosporin (5). 
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Table 1. 1H NMR Spectroscopic Data for Compounds 2 – 5. 
 2 3 4 5 
Position δHa (J in Hz) δHa (J in Hz) δHb (J in Hz) δHb (J in Hz) 
1 2.58, br d (11.4) 2.58, br d (10.2) 2.54, br d (10.6) 2.43, br d (10.6) 
2 a: 1.99, m a: 1.91, m a: 1.89, m a: 1.93, m 
 b: 1.37, qd (11.4, 5.4) b: 1.42, qd (11.7, 5.4) b: 1.50, qd (11.7, 5.5) b: 1.45, qd (11.7, 5.4) 
3 2.08, m a: 2.06, m a: 1.98, m a: 2.08, m 
  b: 1.88, m b: 1.95, m b: 1.93, m 
5 5.79, d (4.1) 5.52, br s  5.71, br d (5.1) 5.57, br d (4.4) 
6 2.04, m 2.10, m 2.11, m 2.10, m 
7 1.53, tt (10.2, 5.1) 1.65, tt (10.2, 5.1) 1.68, td (10.3, 5.1) 1.52, ddd (3.2, 8.7, 10.7) 
8 a: 2.15, dt (19.8, 5.1) a: 2.27, dt (19.8, 5.1) a: 2.38, dt (19.6, 5.1) 4.13, br d (8.7) 
 b: 1.97, m b: 2.02, m b: 2.01, m  
9 7.14, br s 7.10, br s 6.95, br t (3.9) 6.79, d (1.8) 
11 2.03, m 2.05, m  2.25, m 
12 0.83, d (6.8) 3.77 (dd, 4.8, 10.6) 1.23, s 1.00, d (7.1) 
13 0.90, d (6.8) 1.03, d (7.0) 1.18, s 1.10, d (7.1) 
14     
15 4.03, br s 1.68, br s 1.66, br s 1.68, br s 
aCDCl3, 300 MHz. bAcetone-d6, 300 MHz.  
 
 
Table 2. 13C NMR Spectroscopic Data for Compounds 2 – 5. 
 2 3 4 5
Position δC, mult.a,c δC, mult.a, c δC, mult.b, c δC, mult.b, c 
1   34.0, CH   33.8, CH   35.6, CH   35.2, CH 
2   25.1, CH2   25.4, CH2   26.2, CH2   26.0, CH2 
3   26.2, CH2   30.3, CH2   30.8, CH2   31.5, CH2 
4 138.3, qC 135.6, qC 133.7, qC 134.9, qC 
5 124.3, CH 123.0, CH 126.6, CH 125.1, CH 
6   35.5, CH   35.8, CH   36.9, CH   36.2, CH 
7   40.0, CH   38.6, CH   47.2, CH   48.8, CH 
8   25.4, CH2   28.0, CH2   29.7, CH2   68.7, CH 
9 142.6, CH 142.1, CH 140.2, CH 143.7, CH 
10 132.9, qC 133.1, qC 134.3, qC 134.3, qC 
11   26.4, CH   35.3, CH   72.6, qC   27.3, CH 
12   15.0, CH3   64.9, CH2   27.4, CH3   18.9, CH3 
13   21.3, CH3   15.4, CH3   28.7, CH3   21.1, CH3 
14 172.2, qC 172.0, qC 168.0, qC 168.0, qC 
15   67.3, CH2   23.9, CH3   23.9, CH3   23.9, CH3 
aCDCl3, 75.5 MHz. bAcetone-d6, 75.5 MHz.  
d Implied multiplicities determined by DEPT.  
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Stereochemistry 
 
The Cotton effect in the CD spectrum of (+)-sclerosporin (1) was similar to that 
reported in the literature (Kitahara et al., 1985), confirming the absolute configuration 
of 1 to be that of (+)-sclerosporin (see Table 3). The absolute configurations of 
compounds 2 - 5 were established by analyses of CD and NOESY spectra. The CD 
spectra of the hydroxylated compounds 2 - 5 were closely similar to that of (+)-
sclerosporin (1), thus the identical absolute configuration can be proposed for 
compounds 2 – 4 (see Table 3). However, the configuration at position C-11 in 3 
remains unresolved. Interestingly, 5 was the only one with a negative specific rotation 
(see Table 3). This change on specific rotation was most probably caused by the 
additional stereogenic center at C-8. The configuration at C-8 was established making 
use of NOESY correlations and 1H-1H coupling constants. A NOESY correlation 
between H-1 and H-6 is in agreement with the configuration of the other sclerosporin 
derivatives, and further correlations between H-8 and H-6, H-11, H3-12, H3-13 indicate 
these protons to be in the same spatial orientation. Furthermore, a 1H-1H coupling 
constant of 8.7 Hz between H-7 and H-8 indicated a trans-type spatial arrangement. 
Knowing the absolute configuration of H-1, H-6 and H-7 from CD spectroscopic data, 
we can thus assign the configuration of 5 to be 1R, 6S, 7R, 8S.  
We propose the trivial names (+)-15-hydroxysclerosporin, (+)-12-hydroxysclerosporin, 
(+)-11-hydroxysclerosporin and (-)-8-hydroxysclerosporin for compounds 2, 3, 4 and 5, 
respectively. 
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Table 3. Comparison of the CD Spectra and Specific Rotation Values for the Reported 
Sclerosporins (+ and -) and Compounds 1 - 5.  
 
Compound Δε Maxima and Minima in the CD 
Spectra (c 1.6 × 10–6 mol/L, MeOH) 
Optical Rotation 
(+) (+)-sclerosporin7 Δε196 + 11.0a [α]20D + 11.4 (c  0.035, MeOH) 
(-) (-)-sclerosporin5 Δε214 + 17.0a [α]20D -  11.1 (c  0.090, MeOH) 
(1) (+)-sclerosporin Δε196 + 10.1, Δε215 - 12.4 [α]23D + 14  (c  0.033, MeOH) 
(1) (+)-sclerosporin   [α]23D + 57  (c  0.033, CHCl3) 
(2) (+)-15-hydroxy Δε197 +   5.2, Δε214 - 14.8 [α]23D + 64  (c  0.033, CHCl3) 
(3) (+)-12-hydroxy Δε195 +   6.1, Δε214 -   6.2 [α]23D + 69  (c  0.033, CHCl3) 
(4) (+)-11-hydroxy Δε198 +   3.2, Δε213 - 16.3 [α]23D + 73  (c  0.033, CHCl3) 
(5) (-)-8-hydroxy Δε193 +   8.2, Δε215 -   8.0 [α]23D  - 62  (c  0.033, CHCl3) 
aΔε minima for + and – sclerosporin not reported in the literature 
 
 
Bioactivity assays 
 
Compound 2 was evaluated in the protease elastase (HLE) inhibition assay (tested at 
100 µM), in the cytotoxic activity assay against a panel of three cancer cell lines (NCI-
H460, MCF7 and SF268, tested at 100 µM), in the protein kinases DYRK1A and CDK5 
inhibition activity assay (tested at 10 mM), for inhibition of the viral HIV-1 and HIV-2 
induced cytopathogenic effect in MT-4 cells (tested at 50 µg/mL), in the Epstein-Barr 
virus (EBV) assay (tested at 100 µg/mL), and in the antiplasmodial activity assay 
against Plasmodium berghei (tested at 25 µM), but did not show any activity. 
Compound 2 was further tested against a pannel of three respiratory viruses, the severe 
acute respiratory syndrome coronavirus (SARS) assay, Flu A (H5N1) and Flu B (tested 
at 100 µg/mL in the three tests), bud did not show any significant activity. Compound 3 
was evaluated against two influenza viruses, Flu A (H5N1) and Flu B (tested at 100 
µg/mL), but did not show any activity. Compound 5 was evaluated against 3-T3-L1 
murine adipocytes assay and showed weak inhibitory activity with an IC50 of 212 µM 
for triglyceride accumulation inhibition along with an IC50 cytotoxic effect value of 304 
µM (see Appendix – bioactivity results). All compounds were tested for sporogenic 
activity (concentrations from 0.005 µg/mL to 5 µg/mL in BMS-agar plates) but the 
results were inconclusive, i.e. sporogenesis activity was observed but not with direct 
correlation with increasing quantity, probably due to compound unstability. All 
compounds were evaluated in antibacterial (Escherichia coli, Bacillus megaterium), 
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antifungal (Mycotypha microspora, Eurotium rubrum, and Microbotryum violaceum), 
and antialgal (Chlorella fusca) assays but did not showed activity at 50 µg/disc dose. 
 
 
Experimental Section 
General Experimental Procedures See chapter 3 - General methodology.   
 
Fungal material. See chapter 3 - General methodology. 
 
Culture, extraction and isolation. A sporous culture of Cadophora malorum on a 10 L 
solid biomalt medium (biomalt 20 g/L, 15 g/L agar) supplemented with sea salt was 
performed during 3 months. An extraction with 5 L EtOAc yielded 890 mg of extract 
which was subjected to a VLC fractionation in a silica open column using a gradient 
solvent system from PE to acetone, namely 10:1, 5:1, 2:1, 1:1, 100 % acetone and 100 
% MeOH, yielded a total of 6 fractions. Compounds 1 to 5 were isolated from VLC 
fraction 2 (112 mg) by HPLC fractionation using PE-acetone 5:1.  
Sclerosporin (1) was collected in fraction 1 of 7 (2.7 mg, RT 6 min); (+)-15-
hydroxysclerosporin (2) was collected in fraction 7 of 7 (14.0 mg, RT 22 min); (+)-12-
hydroxysclerosporin (3) was collected in fraction 6 of 7 (7.1 mg) which was further 
purified by HPLC fractionation with PE-acetone 26:5 (fraction 1 of 2; 4.5 mg, RT 31 
min); (+)-11-hydroxysclerosporin (4) was collected in fraction 3 of 7 (2.2 mg, RT 13 
min); (-)-8-hydroxysclerosporin (5) was collected in fraction 2 of 7 (3.5 mg, RT 11 
min). 
 
(1R, 6S, 7R)-(+)-sclerosporin (1): [α]23D + 57 (c 0.033, CHCl3); CD (see Table 3); 
HREIMS m/z 234.1623 (calcd for C15H22O2, 234.1620); spectroscopic data were 
identical with the previously reported data.4,5,7 
 
(1R, 6S, 7R)-(+)-15-hydroxysclerosporin (2): yellow amorphous solid (1.4 mg/L, 1.57 
%); [α]23D + 64 (c 0.033, CHCl3); UV (MeOH) λmax (log ε) 217 nm (3.8); CD (see Table 
3); IR (ATR) νmax 3397, 2927, 1682 cm-1; 1H NMR and 13C NMR (see Tables 1 and 2); 
LREIMS m/z 250.1; HREIMS m/z 232.1457 [M-H2O]+ (calcd for C15H20O2, 232.1463). 
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(1R, 6S, 7S)-(+)-12-hydroxysclerosporin (3): yellow amorphous solid (0.71 mg/L, 
0.81 %); [α]23D + 69 (c 0.033, CHCl3); UV (MeOH) λmax (log ε) 218 nm (3.9); CD (see 
Table 3). IR (ATR) νmax 3397, 2923, 1682 cm-1; 1H NMR and 13C NMR (see Tables 1 
and 2); LREIMS m/z 250.1; HREIMS m/z 232.1463 [M - H2O]+ (calcd for C15H20O2, 
m/z 232.1463). 
 
(1R, 6S, 7S)-(+)-11-hydroxysclerosporin (4): yellow amorphous solid (0.22 mg/L, 
0.25 %); [α]23D + 73 (c 0.033, CHCl3); UV (MeOH) λmax (log ε) 219 nm (3.8); CD (see 
Table 3); IR (ATR) νmax 3277, 2928, 1681 cm-1; 1H NMR and 13C NMR (see Tables 1 
and 2); LREIMS m/z 250.1; HREIMS m/z 232.1464 [M - H2O]+ (calcd for C15H20O2, 
m/z 232.1463). 
 
(1R, 6S, 7R, 8S)-(-)-8-hydroxysclerosporin (5): yellow amorphous solid (0.35 mg/L, 
0.39 %); [α]23D - 62 (c 0.033, CHCl3); UV (MeOH) λmax (log ε) 220 nm (3.7); CD (see 
Table 3); IR (ATR) νmax 3397, 2928, 1688 cm-1;1H NMR and 13C NMR (see Tables 1 
and 2); LREIMS m/z 250.1; HREIMS m/z 232.1458 [M - H2O]+ (calcd for C15H20O2, 
m/z 232.1463). 
 
Biological Assays. See chapter 3 - General methodology. 
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10.  Novel Bisabolane Sesquiterpenes from the Marine-derived Fungus 
Verticillium tenerum 
 
 
 
 
 
Abstract  
Chemical investigations of the marine-derived fungus Verticillium tenerum yielded two 
new hydroxylated bisabolane-type sesquiterpenes verticinol A (1) and B (2). The planar 
structures of the new compounds were elucidated by employing spectroscopic (NMR, 
UV, and IR) and mass spectrometric techniques. The absolute configuration of the 
cyclohexenyl moiety was deduced by a combination of CD spectroscopy and NOESY 
measurements. 
 
 
OH
HO
15
3
165
7
14
9
11
12
13
O
OH
HO O
O
15
3
165
7
14
10
12
16 17
13
1 2  
 
Figure 1. Structures of compounds 1 and 2 
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Introduction 
 
Fungi are an extremely valuable source of novel natural products with a wide array of 
biological activities (König and Wright, 1996). Polyketides are the dominant class of 
fungal secondary metabolites, however, peptides and heteroaromatic compounds are 
found in these microorganisms as well (Schneider et al., 2008). Fungal terpenes are 
known as potent toxins, for example trichothecenes and botrydials, and as plant growth 
hormones, for example gibberellins and abscisic acid (Pinedo et al., 2008). 
To date, bisabolane-type sesquiterpenes have been rarely found in fungi. One report 
refers to -bisabolol produced by a mangrove-derived ascomycete (Laurent et al., 
2002), and a second one describes highly oxygenated bicylic bisabolanes from the 
basidiomycete Cheimonophyllum candidissimum (Stadler et al., 1994). Basidiomycetes 
of the genus Lepista were found to contain the volatile - and ß-bisabolenes as well as 
the bicyclic tetrahydrofuran-containing lepistirone (Abraham et al., 1991). Aromatic 
bisabolanes include curcutetraol, sydonol and waraterpol (Muelhaupt et al., 2005). 
 
In a project focusing on new and bioactive natural products from the marine-derived 
fungus Verticillium tenerum, which was isolated from an unknown alga and cultivated 
in a medium supplemented with sea salt, two new bisabolane sesquiterpenes (1, 2) were 
obtained (Figure 1). 
 
 
Results and Discussion 
 
The molecular formula of 1 was deduced from accurate MS measurements (HRESIMS) 
to be C15H26O3, implying three degrees of unsaturation. The IR spectrum showed 
characteristic absorption bands at 3376 and 1706 cm –1, which indicated the presence of 
both hydroxy and carbonyl groups. NMR spectra (Table 1) confirmed the presence of 
15 carbon atoms with 24 carbon-attached protons, indicating that two protons are 
associated with hydroxy groups. A more detailed analysis of NMR chemical shifts 
indicated the presence of one sp3 secondary methyl (H3-14, H = 0.82) and three sp3 
tertiary methyl groups (H3-12, H3-13 and H3-15 with H = 1.37, 1.37 and 1.27). 
Furthermore, 1H NMR signals for four sp3 methylene groups, two of them aliphatic 
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(CH2-8 and CH2-9) and a further two alicyclic (CH2-4 and CH2-5), are present, as well 
as two sp3 quaternary carbons (C-3, C-11), and the carbonyl carbon C-10 (C = 214.5). 
There are two downfield shifted 1H NMR signals for methine protons, i.e. the olefinic 
protons H-1 (H = 5.49) and H-2 (H = 5.63). Two further 1H NMR signals are slightly 
downfield shifted and attached to sp3 hybridized carbons (H-6, H = 2.11 and H-7, H = 
1.46). Moreover, the 13C NMR chemical shifts suggested the presence of two tertiary 
hydroxy groups (C-3, C = 69.7 and C-11, C = 76.1). A significant structural fragment 
of 1 (fragment A) could be deduced from the 1H-1H COSY spectrum, whereas 
 
 
          
 
 
 
 
(a)                  (b) 
 
Figure 2: (a) Fragments of compound 1 as deduced from 1H-1H COSY and 1H-13C 
HMBC correlations; (b) Key NOESY correlations for compounds 1 and 2   
 
fragment B was delineated from heteronuclear couplings in the 1H-13C HMBC spectrum 
(Figure 2a). Thus, mutual correlations in the 1H-1H COSY spectrum between the 
resonances for H-2, H-1, H-6, H2-5 and H2-4 indicated these protons and their 
respective carbons to be adjacent. In addition, the 1H-1H COSY spectrum revealed a 
continuous chain of couplings from H3-14 to H-6 and H-9 through H-7 and H-8. The 
correlations between H3-12/H3-13 and both C-10 and C-11 in the 1H-13C HMBC 
spectrum indicated that methyl groups CH3-12 and CH3-13 are bonded to C-11, which 
is further connected to C-10 giving rise to fragment B. The connection of fragments A 
and B was evidenced by an HMBC correlation between H-9 and C-10. Finally, HMBC 
correlations between H3-15 and C-2, C-3 and C-4 completed the cyclohexenyl ring and 
thus the planar structure of 1. 
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Table 1: 1D and 2D NMR spectroscopic data for compound 1. 
No. ca,b,e Ha,b (mult., J in COSYa,b,c HMBCa,d NOESYa,b,c 
1 131.3, CH 5.49, br d (10.3) 2, 5a, 6 2, 3, 5, 6, 7 2, 6, 8a, 8b, 14 
2 135.1, CH 5.63, br d (10.3) 1, 4a, 6 1, 4, 6 1, 15 
3   69.7, qC     
4   38.1, CH2 a: 1.86, m  
b: 1.65, m 
2, 4b, 5a, 5b 
4a, 5a, 5b 
2, 3, 5, 6 
3, 5, 6 
4b, 5a, 5b, 15 
4a 
5   22.3, CH2 a: 1.67, m  
b: 1.39, m 
4a, 4b, 5b, 6 
4a, 4b,5a, 6 
4, 6 
4, 6 
4a, 5b, 6 
4a, 5a 
6   40.1, CH 2.11, m 1, 2, 5a, 5b, 7 7 1, 5a, 7, 8a, 9, 14 
7   36.3, CH 1.46, m 6, 8a, 8b, 14 14 6, 9, 14 
8   27.9, CH2 a: 1.71, m  
b: 1.44, m 
7, 8b, 9 
7, 8a, 9 
6, 7 
6, 7 
1, 8b, 9 
8a, 9 
9   33.6, CH2 2.55, m 8a, 8b 7, 8, 10 6, 7, 8a, 8b, 12, 13, 14 
10 214.5, qC     
11   76.1, qC     
12   26.5, CH3 1.37, s  10, 11, 13 9 
13   26.5, CH3 1.37, s  10, 11, 12 9 
14   15.5, CH3 0.82, d (6.6) 7, 8a 6, 7, 8 1, 6, 7, 9 
15   28.4, CH3 1.27, s  2, 3, 4 2, 4a 
aChloroform-d1, 300/75 MHz. bAssignments are based on extensive 1D and 2D NMR measurements 
(HMBC, HSQC, COSY). cNumbers refer to proton resonances. dNumbers refer to carbon resonances. 
eImplied multiplicities determined by DEPT.   
 
The molecular formula of 2 was found to be C17H30O4, as deduced from HRMS and 
NMR data, implying three degrees of unsaturation. The 13C NMR spectrum showed 17 
carbon signals attributed to five methyls, four methylenes, five methines and three 
quaternary  carbons (Table 2). Considering the molecular formula and according to the 
IR data (3390 cm –1), it was evident that the two remaining protons had to be part of 
hydroxy groups. The marked similarities in the NMR spectra of 1 and 2 (Tables 1 and 
2) suggested that their structures are closely related. Compound 2 is a reduced and 
acetylated derivative of 1, i.e. the only difference between the molecules is the 
acetylated hydroxy group at C-10 in 2, compared with the carbonyl group in 1. The 
connection of the acetyl group (C-16 with C=172.9 and C-17 with C=21.0) to C-10 is 
supported by a 1H-13C HMBC long range correlation between H-10 and C-16.  
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Table 2: 1D and 2D NMR spectroscopic data for compound 2. 
No. ca,b,e H a,b (mult., J in COSYa,b,c HMBCa,d NOESYa,b,c 
1 132.2, CH 5.50, br d (10.3) 2, 5a, 6 2, 3, 5, 6 2, 6, 7, 8a, 8bw, 14 
2 136.1, CH 5.62, br d (10.3) 1, 4a, 6 6 1, 15 
3 70.2, qC     
4 38.7, CH2 a: 1.84, m 
b: 1.70, m 
5a, 5b 
5a, 5b 
3 
3 
4b, 5b, 15 
4a 
5 23.0, CH2 a: 1.69, m 
b: 1.43, m 
4a, 4b, 5b, 6 
4a, 4b, 5a, 6 
 5b, 6 
4a, 5a 
6 41.0, CH 2.17, m 1, 2, 5a, 5b, 7  1, 5a, 7, 14 
7 37.9, CH 1.53, m 6, 14  1, 6, 14 
8 31.8, CH2 a: 1.39, m 
b: 1.17, m 
8b, 9a, 9b 
8a, 9a, 9b 
7 
7 
8b 
8a 
9 28.5, CH2 a: 1.81, m 
b: 1.50, m 
8a, 8b, 9b, 10 
8a, 8b, 9a, 10 
 9b, 10, 12, 13 
9a 
10 81.3, CH 4.81, dd (1.8, 10.3) 9a, 9b 8, 9, 11, 16 9a, 9b, 12, 13, 17 
11 72.7, qC     
12 25.5, CH3 1.20, s  10, 11, 13 9a, 10, 17 
13 26.0, CH3  1.20, s  10, 11, 12 9a, 10, 17 
14 16.3, CH3 0.87, d (6.6) 7 6, 7, 8 1, 7, 8a, 8b, 9a 
15 28.7, CH3 1.25, s  2, 3, 4 2, 4a, 5b 
16 172.9, qC     
17 21.0, CH3 2.11, s  16 12, 13 
aMethanol-d4, 300/75 MHz. bAssignments are based on extensive 1D and 2D NMR measurements 
(HMBC, HSQC, COSY). cNumbers refer to proton resonances. dNumbers refer to carbon resonances. 
eImplied multiplicities determined by DEPT. wweak signal.   
 
 
 
 
 
 
 
 
(1)         (2) 
                                        
Figure 2. HMBC correlations of compound 1 and 2 
Stereochemistry 
HO
O
O
HO
HO
O
HO
   89
 
The relative configuration at C-3 and C-6 for compounds 1 and 2 was established by 
means of a NOESY measurement. NOESY correlations were observed between H3-15 
and Ha-4, between Ha-4 and both Ha-5 and Hb-5, and between Ha-5 and H-6 (Tables 1 
and 2, Figure 2b) indicating methyl group CH3-15 and proton H-6 to be on opposite 
sides of the molecule. 
To determine the absolute configuration at C-3 and C-6 of compounds 1 and 2, CD 
spectra were measured. Compounds 1 and 2 both revealed a negative Cotton effect at 
around 195 nm. This effect was compared with the Cotton effects of two reference 
compounds of known configuration, as seen in Figure 3 (spectroscopic description for 
reference compounds in Mori, 2006) which possess the same cyclohexene ring as 
compounds 1 and 2, but without the extended side chain (C-7 to C-13). Comparing the 
CD effects, the absolute configuration of 1 and 2 has to be S at C-3, and hence R at C-6, 
as it was evident in a relative sense from the NOESY data. The configuration at C-7 for 
compounds 1 and 2 and at C-10 for compound 2 remains unresolved. Compounds 1 and 
2 are new natural products for which the trivial names verticinol A (1) and B (2) are 
proposed. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: CD spectra of compound 1 (a), compound 2 (b), reference compounds (c) and 
(d). CD values for (c) (c 1.07 x 10-3 mol/L, MeOH)  nm (Δε): 194 (-4.1); CD values 
for (d) (c 1.07 x 10-3 mol/L, MeOH)  nm (Δε): 193 (+7.5). 
 
 
a b 
c d 
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Biological activity 
 
Verticinol A was evaluated for cytotoxic activity against three cancer cell lines (NCI-
H460, MCF7 and SF268, tested at 100 µM), two bacterial species (Escherichia coli, 
Bacillus megaterium) and three fungi (Mycotypha microspora, Eurotium rubrum, and 
Microbotryum violaceum), and the alga Chlorella fusca (at a dose of 50 µg/disc), but 
did not show any activity. Verticinol A was further evaluated for inhibition of HIV-1 
and HIV-2 induced cytopathogenic effects in MT-4 cells (tested at 50 µg/mL), 
antiplasmodial activity against Plasmodium berghei (tested at 25 µM), and activity 
against both the Respiratory Syncytial virus (RSV) and the Influenza virus B (Flu B; 
tested at 100 µg/mL in both assays). However, no activity in any of the assays was 
found. Verticinol B was evaluated for cytotoxic activity against three cancer cell lines 
(NCI-H460, MCF7 and SF268, tested at 100 µM), two protein kinases DYRK1A and 
CDK5 inhibition activity assay (tested at 10 mM), and in the 3T3-L1 murine adipocytes 
assay (tested at 100 µg/mL). There was no activity in any of these assays. 
 
 
Experimental section 
General experimental procedures: See  chapter 3 - General methodology. 
 
Fungal material : See chapter 3 - General methodology. 
  
Culture, extraction and isolation: A 10 L culture of Verticillium tenerum grown on 
solid biomalt medium (biomalt 20 g/L, 15 g/L agar) supplemented with sea salt was 
maintained during 2 months. An extraction with 5 L EtOAc yielded 980 mg extract 
which was subjected to a VLC fractionation in a silica open column using a gradient 
solvent system from PE to acetone, namely 10:1, 5:1, 2:1, 1:1, 100 % acetone and 100 
% MeOH, in a total of six fractions. Fraction 3 was separated in a first step by using 
NP-HPLC with PE – acetone 7:2 to yield 10 subfractions. Subfraction 5 was purified 
utilizing RP-HPLC with MeOH-H2O 70:30, which afforded the new compound 1 (3.0 
mg, R.T. 9 min). Subfraction 9 was purified utilizing RP-HPLC with MeOH-H2O 
(70:30) yielding subfraction 2, that required further purification utilizing RP-HPLC with 
MeOH-H2O (80:20) to yield the new compound 2 (1.6 mg, R.T. 7 min.). 
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Verticinol A (1): Yellowish white oil (0.3 mg/L, 0.31 %); [α]23D -74.3 (c 0.23, 
acetone); UV (MeOH) λmax (log ε): 204 (3.4); IR (ATR): 3376, 2931, 1706 cm-1; CD (c 
1.97 x 10-3 mol/L, MeOH)  nm (Δε): 194 (-2.0); 1H and 13C NMR data: Table 1; 
EIMS: m/z 236 (6), 221 (3), 59 (100); HRMS (ESI, positive mode): m/z (M-H2O)+ calcd 
for C15H24O2: 236.1776; found: 236.1776. 
 
Verticinol B (2): Light yellow (0.16 mg/L, 0.16 %); [α]23D +32.6 (c 0.15, MeOH); UV 
(MeOH) λmax (log ε): 204 (3.25); IR (ATR): 3390, 2928, 1716 cm-1; CD (c 1.68 x 10-3 
mol/L, MeOH)  nm (Δε): 194 (-4.9); 1H and 13C NMR data: Table 2; EIMS: m/z 280 
(10), 265 (5), 262 (2), 223 (7), 93 (44), 91 (18), 59 (42), 42 (100); HRMS (ESI, positive 
mode): m/z (M-H2O)+ calcd for C17H28O3: 280.2038; found: 280.2040. 
 
 
 
Biological activity:  See chapter 3 - General methodology. 
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11.  Discussion 
 
The marine environment is a tremendous source of natural products.  Moreover, many 
of the new compounds isolated from marine micro- and macroorganisms showed 
prominent biological effects, and some turned out to be valuable sources of lead 
structures for the development of promising anticancer drug candidates, e.g., the 
marine-fungal derived lead halimide (Kanoh et al., 1997) or the tunicate-derived 
compound trabectedin (Rinehart, et al. 1990, Wright, et al. 1990). 
The main goal of this study was the isolation, identification and biological evaluation of 
new marine-derived fungal natural products as potential drug leads, from which we 
report the isolation of 57 secondary metabolites. From these, 25 are new natural 
products and were isolated from three different fungal strains (further 10 novel N-
methylated cyclic peptides are in structure elucidation procedures), confirming once 
more that endophytic marine-derived fungi are a valuable source of new and interesting 
secondary natural products. 
 
 
Considerations on the present future of natural products research 
 
Since the major pharmaceutical companies have terminated or considerably scaled 
down their natural product drug discovery projects in the 1990s and early 2000s, the 
academic research in this field is indispensable (Baker et al., 2007). The decline of 
natural product research in the pharmaceutical industry can be explained by an 
incompatibility of automated high throughput screening (HTS) programs and the time-
consuming work on natural products extract libraries on the one hand, and on the other 
hand the development of combinatorial chemistry, which generates large so-called 
screen-friendly synthetic chemical libraries for supporting the HTS efforts (Koehn & 
Carter, 2005). 
 
The interest of the pharmaceutical industry in some areas of natural products research 
have been kept or renewed, mainly on cancer research, which still cannot be effectively 
treated (Hill and Fenical, 2010). The natural products leadfinding success in this area is 
shown by the fact that 60% of all anticancer agents in clinical use are natural products 
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or derivatives thereof (Jacob, 2010; Newman and Cragg, 2007; Buttler, 2004). There is 
currently also a renewed interest from pharmaceutical companies in leadfinding new 
classes of antibiotics to overcome the growing problem of antibiotic resistance in many 
bacterial pathogens (Hill and Fenical, 2010; Jacob, 2010). The incredible potential of 
natural products as leads for new antibiotics is shown by the fact that for bacterial 
infections, about 80% of the medicines in clinical use are either natural products or 
derivatives thereof (Jacob, 2010; Newman and Cragg, 2007; Buttler, 2004). 
 
Although we see nowadays a revival of leadfinding marine natural antibiotics, as 
observed in international natural products conferences, the major research in leadfinding 
new bioactive natural products is almost reduced to three countries USA, Germany and 
Japan, and only some isolated institutes spread worldwide. This means that natural 
products research is still performed by a low number of researchers, taking in 
consideration the size of pharmaceutical industry and the importance of natural products 
in society. 
 
A low point in the worldwide research is the low cooperation between institutes 
isolating new natural products and institutes providing bioassays, as well as the 
motivation of a natural products chemist in finding bioassays for bioactivity attribution, 
after the demanding chemical work necessary. This work was heavily complemented 
with a worldwide cooperation with non-profit institutes and universities for bioassay 
experiments with agreements performed during research. If it is essential to know where 
to find valuable natural products, it is equally essential to have bioassays available. An 
organization connecting bioassay providers and natural product laboratories, where 
economic interests should be equally distributed according to the amount of work would 
be thus a solution.  
 
Traditional cultivation and isolation of fungal-derived natural products is indeed time 
consuming, compound availability is very low and structural complexity can be very 
high, amongst other disadvantages (intellectual property issues, access to natural 
chemistry diversity, supply issues, methodological issues, dereplication, etc.) that make 
it unattractive for pharmaceutical industries, even if the starting biological material has 
great value. We believe that the rise of natural products research will not depend on 
funding, but in understanding the biology of microorganisms, which can increase the 
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rate of isolated new molecules derived from microorganisms, for which a 
multidisciplinary approach is needed (better than having a chemist, an ecologist, a 
microbiologist and a pharmacist working together, would be to have one single person 
with the basic knowledge in all these areas, creating thus a unique vision of nature). 
This, along with the development of low cost methods will attract funds and researchers 
to the field.  
 
Furthermore it is necessary to focus on research areas applicable in a short/medium term 
to the generality of natural product research laboratories worldwide. There has been a 
great deal of efforts in developing tools for over expressing and discovering bioactive 
secondary metabolites, heterologous expression in microbial and plant cell cultures, 
metagenomics or new spectroscopic analytic methods. But low cost methods for the 
discovery of valuable natural products would lead to the integration of low funded 
laboratories worldwide in major pharmaceutical discoveries. For example 
metagenomics is nowadays a hot topic in the field. Its application in cases such as the 
chemical analysis of gene clusters isolated from unculturable bacteria is indeed state of 
the art and of unvaluable scientific interest. But these research areas are still (and will be 
on the next decades) too expensive, time consuming, uncertain regarding success of 
finding new natural products or in over-expressing pharmaceutically valuable natural 
products, hence it is promising but far from being a massive tool for academic/industrial 
natural products discovery. A more interesting approach would be to understand why 
the great majority of bacterial species are unculturable to this day, i.e. by discovering 
the biological needs of these bacterial species, one would create a low cost and probably 
globally applied methodology for the expression of natural products in culture-
independent methods. It is considered obviously a huge barrier, but when overcome it 
would open a new (and applicable massively) world in natural products research. 
 
Natural products laboratories also possess chemical libraries of known but rare 
compounds isolated in house. Though, many are kept in the freezer, when they should 
be tested for bioassays as quick as possible, not only because they may possess 
bioactivity holding the cure for a disease, but because they lose activity during time. 
Nowadays the field is focusing in leadfinding cytotoxic or antimicrobial new natural 
products. Though, if a new natural product does not have these biological properties, it 
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must be seen not as a dead lead, but as the starting point for the remaining immense 
biological assays available.  
 
The future of natural products research will be considered again economically valuable 
when the pharmaceutical industry regains the interest on the field. Fast, low cost, and 
working on biological samples with high probabilities of finding valuable natural 
products are in need. The potential of other areas not commonly explored in this area 
should also be investigated, such as searching bioactive proteins from microorganisms. 
Another poorly understood world but biotechnologically extremely valuable is the study 
of bacteria associated with eucariotic organisms, mainly because the secondary 
metabolites produced by these prokaryotes may be the main reason for 
association/symbiosis, and these kind of associations work as a nature’s pre-clinical 
trial, having thus these molecules more chances of being used for pharmaceutical 
applications. 
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12.  Summary 
 
The marine environment is distinguished by unique groups of organisms being the 
source of a wide array of fascinating structures. Marine microorganisms, such as fungi 
often occur associated with macroorganisms like algae, sponges or tunicates and 
produce secondary metabolites with novel structures and potential pharmaceutical 
significance. The goal of this study was the evaluation of new natural products of 
marine-derived fungi in order to find novel lead structures for drug development. To 
achieve this aim seven fungal strains living associated with marine algae and sponges 
were cultivated during 40 to 60 days, and the extracts tested for bioactivity. 
Subsequently, the natural products were isolated, their structures determined and their 
bioactivity established. 
From algicolous and sponge-derived fungi, 35 new secondary metabolites were isolated, 
14 of which display unprecedented carbon skeletons implying unknown biosynthetic 
reactions in fungi. All pure compounds were subjected to an extensive panel of 
bioactivity tests, in a total of around 850 individual biological activity assays against 
111 bioactivity targets, from which antiproliferative, antiplasmodial and protease 
inhibitory properties, as well as affinity to receptors involved in psychoactive activity 
could be attributed. 
 The fungus Stachylidium sp. was isolated from the tropical marine sponge 
Callyspongia cf. C. flammea. This fungus yielded upon cultivation on marine media a 
plethory of polyketide- (marilines, marilones) and tyrosine-derived metabolites. The 
skeleton of marilines and marilones is most unusual, and its biosynthesis is suggested to 
require unusual biochemical reactions in fungal secondary metabolism. 
 
Ten new phthalide 
derivatives with unusual 
structural motives, i.e. 
marilones A – J were 
obtained. In the epimeric 
compounds marilones I 
and J the phthalide (=isobenzofuranone) nucleus is modified to an isobenzofuran ring 
 
Figure 1. Structure formulae for marilones A and B  
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with ketal and acetal functionality. Marilone A was found to have antiplasmodial 
activity against Plasmodium berghei with an IC50 of 12.1 µM. Marilone B showed 
selective antagonistic activity towards the serotonin receptor 5HT2B with a Ki value of 
7.7 µM.  
 
Further chemical investigation of this marine-derived fungus led to the isolation of the 
novel phthalimidine derivatives 
marilines A - D. Both enantiomers 
marilines A and B  inhibited human 
leucocyte elastase (HLE) with an IC50 
value of 0.86 μM, and 
acetylcholinesterase (AChE) with 
IC50 values of 0.18 μM (offset = 49 
%) and 0.63 μM (offset = 54 %), 
respectively. 
 
 
The diverse secondary metabolism of this 
fungal strain was additionally demonstrated 
by the identification of yet four further new, 
putatively tyrosine-derived natural products, 
i.e. stachylines A – D. The absolute 
configuration of these novel compounds was 
established by Mosher’s method. Stachyline 
A possesses a rare terminal oxime group and 
occurs as an interchangeable mixture of E/Z- 
isomers. 
 
In the more hydrophilic fractions of the fungal extract, ten N-methylated cyclic 
peptides, endolides A-J, could be found. The absolute configuration of these compounds 
and biological activity is currently under investigation.   
O N
OO O
O
R2R1
(A) R1 = CH3 ; R2 = H
(B) R1 = H; R2 = CH3
 
Figure 2. Structure formulae of Marilines A and B. 
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Figure 3. Structure formulae of Stachyline A 
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Further novel compounds, to date with no pharmacological activity attributed, were 
retrieved from the fungus Cadophora malorum. This green alga derived fungus yielded 
four new hydroxylated sclerosporin derivatives, namely 15-hydroxysclerosporin, 12-
hydroxysclerosporin, 11-hydroxysclerosporin and 8-hydroxysclerosporin, the absolute 
configuration of which was established by CD spectroscopy. Furthermore, the chemical 
investigation of Verticillium tenerum yielded the two new hydroxylated bisabolane-type 
sesquiterpenes verticinol A and B. The absolute configuration of the cyclohexenyl 
moiety within these metabolites was deduced by a combination of CD spectroscopy and 
NOESY measurements. 
 
In conclusion, the chemical investigation of marine fungi living associated with algae 
and sponges led to new natural products, of which the marilines A and B represent the 
most unusual and unprecedented structural type. Also, this study identified molecules 
with potent bioactivity, e.g. the HLE and AChE inhibiting activity of marilines A and B. 
The results of this study demonstrate that endophytic marine-derived fungi are 
producers of novel and pharmacologically relevant compounds.  
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13. APPENDIX  
13.1. Bioactivity data 
Marilines 
Figure 1. HLE protease inhibition activity assay results for mariline A (W223_A) and 
mariline B (W223_B). Calculated IC50values in table 7. 
 
Figure 2. ACEase protease inhibition activity assay results for mariline A (W223_A) 
and mariline B (W223_B). Calculated IC50 values in table 7. 
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Table 1. Antiproliferative activity results of mariline A against 5 cancer cell lines 
 
Growth delaying activity (represented by GI50), cytostatic activity (represented by TGI) and cytotoxic 
activity (represented by LC50) were observed. GI50 is different than the IC50 in that it contains a correction 
for the starting population. Results in μM. 
 
CEL LINES     Mariline A 
NCI-H460  
GI50 29,6 
TGI  60,1  
LC5 90,7  
MCF7  
GI50 6,9 
TGI  33,5  
LC5 81,0  
SF268  
GI50 25,3 
TGI  56,0  
LC5 86,6  
A549  
GI50 30,8 
TGI  73,4  
LC5 >100  
PC3  
GI50 29,6 
TGI  80,7  
LC5 <100  
 
cancer cell lines: NCI-H460/lung, A549/lung, MCF7/breast and SF268/CNS and CAKI/renal. Averge 
values in Table 6. 
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Figure 3. Mean graph for antiproliferative activity against 19 cancer cells of mariline B  
 
(GI50s of cell lines are represented as bars vs. the mean of all GI50s (average of all GI50s). Bars to the 
left denote the sensitive cell lines, those to the right the resistant.) 
 
Table 2. Pairwise coefficient correlations (PCC) of the COMPARE data analysis of 
mariline B with the synthetic compounds database. 
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Table 3. Pairwise coefficient correlations (PCC) of the COMPARE data analysis of 
mariline B with the diversity set database. 
 
 
Table 4. Pairwise coefficient correlations (PCC) of the COMPARE data analysis of 
mariline B with the marketed drugs database. 
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Table 5. Pairwise coefficient correlations (PCC) of the COMPARE data analysis of 
mariline B with the standard agents database  
(Standard agents represent a set of compounds with known mechanism of action. PCC>0.6 gives a first 
prediction for a putative mechanism of action. PCC is used to measure the similarity degree of the 
experimental drug (=seed) vs. those of the databases used. Any PCC greater or equal to 0.6 is considered 
as positive match. The closer to 1 the PCC the greatest the similarity). 
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Figure 4 a-c. Antiplasmodial activity data for marilines A and B 
Bioactivity test relates to the inhibition of the infection of Plasmodium berghey on the liver stage. The 
parasite expresses luciferase, thus the infection is measured by luminescence (Bars); the cellular density 
(i.e. the non-toxicity of the compounds) is measured by fluorescence. The tests were performed in 
quadruplicate measurements per compound. Samples were dissolved in acetone which was also tested 
alone. Results show that the solvent has a low effect on the cells of the infection (the X axis of the 
acetone graphic shows not the concentration of the solvent but the highest quantity of acetone present in 
the corresponding compound concentrations. Grey bars indicate the non-treated cells results 
 
Figure 4a. Acetone measurements (control) 
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Figure 4b. Mariline A measurements 
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Figure 4c. Mariline B measurements 
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Figure 5. Ki determination of mariline B (compound 16587) against the receptor 
dopamine transporter DAT 
 
(Erratum, value is 5627 nM) 
 
Figure 6. Ki determination of mariline B (compound 16587) against the adregenic 
receptors Beta 3 
 
 
Figure 7. Ki determination of mariline B (compound 16587) against the histamine 
receptor H2. 
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Figure 8. Ki determination for the ligands Mariline C (compound 16594) and D 
(compound 16595) against the cannabinoid receptor CB2. 
 
 
Table 6. Antiproliferative and antiplasmodial biological activity data for marilines A - 
D 
  
Antiproliferative activity against cancer 
cell lines (GI50)* 
Antiplasmodial activity 
(IC50)** 
Mariline A 24.44 μM  6.68 μM 
Mariline B 5.00 μM 11.61 μM 
Mariline C 48.32 μM 13.84 μM 
Mariline D > 100 μM > 25 μM 
 
*Growth delaying activity represented by GI50 is the average value registered for the tested cell lines; 
mariline A was tested against 10 cancer cell lines, mariline B against 19 cell lines, marilines C and D 
against 5 cancer cell lines. All compounds were tested in two independent experiments, each one run in 
triplicate. Growth rates are the mean of the two experiments. As positive control it was used etoposide 
treated in the same way. 
**Antiplasmodial activity test relate to the inhibition of the infection of Plasmodium berghey on the liver 
stage. The parasite expresses luciferase, thus the infection is measured by luminescence. The tests were 
performed in quadruplicate measurements per compound.  
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Table 7. Protease HLE and cease inhibition data review for marilines A and B 
 
  HLE Porcine Cease 
  equation used for analysis equation used for analysis 
    v = v0/(1+[I]/IC50) v = (v0-offset)/(1+[I]/IC50)+offset 
Mariline A IC50 = 0.86 ± 0.26 μM IC50 = 4.4 ± 1.6 μM IC50 = 0.18 ± 0.08 μM, offset = 49 ± 3% 
Mariline B IC50 = 0.86 ± 0.12 μM IC50 = 6.6 ± 1.8 μM IC50 = 0.63 ± 0.20 μM, offset = 54 ± 3% 
Mariline C > 10 μM > 10 μM > 10 μM 
Mariline D - - - 
IC50 values obtained from quadruplicate measurements at five different inhibitor concentrations. 
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Bioactivity data - Marilones 
 
Figure 9. Antiproliferative activity data for marilones A and C  
 
Growth delaying activity (represented by GI50), cytostatic activity (represented by TGI) and cytotoxic 
activity (represented by LC50) were observed. GI50 is different than the IC50 in that it contains a correction 
for the starting population. Results in μM. 
 
 
 
 
 
 
 
           
 GI50 marilone A           GI50  marilone C 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cancer cell lines: NCI-H460/lung, MCF7/breast and SF268/CNS 
Average values in chapter 4.  
 
 
 
CELL LINES   (A) (C) Etoposide 
NCI-H460 
GI50 42,9 31,0 0,4 
TGI 80,9 73,8 22,4 
LC50 >100 >100 124,2 
MCF7 
GI50 28,8 20,0 22,8 
TGI 67,7 67,0 118,0 
LC50 >100 >100 213,1 
SF268 
GI50 38,4 28,9 7,7 
TGI 70,2 64,2 90,4 
LC50 >100 99,6 201,4 
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Figure 10a-c. Antiplasmodial activity data for marilones A and C  
Bioactivity test relates to the inhibition of the infection of Plasmodium berghey on the liver stage. The 
parasite expresses luciferase, thus the infection is measured by luminescence (Bars); the cellular density 
(i.e. the non-toxiciy of the compounds) is measured by fluorescence. The tests were performed in 
quadruplicate measurements per compound. Samples were dissolved in acetone which was also tested 
alone. Results show that the solvent has a low effect on the cells of the infection (the X axis of the 
acetone graphic shows not the concentration of the solvent but the highest quantity of acetone present in 
the corresponding compound concentrations. Grey bars indicate the non-treated cells results 
 
Figure 10 a. Acetone measurements (control) 
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Figure 10b. Marilone A 
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Figure 10c. Marilone C 
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Figure 11. Ki value determination of the antagonistic effect of Marilone B (compound 
16591) against the serotonin receptor 5HT2B. 
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13.2. Appendix - Protocols and media 
Protocol for Laser Microscopy Sample Preparation 
 
Take a small piece of fungi from a petri dish into an eppendorf 
Take care not to take media 
I 
Add 200-400 μL  0.85% NaCl 
Mix with pipette 
I 
Take 10 μL sample and place in PCR-eppendorf 
I 
Add 0.5 μL stain solution stock 
Mix, and incubate in dark for 15 min 
I 
Place 5 – 10 μL sample in microscope glass slide 
I 
Add  5 μL slow fade reagent enhancer 
I 
Check in laser microscope 
 
Material 
Eppendorfs (normal and PCR-small) 
Live-dead bac viability kit 
Slowfade fluorescence enhancer 
0.85% NaCl 
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Protocol Advanced Marfey’s Method 
(Peptide hydrolysis) 
1. Take a minimum of 0.5 mg of peptide in a small glass vial with metal screw-top 
2. Add 0.5 mL of 6 N HCl 
3. Incubate for 16 hours at 110 ºC 
4. Dry hydrolysed peptide in a N2 flow until dryness 
(Marfey reaction) 
5. Add 50 μL pure water.   
6. Add 40 μL of 1 M NaHCO3 
7. Add 100 μl of 1% L-FDLA (or L-FDAA, both are Marfey reagent) (stock solution,  
    1 mg/100 μL of acetone) 
8. Incubate at 70 ºC for 40 minutes (reaction of Marfey reagent and amino acid 
residues) 
9. Cool at room temperature and add 20 μL 2N HCl in order to stop the reaction 
10. Dry in N2 flow and add 250 μL ACN for LC-MS analysis (method “Christian 1”; 
see solvent system in the peptides articles) 
 
Standard amino acids preparation 
Measure 1 mg of the L-amino acid and in a second vial 0.5 mg of the L-amino acid and 
0.5 mg of the D- amino acid. 
With both vials perform the Marfey reaction above described (point 5. until 10., final 
concentration for LC-MS 1 mg/ml) 
Repeat this with every standard amino acids present in the peptide for comparison. 
 
Notes:  
Hydrolysis is performed to break the peptidic bonds between the amino acid residues. In Marfey’s 
reaction, the L-L configuration (e. g. L-Phe-L-FDLA) usually comes first as the D-L (e.g. D-Phe-L-
FDLA). With both reactions of the standard amino acids we establish first in the mixture of D/L residues 
the retention time of both D- and L- amino acid configurations reacting with the L-Marfey reagent. Then 
the vial with only the L-amino acid configuration is basically to confirm which one is the peak 
corresponding to the product of the reaction L-amino acid with the L-FDLA. You establish then 
unambiguously the configuration of the residues present in each peak. Then analyse the extracted ion of 
the same amino acid in your peptide and compare the retention time, it should be the same as L-residue/L-
FDLA or D-residue/L-FDLA and you can assign the configuration.     
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Protocol Mosher’s Method for Configurational Determination of Chiral 
Centers with a Hydroxyl Group/Proton (Secondary and Tertiary alcohols)  
(a) - Calculations of the mol of Stachymide A in 1 mg 
236.26 g ------- 1 mol 
       0.001 g ----- X    X = 4.233 x 10 -6 mol 
(b) - Calculation of the mg and final volume of MTPA-Cl (M.W 252.62) 
corresponding to 10 eq (normally reaction is made with 3 eq). 
10 eq = 4.223 x 10-5 mol 
 
252.62 g ----- 1 mol 
X         g ------  4.223 x 10-5 mol    X = 10.6 mg 
MTPA-Cl density (ρ) = 1.6, (ρ = m/v) thus vol. of MTPA-Cl to insert is 6.625 μL. 
       
(c) - (R)- and (S)-MTPA esters reaction. Dissolve the secondary alcohol (1 eq, 1 mg, 4.23 x 
10-6 µmol) with the corresponding MTPA-Cl (10 eq) in an adequate quantity of deuterated 
pyridine and DMAP (1 eq) in an NMR tube. The reaction is followed by 1H-NMR to observe 
the downfield proton shift of H-2’. After 1 hour reaction time (or more if needed), record the 
final 1H-NMR, dry the sample and re-dissolve in D-acetone for 1H-13C HSQC measurements if 
necessary.  
(d) The Δ(S-R) values between (S)- and (R)- MTPA esters can be recorded with 1H-NMR 
and/or 1H-13C HSQC and they correspond to the difference of 
the proton shifts near the chiral carbon between the (S)- and 
(R)- MTPA esters. Normally the reaction is confirmed as 
successful if both sides have opposite (+ and -) values of Δ(S-R). 
 
Use the general 
formula in this 
described figure 
(positive side in the 
back, negative in the front, rotate molecule (proton on back side) and determine the R/S configuration. 
 
NOTE: Not even one molecule of water should be present in flasks/pipets/reagents! 
The 3D model for MPA is the REVERSE of the MTPA, i.e. Δ(R-S), negative Δ in the 
back, and positive Δ in the front of the model.  
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UV Spectra Calculations 
UV spectra were recorded on a Perkin-Elmer Lambda 40 with UV WinLab Version 
2.80.03 software, using 1.0 cm quartz cells. The molar absorption coefficient ε was 
determined in accordance with the Lambert-Beer-Law: 
 
ε = A / C.D 
  
A = Absorption at peak maximum (U.A.) 
 C = concentration used in the cuvette (mol/L) 
D = length of the measurement (normally 1 cm) 
 
Results presented as the logarithm of the molar absorption coefficient (log ε) e.g. “UV 
(MeOH) λmax (log Є) 219 nm (log ε 4.11)” 
 
Protocols and Calculations for Circular Dichroism Spectra 
CD spectra were recorded in MeOH at room temperature using a JASCO J-810-150S 
spectropolarimeter. The CD (circular dichroism) is measured as ellipticity Θ (in mdeg, 
millidegrees) and subsequently converted into the molar ellipticity [Θ]M and finally into 
Δε in accordance to the following equation: 
 
[θ] = θ . M / 10 . C . d 
 
[Θ] = molar ellipticity [degrees x cm2/dmol] 
 
 θ = ellipticity (values in mdegrees, which are the Y axis values taken from the 
CD measurement) 
 M = molecular weight (g/mol) 
 C = concentration in the cuvette (mg/ml ) 
 D = measurement distance, or path lenght (normally 0.1 cm) 
 
Results presented as ε =[θ] / 3300, and written with the molar concentration, c,  in 
the cuvette, e.g. “CD (c 2.8 × 10–4  mol/L, MeOH) λ (ε) = 202 (-9.0), 218 (+12.4), 248 
(+6.1)”. 
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Protocol for the effect of (+) sclerosporin and 4 hydroxylated derivatives on 
sporulation and growth of Cadophora malorum. 
 
5 compounds tested, all under LIGHT conditions 
Protocol per compound, made in triplicate. 
sporogenic activity 
compound 
concentration  
(μg/mL medium) 
concentration to use   
in 20 ml BMS media 
from STOCK* 
growth area 
(cm2) = A 
Spore 
number/growth 
area (1 cm2) =B 
total spore number 
(AxB) 
0 0       
0.005 1 μL       
0.5 10 μL       
5 100 μL       
 
*Stock solution: dissolve compounds in acetone (500 μg samples in 500 μL) 
9 cm radium petri dish, 20 mL media 
1 week waiting time. 
Spore number count: take 1 cm2 medium, place in a small quantity of water (e.g. 2 mL) 
and analyze in the microscope with a microscope slide counting chamber. Determine 
the number of spores and multiply the microscopic volume for the total water volume 
and subsequently for the total growth area.  
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Media preparations 
Artificial Sea Water (ASW), 1L 
KBr                          1.0 g 
NaCl                     234.8 g 
MgCl2x6H2O        106.1 g 
CaCl2x2H2O           14.7 g 
KCl                           6.6 g 
SrCl2x6H2O              0.4 g 
Na2SO4                   39.2 g 
NaHCO3                   1.9 g 
H3BO3 (boric acid)   0.3 g 
 
Biomalt medium (BM), 1L 
Biomalt     20 g 
- For BMS, dissolve in ASW 
- For BMS-agar, add 15g/L agar 
 
MYA, 1L 
East extract      4 g 
Malt extract   10 g 
Glucose           4 g 
1L Dist. water and adjust to pH 7.3 
- For MYA-ASW dissolve in ASW 
- For MYA-agar, add 15g/L agar 
  
Czapek medium, 1L 
Dissolve 35 g DifcoTM Czapek-dox   
Broth in 1L distilled water. 
 
 
MPY medium, 1L 
Yeast extract             5 g 
Peptone from Fish     3 g 
Mannitol          25 g 
1L Distilled water  
Minimal Peptone Basal medium 
DifcoTM Minimal Broth Davis without 
Dextrose                         10.6 g 
Peptone from meat           3 g 
1L Distilled water 
Several carbon sources added from 3g/L 
to 10 g/L, insoluble carbon sources 
inoculated with 1% DMSO. 
  
Peptone medium 
Peptone                  10 g 
NaCl           5 g 
1L Distilled water and adjust pH to 7.2 
-For solid-medium add agar 20 g/L   
 
Trypticase Soy medium 
Pancreatic digest of casein    15 g 
Enzymatic digest of soy bean 5 g 
NaCl      5g 
1L Distilled water and adjust pH to 7.3 
- For solid-medium, agar  15 g/L   
 
PDA medium, 1L 
Dissolve 24 g DifcoTM Potato Dextrose 
Broth in 1L distilled water. 
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13.3. Appendix - Complete 2D NMR spectroscopic tables 
Marilines 
Table 1. 1D and 2D NMR spectroscopic data for marilines A/B 
position δN, δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa,b, d NOESYa, c
N 132.4, N        
1 166.2, qC     
2 116.4, qC     
3 157.2, qC     
4 119.4, qC     
5 161.9, qC     
6 101.8, CH 6.95, s  2, 4, 5, 7, 8 8, 9, 1' 
7 150.0, qC     
8 57.5, CH 4.97, q (6.8) 6, 9 1, 7, 9 6, 9 
9 19.4, CH3 1.27, d (6.8) 8 7, 8, N 6, 8 
10 62.1, CH3 3.99, s  3 11 
11 8.8, CH3 2.12, s   3, 4, 5 10, 9' 
12 120.1, qC     
13 156.8, qC     
14 101.2, CH 6.67, d (2.6) 16 12, 13, 15, 16 18, 1'' 
15 160.8, qC     
16 105.5, CH 6.56, dd (2.6, 8.6) 14, 17 12, 14, 15 17, 18 
17 131.9, CH 7.19, d (8.6) 16 12, 13, 15, N 8, 9, 16 
18 55.7, CH3 3.81, brs  15 14, 16 
1' 66.2, CH2 a: 4.68, dd (6.6, 12.3) 1'b, 2' 5, 2', 3' 6, 2', 9' 
  b: 4.72, dd (6.6, 12.3) 1'a, 2' 5, 2', 3'  
2' 120.6, CH 5.53, t (6.6) 1'a, 1b, 9'  4', 9' 1', 4' 
3' 141.5, qC     
4' 40.1, CH2 2.12, m 5' 5' 2' 
5' 27.0, CH2 2.14, m 4', 6' 4' 6' 
6' 124.6, CH 5.10, t (6.6) 5', 8' 5', 8',10' 5', 8' 
7' 132.0, qC     
8' 25.8, CH3 1.63, brs 6' 6', 7', 10' 6' 
9' 16.7, CH3 1.77, brs 2' 2', 3', 4' 1' 
10' 17.7, CH3 1.59, brs 6' 6', 7', 8'  
1'' 66.1, CH2 a: 4.54, dd (6.6, 12.0) 1''b, 2'', 4'', 5'' 11, 2'', 3'' 12, 2'', 4'', 5'' 
  b: 4.58, dd (6.6, 12.0) 1''a, 2'', 4'', 5'' 11, 2'', 3''  
2'' 120.8, CH 5.35, t (6.6) 1''a, 1''b, 4'', 5'' 4'', 5'' 1'', 5'' 
3'' 137.9, qC     
4'' 18.2, CH3 1.68, brs 2'' 2'', 3'', 5'' 1'' 
5'' 25.7, CH3 1.67, brs 2'' 2'', 3'', 4'' 2'' 
aacetone-d6, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments (1H-13C, 
1H-15N HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon 
resonances. e Implied multiplicities determined by DEPT.  
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Table 2. 1D and 2D NMR spectroscopic data for mariline C 
position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 167.3, qC    
2 116.3, qC    
3 156.9, qC    
4 119.3, qC    
5 161.7, qC    
6 101.8, CH 6.92, s 8 2, 3, 4, 5, 7, 8 
7 150.0, qC    
8 56.9, CH 4.62, q (6.8) 6, 9 1, 2, 6, 7, 9 
9 18.9, CH3 1.44, d (6.8) 8 7, 8 
10 62.1, CH3 3.98, s  3 
11 8.8, CH3 2.09, s  3, 4, 5 
12 43.6, CH2 a 3.85, dt (14.0, 5.5) 12b, 13 1, 8, 13 
  b: 3.33, dt (14.0, 5.5) 12a, 13 1, 8, 13 
13 61.7, CH2 3.71, m 12a, 12b 12 
1' 66.2, CH2 a: 4.65, dd (6.6, 12.3) 2', 9' 5, 2', 3' 
  b: 4.71, dd (6.6, 12.3)    
2' 120.6, CH 5.51, t (6.6) 1', 4', 9' 4' 
3' 141.5, qC    
4' 40.1, CH2 2.12, m 2',  3', 5', 6' 
5' 27.0, CH2 2.14, m 6', 8' 3', 4', 6', 7' 
6' 124.6, CH 5.10, t (6.6) 5', 8', 10'  
7' 132.1, qC    
8' 25.8, CH3 1.63, brs 5', 6' 6', 7', 10' 
9' 16.7, CH3 1.76, brs 1', 2' 2', 3', 4' 
10' 17.7, CH3 1.58, brs 6' 6', 7', 8' 
aacetone-d6, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments (1H-
13C, 1H-15N HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon 
resonances. e Implied multiplicities determined by DEPT. * Weak correlation. 
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Table 3. 1D and 2D NMR spectroscopic data for mariline D 
position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 171.7, qC    
2 114.5, qC    
3 158.4, qC    
4 118.9, qC    
5 162.3, qC    
6 105.0, CH 6.68, s  2, 3, 4, 5, 8 
7 152.1, qC    
8 53.2, CH 4.53, q (6.8) 9 1, 2, 6, 7, 9 
9 20.8, CH3 1.42, d (6.8) 8 7, 8 
10 62.5, CH3 3.95, s  3 
11 8.6, CH3 2.15, s   3, 4, 5 
aMeOD, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments (HMBC, 
HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e Implied 
multiplicities determined by DEPT.  
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Marilones 
Table 4. 1D and 2D NMR spectroscopic data for marilone A 
position      δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 168.2, qC    
2 110.0, qC    
3 158.0, qC    
4 120.4, qC    
5 164.2, qC    
6 100.8, CH 6.95, s  2, 3, 4, 5, 7, 8 
7 154.2, qC    
8 77.0, CH 5.43, q (6.6) 11 1, 2, 6, 7, 11 
9 62.1, CH3 3.98, s  3 
10 8.8, CH3 2.09, s  3, 4, 5 
11 20.9, CH3 1.54, d (6.6) 8 7, 8 
1' 
 
66.5, CH2 
 
a: 4.69, dd (6.6, 12.1) 
b: 4.74, dd (6.6, 12.1)  
1’b, 2' 
1’a, 2’ 
5, 2', 3' 
5, 2’, 3’ 
2' 120.1, CH 5.52, t (6.6) 1'a, 1’b, 9' 1', 4', 9' 
3' 142.1, qC    
4' 40.1, CH2 2.10, m 5' 2', 6'  
5' 26.9, CH2 2.13, m 4', 6' 3', 4', 6', 7' 
6' 124.64, CH 5.09, m 4', 5', 8', 10' 4’, 5'; 8’ 
7' 132.1, qC    
8' 25.8, CH3 1.63, br s  6' 6', 7' 
9' 16.7, CH3 1.76, br s 2’ 2', 3', 4' 
10' 17.7, CH3 1.58, br s 6' 6', 7' 
aCD3COCD3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT.  
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Table 5. 1D and 2D NMR spectroscopic data for marilone B 
position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 168.2, qC    
2 109.1, qC    
3 158.9, qC    
4 118.8, qC    
5 163.2, qC    
6 103.6, CH 6.73, s  2, 3, 4, 5, 8 
7 153.9, qC    
8 76.6, CH 5.43, q (6.6) 11 1, 2, 6, 7, 11 
9 62.0, CH3 3.89, s  3 
10 8.6, CH3 2.02, s  3, 4, 5 
11 21.0, CH3 1.44, d (6.6) 8 7, 8 
a MeOD, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. 
e Implied multiplicities determined by DEPT.  
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Table 6. 1D and 2D NMR spectroscopic data for marilone C 
position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 68.9, CH2 5.50, s  2, 3, 5, 7, 8 
2 128.4, qC    
3 153.9, qC    
4 124.8, qC    
5 159.7, qC    
6 102.0, CH 7.03, s  2, 3, 4, 5, 7, 8 
7 125.8, qC    
8 171.1, qC    
9 59.3, CH3 3.96, s  3 
10 9.8, CH3 2.15, s  3, 4, 5 
1' 66.4, CH2 4.7, d (6.6) 2' 5, 2', 3' 
2' 120.5, CH 5.51, t (6.6) 1', 9' 4', 9' 
3' 141.6, qC    
4' 40.1, CH2 2.10, m   2', 3', 6'  
5' 26.9, CH2 2.14, m 4', 6' 3', 4', 6', 7' 
6' 124.6, CH 5.10, m 4', 5', 8', 10' 4', 8', 10' 
7' 132.05, qC    
8' 25.8, CH3 1.63, s (br) 6' 6', 7', 10' 
9' 16.7, CH3 1.78, s (br) 2' 2', 3', 4' 
10' 17.7, CH3 1.58, s (br) 6' 6', 7', 8' 
aCD3COCD3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT.  
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Table 7. 1D and 2D NMR spectroscopic data for marilone D 
position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 
 
66.1, CH2 
 
a: 4.39, d (9.9) 
b: 4.41, d (9.9) 
1b 
1a 
2, 3, 7, 9 
2, 3, 7, 9 
2 119.6, qC    
3 159.3, qC    
4 116.1, qC    
5 157.1, qC    
6 108.5, CH 6.91, s  2, 3, 5, 7, 8, 11 
7 147.2, qC    
8 65.9, CH 5.06, q (6.3) 12 2, 6, 7, 12 
9 61.8, CH3 3.67, s  3 
10 9.1, CH3 2.09, s  3, 4, 5 
11 57.8, CH3 3.32, s  1a, 1b 
12 25.4, CH3 1.33, d (6.3) 8 7, 8 
aCD3COCD3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT.  
 
 
Table 8. 1D and 2D NMR spectroscopic data for mariline E 
position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 66.9, CH2 4.53, s   2, 3, 7, 9 
2 120.3, qC    
3 160.0, qC    
4 117.5, qC    
5 157.9, qC    
6 111.6, CH 6.77, s  2, 3, 4, 5, 7, 8 
7 141.4, qC    
8 62.6, CH2 4.64, s  2, 3, 4, 6, 7 
9 62.2, CH3 3.74, s  3 
10 9.2, CH3 2.15, s   3, 4, 5 
11 58.1, CH3 3.42, s  1 
aCD3COCD3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. 
e Implied multiplicities determined by DEPT.  
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Table 9. 1D and 2D NMR spectroscopic data for marilone F 
position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 10.1, CH3 0.85, t (7.3) 2 2, 3 
2 30.6, CH2 1.35, m 1, 3 1, 3 
3 69.4, CH 3.85, m 2, 4 1 
4 49.5, CH2 a: 2.41, dd (4.4, 16.5) 3, 4b 2, 3, 5 
  b: 2.51, m 4a 2, 3, 5 
5 214.8, qC    
6 48.1, CH 2.87, m 7a, 7b, 16 5, 7, 8, 16 
7 29.8, CH2 a: 2.81, m 6, 7b 5, 6, 8, 9, 13, 16 
  b: 2.53, m 6, 7a  5, 6, 8, 9, 13, 16 
8 122.1, qC    
9 159.2, qC    
10 115.6, qC    
11 155.6, qC    
12 111.5, CH 6.51, s  8, 10, 11, 14 
13 141.9, qC    
14 26.3, CH2 2.52, m 15 8, 12, 13, 15 
15 15.8, CH3 1.10, t (7.5) 14 13, 14 
16 15.9, CH3 0.94, d (6.7) 6 5, 6, 7 
17 60.4, CH3 3.65, s  9 
18 9.4, CH3 2.08, s   9, 10, 11 
aCD3COCD3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT.  
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Table 10. 1D and 2D NMR spectroscopic data for marilone G 
position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 67.1, CH 5.54, dd (1.6, 6.5) 9 2, 3, 7, 8 
2 139.4, qC    
3 158.4, qC    
4 128.1, qC    
5 159.8, qC    
6 103.3, CH 6.87, s  2, 4, 5, 8 
7 137.2, qC    
8 206.4, qC    
9 48.4, CH2 a: 3.08, dd (6.5, 19.1) 1, 9b 1, 2, 8 
  b: 2.50, dd (1.6, 19.1) 1, 9a 1, 2, 8 
10 61.1, CH3 4.01, s  3 
11 10.0, CH3 2.23, s   3, 4, 5, 6 
aMeOD, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments (HMBC, 
HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e Implied 
multiplicities determined by DEPT.  
 
 
Table 11. 1D and 2D NMR spectroscopic data for marilone H 
position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 166.0, qC       
2 98.2, qC    
3 165.6, qC    
4 99.1, CH 6.02, s  2, 3, 5, 6 
5 164.9, qC    
6 27.1, CH2 2.42, q (7.5) 7 4, 5, 7 
7 11.3, CH3 1.13, t (7.5) 6 5, 6 
8 8.5, CH3 1.81, s   1, 2, 3 
aCD3COCD3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT.  
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Table 12. 1D and 2D NMR spectroscopic data for marilone I 
position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d NOEa, d 
1 105.4, CH 6.32, s   2, 3, 6, 7, 8, 13 9, 12, 13 
2 121.4, qC     
3 154.8, qC     
4 119.0, qC     
5 160.4, qC     
6 100.2, CH 6.60, s  1, 2, 3, 4, 5, 7, 8, 10 10, 11, 12, 1' 
7 141.7, qC     
8 111.4, qC     
9   59.8, CH3 3.90, s  3 1 
10     9.3, CH3 2.07, s  2, 3, 4, 5, 6 6 
11   28.1, CH3 1.62, s  7, 8 6, 13 
12   49.7, CH3 2.85, s  8 1, 6 
13   54.2, CH3 3.38, s  1 1, 11 
1'   66.1, CH2 4.64, d (6.6) 2', 9' 2', 3', 5' 6, 9' 
2' 120.8, CH 5.48, t (6.6) 1', 9' 4', 9'  
3' 141.1, qC     
4'   40.1, CH2 2.08, m 5' 2', 3', 5', 6', 9' 6' 
5'   27.0, CH2 2.11, m 6', 4' 3', 4', 6' 6' 
6' 124.6, CH 5.11, m 5', 8', 10'  4', 5', 8' 
7' 132.0, qC     
8'   25.8, CH3 1.64, br s  6' 6', 7', 10' 6' 
9'   16.6, CH3 1.75, br s 2', 1' 2', 3', 4' 1' 
10'   17.7, CH3 1.59, br s 6' 6', 7', 8'   
aCD3COCD3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT.  
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Table 13. 1D and 2D NMR spectroscopic data for marilone J 
position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d NOEa, d 
1 104.8, CH 6.02, s   7, 8, 13 9, 11, 13 
2 121.5, qC     
3 154.9, qC     
4 119.2, qC     
5 160.4, qC     
6 100.2, CH 6.59, s  2, 3, 5, 4, 7, 8, 10 10, 11, 12, 1' 
7 141.3, qC     
8 110.8, qC     
9   59.8, CH3 3.89, s  3 1, 13 
10     9.3, CH3 2.06, s  2, 3, 4, 5, 6 6 
11   27.8, CH3 1.55, s  7, 8 1, 6, 12 
12   50.5, CH3 2.94, s  8 6, 11, 13 
13   55.5, CH3 3.50, s  1 1, 9, 12 
1'   66.2, CH2 4.63, d (6.6) 2', 9' 5, 2', 3' 6, 9' 
2' 120.9, CH 5.48, t (6.6) 1', 9' 4', 9'  
3' 141.1, qC     
4'   40.1, CH2 2.07, m 5' 2', 3', 5', 6', 9' 6' 
5'   27.0, CH2 2.11, m 4', 6' 3', 4', 6' 6' 
6' 124.7, CH 5.10, m 5', 8', 10'  4', 5', 8' 
7' 132.0, qC     
8'   25.8, CH3 1.64, br s 6' 6', 7', 10' 6' 
9'   16.7, CH3 1.75, br s 1', 6' 2', 3', 4' 1' 
10'   17.7, CH3 1.58, br s 6' 6', 7', 8   
aCD3COCD3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT.  
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Stachylines 
Table 14. 1D and 2D NMR spectroscopic data for stachyline A (Z-). 
Position c, mult. a,b,e H a,b (J in Hz) COSYa,b,c HMBCa,d NOESYa,b,c 
1 130.1. qC     
2 130.5, CH 7.17, d (8.4) 3 4, 6 3, 7 
3 115.5, CH 6.88, d (8.4) 2 1, 5 1’a, 1’b, 2 
4 158.5, qC     
5 115.5, CH 6.88, d (8.4) 6 1, 3 1’a, 1’b, 6 
6 130.5, CH 7.17, d (8.4) 5 2, 4 5, 7 
7 31.0, CH2 3.60, d (5.5) 8 6, 8 2, 6, 8 
8 150.0, CH 6.73, t (5.5) 7 1, 7 7 
1’ 72.1, CH2 a: 3.90, dd (7.3, 9.5) 
b: 4.01, dd (3.7, 9.5) 
1’b, 2’ 
1’a, 2’ 
2’, 3’, 4 
2’, 3’, 4 
1’b, 2’, 3, 5 
1’a, 2’, 3, 5  
2’ 73.9, CH 4.39, m 1’a, 1’b   
3’ 146.1, qC     
4’ 112.1, CH2 a: 4.89, br s 
b: 5.08, br s 
4’b, 5’ 
4’a, 5’ 
2’ 
2’, 3’ 
4’b 
4’a 
5’ 18.7, CH3 1.78, s 4’a, 4’ b 2’, 3’, 4’  1’a, 1’b, 2’, 4’a 
a CD3COCD3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT.  
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Table 15. 1D and 2D NMR spectroscopic data for stachyline A (E-) 
Position c, mult. a,b,e H a,b (J in Hz) COSYa,b,c HMBCa,d NOESYa,b,c 
    1 130.1. qC     
    2 130.5, CH 7.13, d (8.4) 3 4, 6 3, 7 
    3 115.5, CH 6.88, d (8.4) 2 1, 5 1’a, 1’b, 2 
    4 158.7, qC     
    5 115.5, CH 6.88, d (8.4) 6 1, 3 1’a, 1’b, 6 
    6 130.5, CH 7.13, d (8.4) 5 2, 4 5, 7 
    7 35.4, CH2 3.39, d (6.2) 8 6, 8 2, 6, 8 
    8 149.7, CH 7.40, t (6.2) 7 1, 7 7 
    1’ 72.1, CH2 a: 3.90, dd (7.3, 9.5) 
b: 4.01, dd (3.7, 9.5) 
1’b, 2’ 
1’a, 2’ 
2’, 3’, 4 
2’, 3’, 4 
1’b, 2’, 3, 5 
1’a, 2’, 3, 5  
   2’ 73.9, CH 4.39, m 1’a, 1’b   
   3’ 146.1, qC     
   4’ 112.1, CH2 a: 4.89, br s 
b: 5.08, br s 
4’b, 5’ 
4’a, 5’ 
2’ 
2’, 3’ 
4’b 
4’a 
   5’ 18.7, CH3 1.78, s 4’a, 4’ b  1’a, 1’b, 2’, 4’a 
a CD3COCD3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT.  
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Table 16. 1D and 2D NMR spectroscopic data for stachyline B. 
Position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 128.0, qC    
2 131.2, CH 7.20, d (8.4) 3 3, 4, 7 
3 115.3, CH 6.87, d (8.4) 2 1, 2, 4 
4 158.8, qC    
5 115.3, CH 6.87, d (8.4) 6 1, 4, 6 
6 131.2, CH 7.20, d (8.4) 5 4, 5, 7 
7 40.5, CH2 3.51, s  1, 2, 6, 8 
8 173.0, qC    
1’ 72.1, CH2 a: 4.01, dd (4.0, 9.8) 1’b, 2’ 4, 2’, 3’ 
  b: 3.90, dd (7.2, 9.8) 1’a, 2’  
2’   73.9, CH 4.40, dd (4.0, 7.2) 1’a, 1’b 1’, 3’, 4’, 5’ 
3’ 146.1, qC    
4’ 112.1, CH2 a: 4.88, br s  4’a, 5’ 2’, 3’, 5’ 
  b: 5.08, br s 4’b, 5’  
5’ 18.8, CH3 1.79, br s 4’a, 4’b 2’, 3’, 4’ 
a CD3COCD3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT.  
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Table 17. 1D and 2D NMR spectroscopic data for stachyline C 
Position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 132.5, qC     
2 130.7, CH 7.13, d (8.4) 3 4, 6, 7 
3 115.2, CH 6.84, d (8.4) 2 1, 2, 4, 5 
4 158.3, qC     
5 115.2, CH 6.84, d (8.4) 6 1, 3, 4, 6 
6 130.7, CH 7.13, d (8.4) 5 2, 4, 7 
7 39.4, CH2 2.72, t (7.1) 8 1, 2, 6, 8 
8 64.1, CH2 3.68, t (7.1) 7 1, 7 
1’ 72.1, CH2 a: 4.00, dd (4.3, 9.8) 1’b, 2’ 4, 2’, 3’ 
  b: 3.89, dd (7.2, 9.8) 1’a, 2’  
2’ 74.0, CH 4.39, dd (4.3, 7.2) 1’a, 1’b 1’, 3’, 4’, 5’ 
3’ 146.2, qC     
4’ 112.0, CH2 a: 4.89, br s 4’b, 5’ 2’, 3’, 5’ 
   b: 5.09, br s 4’a. 5’  
5’ 18.8, CH3 1.79, br s 4’a, 4’b 2’, 3’, 4’ 
a CD3COCD3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT. 
 
 
 
 
OHO1
3
4
5 1' 2'
4'
5'
7
8
OH
 
 
 
 
 
 
 
 
 
 
 
 
   142
Table 18 .1D and 2D NMR spectroscopic data for stachyline D 
Position δC, mult.a, b, e δHa, b (J in Hz) COSYa, c HMBCa, d 
1 127.9, qC    
2 131.2, CH 7.19, d (8.4) 3 3, 4, 6, 7 
3 115.2, CH 6.87, d (8.4) 2 1, 4, 5 
4 159.0, qC    
5 115.2, CH 6.87, d (8.4) 6 1, 3, 4 
6 131.2, CH 7.19, d (8.4) 5 2, 4, 5, 7 
7   40.4, CH2 3.52, br s  1, 2, 6 
8 173.2, qC    
1’ 71.6, CH2 a: 4.00, dd (4.0, 9.8) 1’b, 2' 4, 2', 3' 
  b: 3.89, dd (6.6, 9.8) 1’b, 2’  
2’ 74.6, CH 3.68, m 1'a, 1’b, 3' 1', 3', 4', 5' 
3’ 31.6, CH 1.86, m 2', 4', 5' 1', 2', 5', 4' 
4’ 19.4, CH3 0.97, d (6.8) 3' 2', 3', 5' 
5’ 17.7, CH3 0.97, d (6.8) 3' 2', 3', 4' 
a CD3COCD3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT. 
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Sclerosporins 
Table 19. 1D and 2D NMR Spectroscopic Data for  [(+)-15-hydroxysclerosporin] 
Position δC, mult.a, b, e δHa, b (J in Hz)      COSYa, c HMBCa, d NOESYa, c 
1 34.0, CH 2.58, br d (11.4) 2a, 2b, 6 6, 7, 9, 10 6 
2 25.1, CH2 a: 1.99, m 1, 2b, 3 1, 3, 6 2b 
  b: 1.37, qd (11.4, 5.4) 1, 2a, 3 1, 3, 6 2a, 7 
3 26.2, CH2 2.08, m 2a, 2b 4, 5  
4 138.3, qC     
5 124.3, CH 5.79, d (4.1) 6, 15 1, 3, 6, 15 6, 12, 15 
6 35.5, CH 2.04, m 1, 5, 7 1 1, 8a, 12 
7 40.0, CH 1.53, tt (10.2, 5.1) 6, 8a, 8b 6, 11, 12, 13 2b, 11 
8 25.4, CH2 a: 2.15, dt (19.8, 5.1) 7, 8b, 9 6, 7, 9, 10, 14 8b, 9 
  b: 1.97, m 7, 8a, 9 6, 7, 9, 10, 14 8a, 9 
9 142.6, CH 7.14, br s 8a, 8b 1, 7, 8, 10, 14 8a, 8b 
10 132.9, qC     
11 26.4, CH 2.03, m 7, 12, 13 12, 13 12, 13 
12 15.0, CH3 0.83, d (6.8) 11 7, 11, 13 5, 11 
13 21.3, CH3 0.90, d (6.8) 11 7, 11, 12 11 
14 172.2, qC     
15 67.3, CH2 4.03, br s 5 3, 4, 5 5 
aCDCl3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments (HMBC, 
HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e Implied 
multiplicities determined by DEPT.  
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Table 20. 1D and 2D NMR Spectroscopic Data for  [(+)-12-hydroxysclerosporin] 
Position δC, mult a, b, e δH a, b (J in Hz) COSYa, c HMBCa, d NOESYa, c 
1 33.8, CH 2.58, br d (10.2) 2a, 2b, 6 3 6 
2 25.4, CH2 a: 1.91, m 1, 2b, 3a, 3b 1, 6 2b 
  b: 1.42, qd (11.7, 5.4) 1, 2a, 3a, 3b 1,6 2a, 7 
3 30.3, CH2 a: 2.06, m 2a, 2b, 3b  3b 
  b: 1.88, m 2a, 2b, 3a  2b, 3a 
4 135.6, qC     
5 123.0, CH 5.52, br s  6, 15 1, 3, 6, 15 6, 12a, 12b, 15 
6 35.8, CH 2.10, m 1, 5 8 1, 5 
7 38.6, CH 1.65, tt (10.2, 5.1) 6, 8a, 8b 11, 12 2b, 11 
8 28.0, CH2 a: 2.27, dt (19.8, 5.1) 7, 8b 6, 7, 9, 10 8b, 9 
  b: 2.02, m 7, 8a, 9 6, 7, 9, 10 8a, 9 
9 142.1, CH 7.10, br s 8a, 8b 1, 7, 8, 10, 14 8a, 8b 
10 133.1, qC     
11 35.3, CH 2.05, m 7, 12a, 12b, 13  7 
12 64.9, CH2 a: 3.77 (dd, 4.8, 10.6) 11, 12b 7, 11, 13 5, 6, 12b 
  b: 3.52, t (10.6) 11, 12a 7, 11, 13 5, 6, 12a 
13 15.4, CH3 1.03, d (7.0) 11 7, 11, 12 11 
14 172.0, qC     
15 23.9, CH3 1.68, br s 5 3, 4, 5 5 
aCDCl3, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments (HMBC, 
HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e Implied 
multiplicities determined by DEPT.  
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Table 21. 1D and 2D NMR Spectroscopic Data for [(+)-11-hydroxysclerosporin] 
Position δC, mult. a, b, e δH a, b (J in Hz) COSYa, c HMBCa, d NOESYa, c 
1 35.6, CH 2.54, br d (10.6) 2a, 2b, 6  6 
2 26.2, CH2 a: 1.89, m 1, 2b, 3a, 3b 1, 6 2b 
  b: 1.50, qd (11.7, 5.5) 1, 2a, 3a, 3b  2a, 7 
3 30.8, CH2 a: 1.98, m 2a, 2b   
  b: 1.95, m 2a, 2b   
4 133.7, qC     
5 126.6, CH 5.71, br d (5.1) 6, 15 1, 3, 6, 15 6, 12, 15 
6 36.9, CH 2.11, m 1, 5 5, 7, 8 1, 5, 12 
7 47.2, CH 1.68, td (10.3, 5.1) 8a, 8b 6, 11 2b, 8a, 12, 13
8 29.7, CH2 a: 2.38, dt (19.6, 5.1) 7, 8b, 9 6, 7, 9, 10, 11 7, 8b, 9, 13 
  b: 2.01, m 7, 8a, 9  8a, 9 
9 140.2, CH 6.95, br t (3.9) 8a, 8b 1, 7, 8, 10, 14 8a, 8b 
10 134.3, qC     
11 72.6, qC     
12 27.4, CH3 1.23, s  7, 11, 13 5 
13 28.7, CH3 1.18, s  7, 11, 12  
14 168.0, qC     
15 23.9, CH3 1.66, br s 5 3, 4, 5 5 
aAcetone-d6, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT.  
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Table 22. 1D and 2D NMR Spectroscopic Data for [(-)-8-hydroxysclerosporin] 
Position    δC, mult. a, b, e       δH a, b (J in Hz) COSYa, c      HMBCa, d NOESYa, c 
1 35.2, CH 2.43, br d (10.6) 2a, 2b, 6 7 6 
2 26.0, CH2 a: 1.93, m 1, 2b, 3a, 3b  2b 
  b: 1.45, qd (11.7, 5.4) 1, 2a, 3a, 3b  2a 
3 31.5, CH2 a: 2.08, m 2a, 2b, 3b  3b 
  b: 1.93, m 2a, 2b, 3a  3a 
4 134.9, qC     
5 125.1, CH 5.57, br d (4.4) 6, 15 1, 3, 6, 15 6, 11, 12, 13, 15 
6 36.2, CH 2.10, m 1, 5, 7 1, 7, 11 1 
7 48.8, CH 1.52, ddd (3.2, 8.7, 10.7) 6, 8, 11 1, 6, 8 12, 13 
8 68.7, CH 4.13, br d (8.7) 7, 9 7, 9, 10, 11 6, 9, 11, 12, 13 
9 143.7, CH 6.79, d (1.8) 8 1, 7, 10, 14 8 
10 134.3, qC     
11 27.3, CH 2.25, m 7, 12, 13 7, 8 7, 8, 9, 12, 13 
12 18.9, CH3 1.00, d (7.1) 11 7, 11, 13 5, 7, 8, 11 
13 21.1, CH3 1.10, d (7.1) 11 7, 11, 12 5, 7, 8, 11 
14 168.0, qC     
15 23.9, CH3 1.68, br s 5 3, 4, 5 5 
aAcetone-d6, 300/75.5 MHz. b Assignments are based on extensive 1D and 2D NMR experiments 
(HMBC, HSQC, COSY). c Numbers refer to proton resonances. d Numbers refer to carbon resonances. e 
Implied multiplicities determined by DEPT.  
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2D NMR tables for Verticinols in the main text 
2D NMR tables for the novel furyl derivative in the main text 
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13.4. Appendix - Spectroscopic data Supporting Information 
 
Note: Supporting information of verticinols A and B, and the furyl derivative 2-(furan-3-yl)acetic 
acid were integrated in the respective chapters 
 
Supporting Information for Marilines A – D (Stachylidium sp.) 
 
Figure 1. Key HMBC and NOE correlations of marilines A – D 
 
 
 
 
 
 
      NOE Correlations (marilines A and B) 
 
 
 
 
 
HMBC correlations (marilines A and B) 
(15N HMBC correlations in red arrows) 
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Figure 2. HMBC NMR data for marilines A and B 
 
 
Figure 3. NOE NMR data for marilines A and B 
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Figure 4. Separation chromatogram for marilines A (compound 1) and B (compound 2) 
 
 
 
 
Figure 5. Formation of 2, 4-dihydroxyaniline, putative precursor of marilines A/B 
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Figure 6. Reported structures similar to marilines A-D referred in the marilines chapter 
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Figure 7. Reported natural products with similar backbones related to 2,4-
dihydroxyaniline 
 
 
 
 
 
Fungal endophyte DAOM 221611 from spruce needles:  
(Findlay et al., 2003) 
and from Penicillium sp.:  
(El-Beih et al., 2007) 
 
 
 
Porifera Oceanapia sp.: 
(Venkateswarlu et al., 1999) 
 
 
 
 
 
 
 
 
 
Fungus Chaetosphaeria sp.: 
(Zikmundova et al., 2002)  
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Supporting Information for Marilones A – J ( Stachylidium sp.) 
 
 
Figure 8. Key HMBC correlations for marilones A - J 
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Table 1. 1H-NMR spectroscopic data comparison of reported values for silvaticol and 
nidulol with compound 9 (marilones chapter) for the conclusive elucidation 
as silvaticol 
  1H NMR (CDCl3) 
Position Compound 9 Silvaticol* Nidulol*
1    
2    
3    
4    
5    
6 7.05 7.04 6.59 
7    
8 5.39 5.39 5.15 
9 3.90 3.91 4.08 
10 2.23 2.23 2.19 
 
 
* (Kawahara et al, 1988) 
 
Table 2. 1H-NMR spectroscopic data comparison of compounds 1 and 3 with silvaticol 
and nidulol derivatives 
  1H NMR (CDCl3)
position 
Marilone 
A 
Marilone 
C 
6-(3',3'-dimethylallyloxy-4-
methoxy-5-methylphthalide** 
5-(3',3'-dimethylallyloxy-7-
methoxy-6-methylphthalide** 
1         
2     
3     
4     
5     
6 6.54 7.05 7.08 6.62 
7     
Protons at C-1/C8 5.39 5.39 5.38 5.18 
9 4.04 3.90 3.89 4.03 
10 2.18 2.23 2.21 2.15 
      silvaticol derivative nidulol derivative 
 
 
 
 
 
 
** (Suemitsu et al., 1995) 
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
marilone A
marilone C
silvaticol derivative nidulol derivative
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Supporting Information for Stachylines A – D (Stachylidium sp.) 
 
Figure 9a and b. CD spectra of stachylines B and C 
 
a) CD spectra of stachyline B 
 
b) CD spectra of stachyline C 
 
 
 
 
 
 
 
Figure 10. Key HMBC correlations of stachylines A - D 
 
 
 
 
 
      (A)                    (B)     
  
 
 
   
          
 (C)              (D)   
 
OHO
HOOC
OHO
HO
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Figure 11. 1H NMR spectroscopic data of the respective (R)- and (S)-MTPA esters of 
stachyline B. 
 
Figure 12 (a-c). 1H-13C HSQC spectroscopic data of stachyline B and the respective 
(R)- and (S)-MPTA esters. 
a) HSQC spectrum of stachyline B: 
 
H3-5’ 
H3-5’ 
H2-1’ 
H2-1’ H-
H-3’ 
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b) HSQC spectrum of S- Mosher 
 
c) HSQC spectrum of R- Mosher 
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Figure 13. LC-MS (ESI, 2 experiments in + mode) data for stachyline A (E- and Z-) 
 
Peak 16.05 min., 236.4 and 236.3 (M+H)+ 
Peak 16.61 min., 236.1 and 236.3 (M+H)+ 
TWC of DAD Spectral Data: from Sample 6 (VLC 3.3.2) of 2009-11-20.wiff Max. 4,4e4 mAU.
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Supporting Information for Hydroxylated Sclerosporin Derivatives (Cadophora 
malorum) 
 
Figure 14. Infra-red spectra of sclerosporin and the four novel hydroxylated 
sclerosporin derivatives 
 
 
 
 
 
 
 
 
 
 
Figure 15. Key HMBC correlations for the four novel hydroxylated sclerosporin 
derivatives 
 
 
 
 
 
                 
 (+)-15-hydroxysclerosporin (2)               (+)-12-hydroxysclerosporin (3)             (+)-11-hydroxysclerosporin (4)           (-)-8-hydroxysclerosporin (5)
  
 
Figure 16. Key NOESY correlations for four novel hydroxylated sclerosporin 
derivatives 
 
 
 
 
 
 
(+)-15-hydroxysclerosporin (2)                  (+)-12-hydroxysclerosporin (3)              (+)-11-hydroxysclerosporin (4)                   (-)-8-hydroxysclerosporin (5)  
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Figures 17 a-e.  CD spectra for sclerosporin and the hydroxylated sclerosporin 
derivatives. Respective absolute configuration on the right side. 
a)  (+)-15-hydroxysclerosporin 
 
 
 
 
 
b)  (+)-12-hydroxysclerosporin 
 
 
 
(-)-8-Hydroxy 
 
c)  (+)-11-hydroxysclerosporin 
 
 
 
 
 
 
d)  (-)-8-hydroxysclerosporin 
 
 
 
 
 
e)  (+)-sclerosporin 
 
 
 
 
 
 
O OH
H
H
J = 4.9 Hz J = 10.7 Hz
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13.5. 1H and 13C NMR spectra 
13.5.1. 1H and 13C NMR spectra of new molecules 
 
New molecules from Stachylidium sp. 
 
New sclerosporing derivatives from Cadophora malorum   
 
 
New molecules from Verticillium tenerum  
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1H NMR spectra (300 MHz, CD3COCD3) of marilines A and B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectra (75 MHz, CD3COCD3) of marilines A and B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O N
OO O
O
R2R1
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1H NMR spectrum (300 MHz, CD3COCD3) of mariline C 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum (75 MHz, CD3COCD3) of mariline C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   163
1H NMR spectrum (300 MHz, MeOD) of mariline D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13C NMR spectrum (75 MHz, MeOD) of mariline D 
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 1H NMR (300 MHz, CD3COCD3) of marilone A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13C NMR (75 MHz, CD3COCD3) of marilone A 
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1H NMR (300 MHz, CD3COCD3) of marilone B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (75 MHz, CD3COCD3) of marilone B 
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 1H NMR (300 MHz, CD3COCD3) of marilone C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13C NMR (75 MHz, CD3COCD3) of marilone C 
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1H NMR (300 MHz, CD3COCD3) of marilone D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (75 MHz, CD3COCD3) of marilone D 
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1H NMR (300 MHz, MeOD) of marilone E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13C NMR (75 MHz, MeOD) of marilone E 
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1H NMR (300 MHz, CD3COCD3) of marilone F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13C NMR (300 MHz, CD3COCD3) of marilone F 
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 1H NMR (300 MHz, MeOD) of marilone G 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13C NMR (75 MHz, MeOD) of marilone G 
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 1H NMR (300 MHz, CD3COCD3) of marilone H 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (75 MHz, CD3COCD3) of marilone H 
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1H NMR (300 MHz, CD3COCD3) of marilone I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (75 MHz, CD3COCD3) of marilone I 
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 1H NMR (300 MHz, CD3COCD3) of marilone J 
 
 13C NMR (75 MHz, CD3COCD3) of marilone J 
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1H NMR (300 MHz, CD3COCD3) of stachyline A 
                                                                                                    H-5`(E- and Z-) 
   
          
 
  H-3,5 (E- and Z-) 
         H-7 (Z-)    H-7 (E-)    
  
   
    H-8 (E-)        H-8 (Z-)      
            H-2,6           H-4`(E-and Z-)                                                        
     
                           H-2` 
 
 
 
 
13C NMR (75 MHz, CD3COCD3) of stachyline A 
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1H NMR (300 MHz, CD3COCD3) of stachyline B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13C NMR (75 MHz, CD3COCD3) of stachyline B 
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 1H NMR (300 MHz, CD3COCD3) of stachyline C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (75 MHz, CD3COCD3) of stachyline C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OHO
HOH2C
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1H NMR (300 MHz, CD3COCD3) of stachyline D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (75 MHz, CD3COCD3) of stachyline D 
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1H NMR (300 MHz, CD3COCD3) of 2-(furan-3-yl)acetic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (75 MHz, CD3COCD3) of 2-(furan-3-yl)acetic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   179
 1H NMR spectrum (300 MHz, CDCl3) of 15-hydroxysclerosporin 
 
 
13C NMR spectrum (75 MHz, CDCl3) of 15-hydroxysclerosporin 
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1H NMR spectrum (300 MHz, CDCl3) of 12-hydroxysclerosporin 
 
 
13C NMR spectrum (75 MHz, CDCl3) of 12-hydroxysclerosporin 
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 1H NMR spectrum (300 MHz, acetone-d6) of 11-hydroxysclerosporin 
  
 
13C NMR spectrum (75 MHz, acetone-d6) of 11-hydroxysclerosporin 
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 1H NMR spectrum (300 MHz, acetone-d6) of 8-hydroxysclerosporin 
 
 
 13C NMR spectrum (75 MHz, acetone-d6) of 8-hydroxysclerosporin 
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 1H NMR (300 MHz, CDCl3) of verticinol A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (75 MHz, CDCl3) of verticinol A 
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1H NMR (300 MHz, MeOD) of verticinol B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (75 MHz, MeOD) of verticinol B 
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13.5.2. 1H and 13C NMR spectra of known molecules 
 (trivial names in the 1D NMR spectra) 
Eurotium sp. 
 
 
                   (1)                         (2)                                                 (3) 
1 - 3. (Arai et al., 1989) 
Phialophorophoma litoralis 
 
 
                  (4)                                      (5)                                                  (6)  
4. (Garson et al., 1984) 
5 - 6. (Klemke et al., 2004) 
 
      Cadophora Malorum                Verticillium cinnabarinum            Verticillium 
tenerum 
 
  
 
                 (7)                                            (8)                                                 (9)  
7. (Kitahara et al., 1984) 
8. (Bull et al., 1998) 
9. (Boeesenken, 1939) 
Acremonium sp 
 
 
 
                       (10)                      (11)                                                (12)  
 
10. (Gyimesi, 1965) 
11. artefact derived from 10.  
12. (Schulte et al., 1968; Jinming et al., 2001) 
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Stachyllidium sp. 
                           
 
 
  
     (13)               (14)               (15)                           (16)                                   (17) 
 
 
 
 
  
          (18)                (19)             (20)    (21)                  (22) 
   
 
 
 
 
     (23)     (24)          (25)  (26) 
 
13. (Andersen, 1987; Alves et al., 2009). 
14. (Ayer et al., 1993) 
15. (Schneider et al., 1996) 
16. (Yue et al., 2001) 
17. (Kawahara et al., 1988) 
18. (Schneider et al., 1996) 
19. (Awad et al., 2005). 
20. (Chen, 1958; Crowden and Ralph, 1961) 
21. (Nair and Burke, 1988) 
22. (Barrero et al., 1996) 
23. (Jinming et al., 2001) 
24. (Hong, 1981) 
25. (Turner, 1971) 
26. (Lu et al., 2008).  
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Compound 1, (tetrahidroauroglaucin/aspergin), Eurotium sp., D-acetone 
1H NMR  
 
13C NMR 
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Compound 2, (flavoglaucin), Eurotium sp., CD3COCD3. 
1H NMR  
 
13C NMR 
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Compound 3, (isotetrahydroauroglaucin), Eurotium sp., CD3COCD3. 
1H NMR  
 
 
13C NMR 
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Compound 4, (R-mellein), Phialophorophoma litoralis, CDCl3. 
1H NMR  
13C NMR 
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Compound 5, [(-)-hexylitaconic acid], Phialophorophoma litoralis, CDCl3. 
1H NMR  
 
13C NMR 
 
O
OH
O
Hexylitaconic acid
OH
Chemical Formula: C11H18O4
Exact Mass: 214,1205
Molecular Weight: 214,2582
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Compound 6, [(-)-9-hydroxy Hexylitaconic acid 1-half-methyl ester], 
Phialophorophoma litoralis, CDCl3. 
1H NMR  
 
13C NMR 
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Compound 7, [(+)-sclerosporin], Cadophora malorum, CDCl3. 
1H NMR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR 
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Compound 8, (cyclo-proline-isoleucine), Verticillium cinnabarinum, MeOD 
1H NMR  
 
 
13C NMR 
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Compound 9, (3, 4-dimethoxy phenol) , Verticillium tenerum , CDCl3. 
1H NMR  
 
13C NMR 
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Compound 10, (crotocin), Acremonium  sp., CDCl3. 
1H NMR  
 
 
 
13C NMR 
 
 
 
   197
Compound 11, (probable Crotocin artefact - open epoxyde), Acremonium  sp., MeOD. 
1H NMR  
 
 
13C NMR 
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Compound 12, (ergosta-4,6,8 (14), 22-tetraen-3-one, impure sample), Acremonium  sp., 
CDCl3. 
1H NMR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR 
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Compound 13,(1, 2, 4-trimethoxy-benzene), Stachyllidium sp.,CDCl3. 
1H NMR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR 
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Compound 14  (isosclerone), Stachyllidium sp.,CDCl3. 
1H NMR  
 
 
13C NMR 
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Compound 15, (tirosol), Stachyllidium sp.,CDCl3. (H-NMR in MeOD, C-NMR in D-
acetone) 
1H NMR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR 
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Compound 16,  (sterol), Stachyllidium sp., D-acetone 
1H NMR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR 
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Compound 17, (nidulol), Stachylidium sp., D-acetone 
1H NMR  
 
13C NMR 
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Compound (18) (furyl derivative) Stachylidium sp., MeoD   
1H NMR  
 
 
13C NMR 
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Compound (19), (tyrosine derivative), Stachylidium sp., MeoD  
1H NMR 
 
 
13C NMR 
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Compound 20, para-hydroxyphenylacetic acid, Stachylidium sp., MeoD 
1H NMR  
 
13C NMR 
 
 
   207
Compound 21, phenylacetic acid, Stachylidium sp., D-acetone 
1H NMR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR  
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Compound 22, benzoic acid, Stachylidium sp., D-acetone 
1H NMR  
 
 
13C NMR 
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Compound 23, sterol, Stachylidium sp., D-acetone 
1H NMR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR 
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Compound 24, (2-furoic acid), Stachylidium sp., MeoD 
1H NMR  
 
No 13C NMR ; m/z 112.02; LR-LC-MS, found 110.8 (M–H)+  
The assignment of NMR shifts was supported using the ACD NMR predictor software 
(ACD/Labs®). 
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Compound 25, (3,4-dihydroxybenzoic acid/Catechuic acid), Stachylidium sp., MeoD 
1H NMR  
 
13C NMR 
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Compound 26, (-(furan-2-yl)ethane-1,2-diol ), Stachylidium sp., MeoD  
1H NMR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
